WO2016001449A1 - Subtilase variants and polynucleotides encoding same - Google Patents

Subtilase variants and polynucleotides encoding same Download PDF

Info

Publication number
WO2016001449A1
WO2016001449A1 PCT/EP2015/065375 EP2015065375W WO2016001449A1 WO 2016001449 A1 WO2016001449 A1 WO 2016001449A1 EP 2015065375 W EP2015065375 W EP 2015065375W WO 2016001449 A1 WO2016001449 A1 WO 2016001449A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
subtilase
subtilase variant
substitution
Prior art date
Application number
PCT/EP2015/065375
Other languages
French (fr)
Inventor
Frank Winther Rasmussen
Peter Kamp Hansen
Lars Lehmann Hylling Christensen
Original Assignee
Novozymes A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53541651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016001449(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BR112017000102-0A priority Critical patent/BR112017000102B1/en
Priority to CN201580035374.XA priority patent/CN106661566A/en
Priority to US15/323,633 priority patent/US10550381B2/en
Priority to CA2950380A priority patent/CA2950380A1/en
Priority to EP17206371.1A priority patent/EP3327122B1/en
Application filed by Novozymes A/S filed Critical Novozymes A/S
Priority to EP21156683.1A priority patent/EP3878960A1/en
Priority to EP15736432.4A priority patent/EP3140399B1/en
Priority to CN202211569078.6A priority patent/CN116240202A/en
Publication of WO2016001449A1 publication Critical patent/WO2016001449A1/en
Priority to US16/715,806 priority patent/US11015183B2/en
Priority to US17/246,266 priority patent/US20220064620A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0047—Detergents in the form of bars or tablets
    • C11D17/0065—Solid detergents containing builders
    • C11D17/0073—Tablets
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/04—Detergent materials or soaps characterised by their shape or physical properties combined with or containing other objects
    • C11D17/041—Compositions releasably affixed on a substrate or incorporated into a dispensing means
    • C11D17/042—Water soluble or water disintegrable containers or substrates containing cleaning compositions or additives for cleaning compositions
    • C11D17/045—Multi-compartment
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38663—Stabilised liquid enzyme compositions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38681—Chemically modified or immobilised enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)

Definitions

  • the present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance.
  • the variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.
  • the present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.
  • Enzymes used in such formulations comprise proteases, lipases, amylases, cellulases, mannosidases as well as other enzymes or mixtures thereof.
  • proteases are most important enzymes.
  • proteases protein engineered variants of naturally occurring wild type proteases Everlase ® , Relase ® , Ovozyme ® , Polarzyme ® , Liquanase ® , Liquanase Ultra ® and Kannase ® (Novozymes a/s), Purafast ® , Purafect OXP ® , FN3 ® , FN4 ® and Eraser ® , Excellase ® (Genencor International, Inc.).
  • subtilase variants exhibiting alterations relative to the parent subtilase in e.g. wash performance, thermal stability, storage stability or catalytic activity.
  • the variants are suitable for use in e.g. cleaning or detergent compositions.
  • the present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to its parent subtilase.
  • the invention relates to subtilase variants having protease activity and comprising one or more substitutions selected from the group consisting X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C,
  • subtilase variants having protease activity comprising two or more substitutions selected from the group consisting of: X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C
  • the present invention also relates to subtilase variants having improved stability, in particular improved in wash stability, and preferably on par or improved wash performance compared to the parent or compared to a reference protease.
  • the present invention further relates to polynucleotides encoding the subtilase variants; compositions, preferably detergent compositions, comprising a subtilase variant; use of the compositions in a cleaning process and methods for obtaining a subtilase variant and for removing a stain from a surface.
  • allelic variant means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.
  • An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.
  • cDNA means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA.
  • the initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
  • coding sequence means a polynucleotide, which directly specifies the amino acid sequence of a variant.
  • the boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG or TTG and ends with a stop codon such as TAA, TAG, or TGA.
  • the coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.
  • control sequences means nucleic acid sequences necessary for expression of a polynucleotide encoding a variant of the present invention.
  • Each control sequence may be native (i.e., from the same gene) or foreign (i.e., from a different gene) to the polynucleotide encoding the variant or native or foreign to each other.
  • control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator.
  • the control sequences include a promoter, and transcriptional and translational stop signals.
  • the control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a variant.
  • detergent component is defined herein to mean the types of chemicals which can be used in detergent compositions.
  • detergent components are surfactants, hydrotropes, builders, co-builders, chelators or chelating agents, bleaching system or bleach components, polymers, fabric hueing agents, fabric conditioners, foam boosters, suds suppressors, dispersants, dye transfer inhibitors, fluorescent whitening agents, perfume, optical brighteners, bactericides, fungicides, soil suspending agents, soil release polymers, anti- redeposition agents, enzyme inhibitors or stabilizers, enzyme activators, antioxidants, and solubilizers.
  • the detergent composition may comprise of one or more of any type of detergent component.
  • detergent composition includes, unless otherwise indicated, all forms of detergent compositions such as gel, granulate, liquid, paste, powder, spray or tablet compositions including heavy-duty liquids (HDL), fine-fabric liquid detergents, liquid and/or solid laundry detergents and fine fabric detergents; hard surface cleaning formulations for e.g.
  • HDL heavy-duty liquids
  • fine-fabric liquid detergents liquid and/or solid laundry detergents and fine fabric detergents
  • hard surface cleaning formulations for e.g.
  • dish wash detergents such as hand dishwashing agents, light duty dishwashing agents, machine dishwashing agents; all-purpose or heavy-duty washing agents, liquid, gel or paste-form all-purpose washing agents, liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car or carpet shampoos, bathroom cleaners; hair shampoos and hair-rinses; shower gels, foam baths; metal cleaners; as well as cleaning auxiliaries such as bleach additives and "stain-stick" or pre-treat types.
  • the detergent formulation may contain one or more additional enzymes (such as proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidaes, haloperoxygenases, catalases and mannanases, or any mixture thereof), and/or components such as surfactants, builders, chelators or chelating agents, bleach system or bleach components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfume, tannish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, anti-corrosion agents, enzyme inhibitors or stabilizers, enzyme activators, transferase(s), hydrolytic enzymes, oxido reductases, bluing agents and fluorescent dyes, antioxidants, and solubilizer
  • additional enzymes such as proteases, amylases
  • wash refers to all forms of washing dishes, e.g. by hand or automatic dish wash. Washing dishes includes, but is not limited to, the cleaning of all forms of crockery such as plates, cups, glasses, bowls, all forms of cutlery such as spoons, knives, forks and serving utensils as well as ceramics, plastics such as melamine, metals, china, glass and acrylics.
  • dish washing composition refers to all forms of compositions for cleaning hard surfaces.
  • the present invention is not restricted to any particular type of dish wash composition or any particular detergent.
  • expression includes any step involved in the production of a variant including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
  • expression vector means a linear or circular DNA molecule that comprises a polynucleotide encoding a variant and is operably linked to control sequences that provide for its expression.
  • hard surface cleaning is defined herein as cleaning of hard surfaces wherein hard surfaces may include floors, tables, walls, roofs etc. as well as surfaces of hard objects such as cars (car wash) and dishes (dish wash). Dish washing includes but are not limited to cleaning of plates, cups, glasses, bowls, and cutlery such as spoons, knives, forks, serving utensils, ceramics, plastics such as melamine, metals, china, glass and acrylics.
  • host cell means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention.
  • host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
  • improved property means a characteristic associated with a subtilase variant that is improved compared to the parent subtilase or compared to the polypeptide of SEQ ID NO: 1 , or compared to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant.
  • improved properties include, but are not limited to, wash performance, protease activity, thermal activity profile, thermostability, pH activity profile, pH stability, substrate/cofactor specificity, improved surface properties, substrate specificity, product specificity, increased stability, improved stability under storage conditions, and chemical stability.
  • the term "stability" includes storage stability and stability during use, e.g. during a wash process and reflects the stability of the subtilase variant according to the invention as a function of time e.g. how much activity is retained when the subtilase variant is kept in solution in particular in a detergent solution.
  • the stability is influenced by many factors e.g. pH, temperature, detergent composition e.g. amount of builder, surfactants etc.
  • the stability of the subtilase variant may be measured using the assay described in Example 3
  • improved stability or “increased stability” is defined herein as a variant subtilase displaying an increased stability in solutions, relative to the stability of the parent subtilase, relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant or relative to SEQ ID NO: 1 .
  • improved stability and “increased stability” includes “improved chemical stability", “detergent stability” or "improved detergent stability.
  • improved chemical stability is defined herein as a variant subtilase displaying retention of enzymatic activity after a period of incubation in the presence of a chemical or chemicals, either naturally occurring or synthetic, which reduces the enzymatic activity of the parent enzyme. Improved chemical stability may also result in variants being more able to catalyze a reaction in the presence of such chemicals.
  • the improved chemical stability is an improved stability in a detergent, in particular in a liquid detergent.
  • detergent stability or “improved detergent stability is in particular an improved stability of the protease activity when a subtilase variant of the present invention is mixed into a liquid detergent formulation, especially into a liquid detergent formulation according to table 1 and then stored at temperatures between 15 and 50 °C, e. g. 20°C, 30°C or 40°C.
  • improved thermal activity means a variant displaying an altered temperature- dependent activity profile at a specific temperature relative to the temperature-dependent activity profile of the parent, relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant or relative to a protease with SEQ ID NO: 1 .
  • Thermal activity value provides a measure of the variant's efficiency in enhancing catalysis of a hydrolysis reaction over a range of temperatures.
  • a more thermo active variant will lead to an increase in enhancing the rate of hydrolysis of a substrate by an enzyme composition thereby decreasing the time required and/or decreasing the enzyme concentration required for activity.
  • a variant with a reduced thermal activity will enhance an enzymatic reaction at a temperature lower than the temperature optimum of the parent defined by the temperature- dependent activity profile of the parent.
  • improved wash performance is defined herein as a subtilase variant according to the invention displaying an improved wash performance relative to the wash performance of the parent protease, relative to a polypeptide with SEQ ID NO: 1 or relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant e.g. by increased stain removal.
  • wash performance includes wash performance in laundry but also e.g. in dish wash. The wash performance may be quantified as described under the definition of "wash performance” herein.
  • isolated means a substance in a form or environment which does not occur in nature.
  • isolated substances include (1 ) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance).
  • An isolated substance may be present in a fermentation broth sample.
  • laundering relates to both household laundering and industrial laundering and means the process of treating textiles and/or fabrics with a solution containing a detergent composition of the present invention.
  • the laundering process can for example be carried out using e.g. a household or an industrial washing machine or can be carried out by hand.
  • mature polypeptide means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, autocatalytic activation etc.
  • the mature polypeptide is amino acids 1 to 269 of SEQ ID NO: 1 and 1 to 275 of SEQ ID NO: 2. It is known in the art that a host cell may produce a mixture of two of more different mature polypeptides (i.e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide.
  • mature polypeptide coding sequence means a polynucleotide that encodes a mature polypeptide having protease activity.
  • mutant means a polynucleotide encoding a variant.
  • nucleic acid construct means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.
  • operably linked means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.
  • parent means a protease to which an alteration is made to produce the subtilase variants of the present invention.
  • the parent is a subtilase having the identical amino acid sequence of the variant but not having the alterations at one or more e.g. two or more of the specified positions. It will be understood that in the present context the expression “having identical amino acid sequence” relates to 100% sequence identity.
  • the parent is a protease with at least 60 % identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any of the polypeptides comprising the amino acid sequence of SEQ ID NO: 1 .SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12. Examples of parent proteases and parent subtilases are described in "parent proteases”.
  • protease is defined herein as an enzyme that hydrolyses peptide bonds. It includes any enzyme belonging to the EC 3.4 enzyme group (including each of the thirteen subclasses thereof).
  • the EC number refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including supplements 1 -5 published in Eur. J. Biochem. 1994, 223, 1 -5; Eur. J. Biochem. 1995, 232, 1 -6; Eur. J. Biochem. 1996, 237, 1 -5; Eur. J. Biochem. 1997, 250, 1 -6; and Eur. J. Biochem. 1999, 264, 610-650; respectively.
  • proteases in the detergent industry such as laundry and dish wash are the serine proteases or serine peptidases which is a subgroup of proteases characterised by having a serine in the active site, which forms a covalent adduct with the substrate. Further the subtilases (and the serine proteases) are characterised by having two active site amino acid residues apart from the serine, namely a histidine and an aspartic acid residue. Subtilase refer to a sub-group of serine protease according to Siezen et al., Protein Engng. 4 (1991 ) 719-737 and Siezen et al. Protein Science 6 (1997) 501 -523.
  • the subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family.
  • proteolytic activity means a proteolytic activity (EC 3.4).
  • Proteases usably in detergents are mainly endopeptidases (EC 3.4.21 ).
  • protease activity types There are several protease activity types: The three main activity types are: trypsin-like where there is cleavage of amide substrates following Arg or Lys at P1 , chymotrypsin-like where cleavage occurs following one of the hydrophobic amino acids at P1 , and elastase-like with cleavage following an Ala at P1.
  • protein activity such as protease activity is determined according to the procedure described in the Examples section below.
  • the subtilase variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the enzyme activity of the mature polypeptide of the parent enzyme.
  • the subtilase variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the protease activity of the polypeptide of SEQ ID NO: 1.
  • protease activity means a proteolytic activity (EC 3.4).
  • Proteases of the invention are endopeptidases (EC 3.4.21 ).
  • protease activity is determined according to the Suc-AAPF-pNA activity assay described in "Materials and Methods" herein.
  • the subtilase variants of the present invention preferably have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, and at least 100% of the protease activity of the polypeptide of SEQ ID NO: 1 .
  • sequence identity The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity".
  • sequence identity is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later.
  • the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
  • the output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
  • the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or later.
  • the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix.
  • the output of Needle labeled "longest identity" is used as the percent identity and is calculated as follows:
  • substantially pure variant means a preparation that contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polypeptide material with which it is natively or recombinantly associated.
  • the variant is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation.
  • the variants of the present invention are preferably in a substantially pure form. This can be accomplished, for example, by preparing the variant by well-known recombinant methods or by classical purification methods.
  • substantially pure polynucleotide means a polynucleotide preparation free of other extraneous or unwanted nucleotides and in a form suitable for use within genetically engineered polypeptide production systems.
  • a substantially pure polynucleotide contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polynucleotide material with which it is natively or recombinantly associated.
  • a substantially pure polynucleotide may, however, include naturally occurring 5'- and 3'- untranslated regions, such as promoters and terminators.
  • the substantially pure polynucleotide is at least 90% pure, e.g., at least 92% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, and at least 99.5% pure by weight.
  • the polynucleotides of the present invention are preferably in a substantially pure form.
  • textile means any textile material including yarns, yarn intermediates, fibers, non-woven materials, natural materials, synthetic materials, as well as fabrics made of these materials such as garments, cloths and other articles.
  • fabric or garment it is intended to include the broader term textiles as well.
  • variant means a polypeptide having protease activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions compared to the parent protease.
  • a substitution means replacement of the amino acid occupying a position with a different amino acid;
  • a deletion means removal of the amino acid occupying a position; and
  • an insertion means adding one or more (e.g. several) amino acids, e.g. 1 , 2, 3, 4 or 5 amino acids adjacent to and immediately following the amino acid occupying a position.
  • subtilase variant means a variant of a subtilase parent i.e.
  • subtilase variant and is a subtilase which comprises alterations i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions compared to the parent subtilase.
  • wash performance is used as an enzyme's ability to remove stains present on the object to be cleaned during e.g. wash, such as laundry or hard surface cleaning.
  • the improvement in the wash performance may be quantified by calculating the so-called intensity value (Int) defined in AMSA assay, as described in Materials and Methods section.
  • wild-type subtilase means a protease expressed by a naturally occurring organism, such as a bacterium, archaea, yeast, fungus, plant or animal found in nature.
  • An example of a wild-type subtilase is Savinase i.e. amino acid 1 to 269 of SEQ ID NO 1 or BPN' i.e. amino acid 1 to 275 of SEQ ID NO: 2.
  • the polypeptide ( ⁇ ') disclosed in SEQ ID NO: 2 is used to determine the corresponding amino acid residue in another protease.
  • the amino acid sequence of another protease is aligned with the mature polypeptide disclosed in SEQ ID NO: 2, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the polypeptide disclosed in SEQ ID NO: 2 is determined using the Needleman- Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later.
  • the parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
  • Identification of the corresponding amino acid residue in another protease can be determined by an alignment of multiple polypeptide sequences using several computer programs including, but not limited to, MUSCLE (multiple sequence comparison by log- expectation; version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, Nucleic Acids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research 33: 51 1 -518; Katoh and Toh, 2007, Bioinformatics 23: 372- 374; Katoh et al., 2009, Methods in Molecular Biology 537:_39-64; Katoh and Toh, 2010, Bioinformatics 26:_1899-1900), and EMBOSS EMMA employing ClustalW (1 .83 or later; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680), using their respective default parameters.
  • MUSCLE multiple sequence comparison
  • proteins of known structure For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of proteins have been structurally aligned, and those alignments are accessible and downloadable.
  • Two or more protein structures can be aligned using a variety of algorithms such as the distance alignment matrix (Holm and Sander, 1998, Proteins 33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998, Protein Engineering 1 1 : 739-747), and implementation of these algorithms can additionally be utilized to query structure databases with a structure of interest in order to discover possible structural homologs (e.g., Holm and Park, 2000, Bioinformatics 16: 566-567).
  • substitutions For an amino acid substitution, the following nomenclature is used: Original amino acid, position, substituted amino acid. Accordingly, the substitution of Histidine at position 226 with alanine is designated as "His226Ala” or ⁇ 226 ⁇ ". Multiple mutations may be separated by addition marks ("+"), e.g., "Ne205Arg + Leu217Phe” or "I205R + L217F", representing substitutions at positions 205 and 217 of isoleucine (I) with arginine (R) and leucine (L) with phenylalanine (F), respectively.
  • addition marks e.g., "Ne205Arg + Leu217Phe” or "I205R + L217F”
  • substitutions are usually indicated with the amino acid present in Savinase (SEQ ID NO 1 ) at a position corresponding to the position of BPN' (SEQ ID NO 2).
  • various parent proteases are suitable for making the variants disclosed. It will be clear to the skilled artisan that the amino acid substituted i.e. the preceding amino acid may be different from those of Savinase (SEQ ID NO 1 ) if the variants is made from another parent. This could be shown by an X representing any amino acid indicating that any original amino acid at the position may be substituted. For example, X9E means that any amino acid residue at position 9 other than E is substituted with E.
  • Insertions The insertion of an additional amino acid residue such as e.g. a lysine after G195 may be indicated by: Gly195Glyl_ys or G195GK. Alternatively insertion of an additional amino acid residue such as lysine after G195 may be indicated by: * 195aK. When more than one amino acid residue is inserted, such as e.g. a Lys and Ala after G195 this may be indicated as: Gly195Glyl_ysAla or G195GKA. In such cases, the inserted amino acid residue(s) may also be numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s), in this example: * 195aK * 195bA. In the above example, the sequences 194 to 196 would thus be:
  • Variants comprising multiple alterations are separated by addition marks ("+"), e.g., "Arg170Tyr+Gly195Glu” or "R170Y+G195E” representing a substitution of arginine and glycine at positions 170 and 195 with tyrosine and glutamic acid, respectively.
  • multiple alterations may be separated be space or a comma e.g. R170Y G195E or R170Y, G195E respectively.
  • alterations or optional substitutions may be indicated in brackets e.g. Arg170[Tyr, Gly] or Arg170 ⁇ Tyr, Gly ⁇ or in short R170 [Y,G] or R170 ⁇ Y, G ⁇ .
  • subtilase BPN' The amino acid sequence of subtilisin BPN' is the sequence of amino acids 1 to 275 of SEQ ID NO: 2 (Siezen et al., 1991 , Protein Eng. 4: 719-737).
  • Table 1 of WO 89/06279 shows the alignment of the mature polypeptide of the subtilase BPN' (BASBPN) sequence (sequence c in table 1 ) and the mature polypeptide of subtilisin 309 from B. Lentus, also known as Savinase®, (BLSAVI) (sequence a in table 1 ).
  • the present invention relates to subtilase variants with improved stability compared to its parent subtilase.
  • a particular preferred aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to its parent subtilase.
  • the subtilase variants according to the invention have at least 25% improved stability when measured as described in the accelerated storage stability assay in Example 3 herein compared to a subtilase with SEQ ID NO 1 .
  • a preferred aspect of the invention relates to variants of a subtilase parent, i.e.
  • subtilase variants having protease activity and having at least 25% improved stability compared to the parent subtilase when measured as described in the accelerated storage stability assay in Example 3, wherein the subtilase variant comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q
  • subtilase parent wherein the subtilase variant has at least 25% improved stability compared to the parent subtilase, wherein the subtilase variant comprises two or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N
  • the parent protease is preferably selected from proteases with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any of the polypeptides comprising the amino acid sequence SEQ ID NO: 1 ,SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ I D NO: 1 .
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 2.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 3.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 4.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 5.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 6.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 7,
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 9.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 10.
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 1 1 .
  • the subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 12.
  • subtilase variant has at least 25% improved stability compared to the parent subtilase
  • subtilase variant comprises two or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K,
  • subtilase variants having protease activity and having at least 50% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V
  • subtilase variants having protease activity and having at least 75% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V,
  • subtilase variants having protease activity and having at least 100% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V
  • subtilase variants having protease activity and having at least 25%, such as at least 30%, such as at least 35% such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 100%, such as at least 105%, such as at least 1 10%, such as at least 1 15% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15
  • Improved stability is in this context measured by the improvement factor as described in example 4 herein. Decrease in activity during incubation with detergent was assumed to be exponential. Half lifes (T1 ⁇ 2) were found from linear regression of Log(Activity) versus incubation time (0, 1 -4 and 20-25 hours), and half life improvement factors (T1 ⁇ 2 IF) were calculated as half life of subtilase variant relative to half life of the reference enzyme.
  • the reference enzyme in example 3 is Savinase (SEQ ID NO 1 ) with N76D mutation (SEQ ID NO 3).
  • the reference enzyme in examples 5 and 6 is SEQ ID NO 8.
  • the reference enzyme is preferably the parent subtilase in that way the contribution of each mutation can be measured.
  • the term improved stability is in this context the improvement factor as calculated above indicated as a percent improvement. Thus 25 % improvement corresponds to an improvement factor of 1 .25 and so forth.
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 1 comprises one or more, preferably two or more of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 2 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 2 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 3 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 3 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q
  • a preferred aspect relates to subtilase variants having protease activity, wherein the subtilase comprises the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185
  • subtilase variants having protease activity comprising the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E
  • subtilase variants having protease activity comprising the substitution N76D and two or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E
  • subtilase variants having protease activity comprising the substitution N76D and one or more, preferably two or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, N18S, S49T, G53A, G53L, G61 D, S78N, V104P, V104T, V104Y, V149Q, S161Y, I 162L, A194D, A194E, V205L, Y209L, M222A, P225S, V244H, N248H, T255Q, T260A, N261 R and L262Y, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1 .
  • subtilase variants having protease activity comprising the substitution N76D and one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L,
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 4 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 4 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 5 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 5 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 6 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 6 comprises, one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, S188E, S188C
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 7 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 7 comprises, one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H 120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E,
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 8 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q
  • subtilase variants having protease activity wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more substitutions selected from the group consisting of S3V, S3Y, S9M, P40E, N43E, N43D, R45E, H120I, H120D, A133E, Q182E, S188T, V205I, Q206E, S212D, N218D, A228S, Q236E, Q245R,S259D, L262Y and A270G, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 8.
  • subtilase variants having protease activity wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more, substitutions selected from the group consisting of S3V, S3Y, S9M, S9C, S9D, S9E, S9Q, P40E, N43E, N43D, N43A, N43C, N43L, N43R, N43W, R45E, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120D, H120I, H120T, H120V, P129D, A133E, V147W, V149C, 149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182E,Q182C, Q182E, N185C, N185E, S188T, S188C
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 9 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 9 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H 120I, H 120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, S188E, S188C
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 10 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 10 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 1 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 1 1 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, ⁇ 58 ⁇ , G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E
  • subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 12 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 12 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191
  • the subtilase variant has improved stability, in particular improved storage stability, compared to the mature polypeptide of the parent subtilase or to the polypeptide of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the subtilase variant has improved stability, in particular improved storage stability, and on par or improved wash performance compared to the polypeptide of the parent subtilase, to the polypeptide of SEQ ID NO: 1 SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variant comprise one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I,
  • the subtilase variant has at least 65% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 70% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 75% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 80% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 85% but less than 100% sequence identity to the mature polypeptide of the parent subtilase.
  • the subtilase variant has at least 90% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 93% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 95% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 96% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 97% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 98% but less than 100% sequence identity to the mature polypeptide of the parent subtilase.
  • the subtilase variant is encoded by a polynucleotide that has at least 65% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 70% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 75% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
  • the subtilase variant is encoded by a polynucleotide that has at least 80% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 85% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 90% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
  • the subtilase variant is encoded by a polynucleotide that has at least 93% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 95% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 96% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
  • the subtilase variant is encoded by a polynucleotide that has at least 97% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 98% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
  • the total number of alterations in the subtilase variant compared to the parent subtilase is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations.
  • total number of alterations in the parent subtilase is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
  • the parent subtilase may be any subtilase.
  • the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 1 .
  • the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 2.
  • the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 3.
  • the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 4.
  • the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 5.
  • the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 6.
  • the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 7.
  • the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 8. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 9. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 10. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 1 1 . In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 12.
  • subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q
  • the subtilase variant has at least 65% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In an embodiment, the subtilase variant has at least 70% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 75% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 80% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 85% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 .
  • the subtilase variant has at least 90% but less than 100% sequence identity to the polypeptide of SEQ I D NO: 1 . In an embodiment, the subtilase variant has at least 93% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 95% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 96% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 97% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.
  • the total number of alterations in the polypeptide of SEQ ID NO: 1 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations. In another aspect, total number of alterations in the polypeptide of SEQ ID NO: 1 is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
  • the subtilase variant has improved stability, in particular improved in storage stability, compared to the polypeptide of SEQ ID NO: 1 .
  • the subtilase variant has improved stability, in particular improved in wash stability, and/or on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 .
  • the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID N0:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more substitutions selected from the group consisting of X9C, 9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, 1201, X120T, X120V, X129D, X147W, X149C, X149
  • the subtilase variant has at least 65%, such as at least 70 %, such as at least 75 % , such as at least 80 % , such as at least 81 %, such as at least 82 %, such as at least 83 %, such as at least 84 %, such as at least 85 %, such as at least 86 %, such as at least 87 %, such as at least 88 %, such as at least 89 %, such as at least 90 % , such as at least 91 % , such as at least 92 % , such as at least 93 % , such as at least 94 % , such as at least 95 %, such as at least 96 % , such as at least 97 % , such as at least 98 % , such as at least 99%but less than 100% sequence identity to any of the polypeptides comprising the amino acid sequences of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4,
  • the total number of alterations in any of the parent polypeptides selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations.
  • total number of alterations in any of the parent polypeptides selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 and SEQ ID NO:12 is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
  • the subtilase variant has improved stability, in particular improved in storage stability, compared to any of the polypeptides with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the subtilase variant has improved stability, in particular improved in wash stability, and/or on par or improved wash performance compared to any of the polypeptides with SEQ ID NO:2, SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the parent subtilase is any of the subtilases SEQ ID NO 1 ,
  • SEQ ID NO:2 SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 and stabilizing mutations any of the particular preferred selected from the following substitutions S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261 C, N261 E, N2
  • subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase parent when measured in the accelerated storage stability assay in Example 3 herein wherein the subtilase variant comprise two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T,
  • stabilizing mutations are selected from the following substitutions S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E.
  • subtilase variants having protease activity and having at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2, wherein subtilase variant is a polypeptide that has at least 60% identity to the parent protease and wherein the parent protease is selected from SEQ ID NO 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO
  • the subtilase variant comprises or consists of one or more, preferably two or more, of the substitutions in table 1 , wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of one or more, preferably two or more of the substitutions in table 1 , wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1 .
  • the subtilase variant comprises an amino acid sequence that comprises one or more, preferably two or more, substitution(s) in comparison to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12, wherein the substitution(s) is/are selected from the substitutions of table 1 and wherein the positions correspond to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • Table 1 Subtilase Variants SEQ ID NO 1 , SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:
  • the parent subtilase is the subtilase having the amino acid sequence of SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S9C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S9D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S9Q in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N43A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution N43C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N43L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N43R in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N43W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution I72A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution I72V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S78D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution V104F in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • the subtilase variant comprises or consists of the substitution G1 15W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution H120I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution H120T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution H120V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution P129D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution V147W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • V149C in the polypeptide of SEQ ID NO: 1 wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution V149N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution A158E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution G160D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution G160P in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • the subtilase variant comprises or consists of the substitution S161 E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S163A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S163D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution Q182C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q182E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N185C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • N185E in the polypeptide of SEQ ID NO: 1 wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S188C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S188D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S188E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q191 N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • N204D in the polypeptide of SEQ ID NO: 1 wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N204V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution V205I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q206C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution Q206E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q206I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q206K in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • the subtilase variant comprises or consists of the substitution Q206V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q206W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Q206L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • the subtilase variant comprises or consists of the substitution S212D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S212G in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S212N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution S216I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S216T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S216V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution L217C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution L217M in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N218T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution M222C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution M222R in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • P225A in the polypeptide of SEQ ID NO: 1 wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution T255C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution T255E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S256A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution S256C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S256D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution S256V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • the subtilase variant comprises or consists of the substitution S259D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution T260E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution T260P in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261 C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • N261 E in the polypeptide of SEQ ID NO: 1 wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261 L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261 M in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution N261W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261Y in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution N261 F in the polypeptide of SEQ ID NO: 1 , wherein each position corresponds to the position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution L262C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution L262E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution L262Q in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • the variant is a polypeptide having the substitutions according to the invention and having an amino acid sequence which is at least 60 % identical to SEQ ID NO 1.
  • the subtilase variant comprises or consists of the substitution S9C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide having at least 60% such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1.
  • the subtilase variant comprises or consists of the substitution S9D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S9E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S9Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N43A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N43C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N43L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N43R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N43W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution I72A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution I72V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S78D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution H120I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least
  • the subtilase variant comprises or consists of the substitution H120T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution H120V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution P129D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution V147W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution V149C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution V149N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution A158E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution G160D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution G160P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S161 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S161 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence
  • the subtilase variant comprises or consists of the substitution S163A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S163D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Q182C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Q182E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N185C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N185E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S188C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S188D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S188E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Q191 N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N204D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N204V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution V205I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • subtilase variant comprises or consists of the substitution
  • subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Q206W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Q206L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution Y209W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S212A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S212D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S212G, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S212N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S216I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S216T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S216V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution L217C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution L217M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N218T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution M222C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution M222R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution P225A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution T255C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution T255E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S256A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S256C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S256D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S256V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S256Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution S259D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution T260E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution T260P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution N261 F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1.
  • the subtilase variant comprises or consists of the substitution L262C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution L262E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution L262Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
  • the subtilase variant comprises or consists of the substitution X9C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X9D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X9E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X9Q in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X43A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X43C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X43L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X43R in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X43W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X72A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X72V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X78D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X104F in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X1 14V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X1 15T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X1 15W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X120I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X120T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X120V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X129D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • subtilase variant comprises or consists of the substitution
  • X149C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X149N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X158E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X160D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X160P in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X161 C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X161 E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X163A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X163D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X182C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X182E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X185C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X185E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X188C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X188D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X188E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X191 N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X204D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X204V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X205I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206K in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X206L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X209W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X212A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X212D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X212G in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X212N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X216I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X216T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X216V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X217C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X217M in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X218T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X222C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X222R in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X225A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X255C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X255E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X256A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X256C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X256D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X256V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X256Y in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X259D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X260E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X260P in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261 C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261 E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261 L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X261 M in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • subtilase variant comprises or consists of the substitution
  • X261 V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261 W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261Y in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X261 F in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X262C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X262E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant comprises or consists of the substitution X262Q in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
  • the variant is a polypeptide having the substitutions according to the invention and having an amino acid sequence which is at least 60 % identical to SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution S9C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2..
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2..
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X72A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X72V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X78D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D N0:6, SEQ ID N0:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12 comprises or consists of the substitution X104F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 14V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 15T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 15W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X129D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X147W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X149C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X149N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X158E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X160D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X160P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X161 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X161 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X163A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X163D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X182C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X182E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X185C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X185E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X191 N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X204D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X204V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X205I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206K, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X209W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212G, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X217C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X217M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X218T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X222C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X222R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X225A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X255C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X255E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X259D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X260E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X260P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C,E,I,K,T,V, L or W preferably with L, C or W.
  • the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 1 ( ⁇ ' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2 is substituted with C, E or Q preferably with E or C.
  • the variant comprises or consists of the substitution L262E or L262C in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A
  • the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted with C, D, E or Q preferably with E.
  • the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted with L or W preferably with W.
  • the variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 212 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 212 of the polypeptide of SEQ ID NO: 2 is substituted with A, D, G or N preferably with D, G or N.
  • the variant comprises or consists of the substitution S212D, S212G or S212N in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, L, M V, W, Y or F preferably with W.
  • the variant comprises or consists of the substitution N261 W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C,E,I,K,T,V, L or W preferably with L, C or W.
  • the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 2 ( ⁇ ' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 262 of the polypeptide of SEQ ID NO 2 is substituted with C, E or Q preferably with E or C.
  • the variant comprises or consists of the substitution Y262E or Y262C in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A.
  • the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted with C, D, E or Q preferably with E.
  • the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted with W.
  • the variant comprises or consists of the substitution L209W in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
  • the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2.
  • the amino acid at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, L, M, V, W or Y preferably with W.
  • the variant comprises or consists of the substitution F261 W in the polypeptide of SEQ ID NO: 2 (BPN' numbering)
  • subtilase variants having protease activity wherein the variant comprises two of the substitutions selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A,
  • subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261 C, N261 E, N261 L, N261V, N261Y, N2
  • subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise two or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1
  • the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or to the polypeptide of SEQ ID NO: 2.
  • the subtilase variant has improved stability, in particular improved storage stability,
  • the subtilase variant comprises or consists of one or more of the substitutions set in table 2, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1 .
  • the subtilase variant comprises an amino acid sequence that comprises one or more substitution(s) in comparison to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ I D NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12, wherein the substitution(s) is/are selected from one or more of the substitutions sets of table 2 and wherein the positions correspond to the corresponding position of the polypeptide of SEQ ID NO: 2.
  • Table 2 Subtilase Variants SEQ ID NO 1 , SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:
  • G115W+N261E G115W+N261L G115W+N261M G115W+N261V G1 15W+N261Y G1 15W+N261W G1 15W+L262C G1 15W+L262E
  • V149C+N261 C V149C+N261 E V149C+N261 L V149C+N261 M

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.

Description

SUBTILASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME
Reference to a Sequence Listing
This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference.
Background of the Invention
Field of the Invention
The present invention relates to novel subtilase variants exhibiting increased stability and preferably on par or improved wash performance. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions. The present invention also relates to isolated DNA sequences encoding the variants, expression vectors, host cells, and methods for producing and using the variants of the invention.
Description of the Related Art
In the detergent industry, enzymes have for many decades been implemented in washing formulations. Enzymes used in such formulations comprise proteases, lipases, amylases, cellulases, mannosidases as well as other enzymes or mixtures thereof. Commercially the most important enzymes are proteases.
An increasing number of commercially used proteases are protein engineered variants of naturally occurring wild type proteases Everlase®, Relase®, Ovozyme®, Polarzyme®, Liquanase®, Liquanase Ultra® and Kannase® (Novozymes a/s), Purafast®, Purafect OXP®, FN3®, FN4® and Eraser®, Excellase® (Genencor International, Inc.). Further, a number of variants are described in the art, such as in WO2004/041979 (Novozymes A S) which describes subtilase variants exhibiting alterations relative to the parent subtilase in e.g. wash performance, thermal stability, storage stability or catalytic activity. The variants are suitable for use in e.g. cleaning or detergent compositions.
A number of useful subtilase variants have been described many of which have provided improved activity, stability, and solubility in different detergents
However, various factors make further improvement of the proteases advantageous. The washing conditions such as temperature and pH changes over time and many stains are still difficult to completely remove under conventional washing conditions. Further, in wash conditions can result in inactivation of the enzymes (due to e.g. pH, temperature or chelation instability) resulting in loss of wash performance during the wash cycle. Thus despite the intensive research in protease development there remains a need for new and improved proteases that have improved stability, in particular improved in wash stability, and preferably similar or improved wash performance compared to the parent subtilase.
Summary of the Invention
The present invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to its parent subtilase.
In one aspect, the invention relates to subtilase variants having protease activity and comprising one or more substitutions selected from the group consisting X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261W, X261Y, X261 F, X262C, X262E and X262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Another aspect of the invention relates to subtilase variants having protease activity, comprising two or more substitutions selected from the group consisting of: X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261W, X261Y, X261 F, X262C, X262E and X262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
The present invention also relates to subtilase variants having improved stability, in particular improved in wash stability, and preferably on par or improved wash performance compared to the parent or compared to a reference protease. The present invention further relates to polynucleotides encoding the subtilase variants; compositions, preferably detergent compositions, comprising a subtilase variant; use of the compositions in a cleaning process and methods for obtaining a subtilase variant and for removing a stain from a surface.
Definitions
The term "allelic variant" means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.
The term "cDNA" means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
The term "coding sequence" means a polynucleotide, which directly specifies the amino acid sequence of a variant. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon such as ATG, GTG or TTG and ends with a stop codon such as TAA, TAG, or TGA. The coding sequence may be a genomic DNA, cDNA, synthetic DNA, or a combination thereof.
The term "control sequences" means nucleic acid sequences necessary for expression of a polynucleotide encoding a variant of the present invention. Each control sequence may be native (i.e., from the same gene) or foreign (i.e., from a different gene) to the polynucleotide encoding the variant or native or foreign to each other. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding a variant.
The term "detergent component" is defined herein to mean the types of chemicals which can be used in detergent compositions. Examples of detergent components are surfactants, hydrotropes, builders, co-builders, chelators or chelating agents, bleaching system or bleach components, polymers, fabric hueing agents, fabric conditioners, foam boosters, suds suppressors, dispersants, dye transfer inhibitors, fluorescent whitening agents, perfume, optical brighteners, bactericides, fungicides, soil suspending agents, soil release polymers, anti- redeposition agents, enzyme inhibitors or stabilizers, enzyme activators, antioxidants, and solubilizers. The detergent composition may comprise of one or more of any type of detergent component.
The term "detergent composition" includes, unless otherwise indicated, all forms of detergent compositions such as gel, granulate, liquid, paste, powder, spray or tablet compositions including heavy-duty liquids (HDL), fine-fabric liquid detergents, liquid and/or solid laundry detergents and fine fabric detergents; hard surface cleaning formulations for e.g. glass, wood, ceramic and metal counter tops and windows; carpet cleaners; oven cleaners; fabric fresheners; fabric softeners; textile and laundry pre-spotters, as well as dish wash detergents such as hand dishwashing agents, light duty dishwashing agents, machine dishwashing agents; all-purpose or heavy-duty washing agents, liquid, gel or paste-form all-purpose washing agents, liquid cleaning and disinfecting agents, including antibacterial hand-wash types, cleaning bars, mouthwashes, denture cleaners, car or carpet shampoos, bathroom cleaners; hair shampoos and hair-rinses; shower gels, foam baths; metal cleaners; as well as cleaning auxiliaries such as bleach additives and "stain-stick" or pre-treat types.
In addition to containing a subtilase variant of the invention, the detergent formulation may contain one or more additional enzymes (such as proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidaes, haloperoxygenases, catalases and mannanases, or any mixture thereof), and/or components such as surfactants, builders, chelators or chelating agents, bleach system or bleach components, polymers, fabric conditioners, foam boosters, suds suppressors, dyes, perfume, tannish inhibitors, optical brighteners, bactericides, fungicides, soil suspending agents, anti-corrosion agents, enzyme inhibitors or stabilizers, enzyme activators, transferase(s), hydrolytic enzymes, oxido reductases, bluing agents and fluorescent dyes, antioxidants, and solubilizers.
The term "dish wash" refers to all forms of washing dishes, e.g. by hand or automatic dish wash. Washing dishes includes, but is not limited to, the cleaning of all forms of crockery such as plates, cups, glasses, bowls, all forms of cutlery such as spoons, knives, forks and serving utensils as well as ceramics, plastics such as melamine, metals, china, glass and acrylics.
The term "dish washing composition" refers to all forms of compositions for cleaning hard surfaces. The present invention is not restricted to any particular type of dish wash composition or any particular detergent.
The term "expression" includes any step involved in the production of a variant including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
The term "expression vector" means a linear or circular DNA molecule that comprises a polynucleotide encoding a variant and is operably linked to control sequences that provide for its expression.
The term "hard surface cleaning" is defined herein as cleaning of hard surfaces wherein hard surfaces may include floors, tables, walls, roofs etc. as well as surfaces of hard objects such as cars (car wash) and dishes (dish wash). Dish washing includes but are not limited to cleaning of plates, cups, glasses, bowls, and cutlery such as spoons, knives, forks, serving utensils, ceramics, plastics such as melamine, metals, china, glass and acrylics.
The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, or the like with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
The term "improved property" means a characteristic associated with a subtilase variant that is improved compared to the parent subtilase or compared to the polypeptide of SEQ ID NO: 1 , or compared to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant. Such improved properties include, but are not limited to, wash performance, protease activity, thermal activity profile, thermostability, pH activity profile, pH stability, substrate/cofactor specificity, improved surface properties, substrate specificity, product specificity, increased stability, improved stability under storage conditions, and chemical stability.
The term "stability" includes storage stability and stability during use, e.g. during a wash process and reflects the stability of the subtilase variant according to the invention as a function of time e.g. how much activity is retained when the subtilase variant is kept in solution in particular in a detergent solution. The stability is influenced by many factors e.g. pH, temperature, detergent composition e.g. amount of builder, surfactants etc. The stability of the subtilase variant may be measured using the assay described in Example 3 The term "improved stability" or "increased stability" is defined herein as a variant subtilase displaying an increased stability in solutions, relative to the stability of the parent subtilase, relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant or relative to SEQ ID NO: 1 . The terms "improved stability" and "increased stability" includes "improved chemical stability", "detergent stability" or "improved detergent stability.
The term "improved chemical stability" is defined herein as a variant subtilase displaying retention of enzymatic activity after a period of incubation in the presence of a chemical or chemicals, either naturally occurring or synthetic, which reduces the enzymatic activity of the parent enzyme. Improved chemical stability may also result in variants being more able to catalyze a reaction in the presence of such chemicals. In a particular aspect of the invention the improved chemical stability is an improved stability in a detergent, in particular in a liquid detergent. The term "detergent stability" or "improved detergent stability is in particular an improved stability of the protease activity when a subtilase variant of the present invention is mixed into a liquid detergent formulation, especially into a liquid detergent formulation according to table 1 and then stored at temperatures between 15 and 50 °C, e. g. 20°C, 30°C or 40°C.
The term "improved thermal activity" means a variant displaying an altered temperature- dependent activity profile at a specific temperature relative to the temperature-dependent activity profile of the parent, relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant or relative to a protease with SEQ ID NO: 1 . Thermal activity value provides a measure of the variant's efficiency in enhancing catalysis of a hydrolysis reaction over a range of temperatures. A more thermo active variant will lead to an increase in enhancing the rate of hydrolysis of a substrate by an enzyme composition thereby decreasing the time required and/or decreasing the enzyme concentration required for activity. Alternatively, a variant with a reduced thermal activity will enhance an enzymatic reaction at a temperature lower than the temperature optimum of the parent defined by the temperature- dependent activity profile of the parent.
The term "improved wash performance" is defined herein as a subtilase variant according to the invention displaying an improved wash performance relative to the wash performance of the parent protease, relative to a polypeptide with SEQ ID NO: 1 or relative to a subtilase having the identical amino acid sequence of the variant but excluding the alterations in the variant e.g. by increased stain removal. The term "wash performance" includes wash performance in laundry but also e.g. in dish wash. The wash performance may be quantified as described under the definition of "wash performance" herein.
The term "isolated" means a substance in a form or environment which does not occur in nature. Non-limiting examples of isolated substances include (1 ) any non-naturally occurring substance, (2) any substance including, but not limited to, any enzyme, variant, nucleic acid, protein, peptide or cofactor, that is at least partially removed from one or more or all of the naturally occurring constituents with which it is associated in nature; (3) any substance modified by the hand of man relative to that substance found in nature; or (4) any substance modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.
The term "laundering" relates to both household laundering and industrial laundering and means the process of treating textiles and/or fabrics with a solution containing a detergent composition of the present invention. The laundering process can for example be carried out using e.g. a household or an industrial washing machine or can be carried out by hand.
The term "mature polypeptide" means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, autocatalytic activation etc. In one aspect, the mature polypeptide is amino acids 1 to 269 of SEQ ID NO: 1 and 1 to 275 of SEQ ID NO: 2. It is known in the art that a host cell may produce a mixture of two of more different mature polypeptides (i.e., with a different C-terminal and/or N-terminal amino acid) expressed by the same polynucleotide.
The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide having protease activity.
The term "mutant" means a polynucleotide encoding a variant. The term "nucleic acid construct" means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic, which comprises one or more control sequences.
The term "operably linked" means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs expression of the coding sequence.
The term "parent" means a protease to which an alteration is made to produce the subtilase variants of the present invention. Thus the parent is a subtilase having the identical amino acid sequence of the variant but not having the alterations at one or more e.g. two or more of the specified positions. It will be understood that in the present context the expression "having identical amino acid sequence" relates to 100% sequence identity. In a particular embodiment the parent is a protease with at least 60 % identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any of the polypeptides comprising the amino acid sequence of SEQ ID NO: 1 .SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12. Examples of parent proteases and parent subtilases are described in "parent proteases".
The term "protease" is defined herein as an enzyme that hydrolyses peptide bonds. It includes any enzyme belonging to the EC 3.4 enzyme group (including each of the thirteen subclasses thereof). The EC number refers to Enzyme Nomenclature 1992 from NC-IUBMB, Academic Press, San Diego, California, including supplements 1 -5 published in Eur. J. Biochem. 1994, 223, 1 -5; Eur. J. Biochem. 1995, 232, 1 -6; Eur. J. Biochem. 1996, 237, 1 -5; Eur. J. Biochem. 1997, 250, 1 -6; and Eur. J. Biochem. 1999, 264, 610-650; respectively. The most widely used proteases in the detergent industry such as laundry and dish wash are the serine proteases or serine peptidases which is a subgroup of proteases characterised by having a serine in the active site, which forms a covalent adduct with the substrate. Further the subtilases (and the serine proteases) are characterised by having two active site amino acid residues apart from the serine, namely a histidine and an aspartic acid residue. Subtilase refer to a sub-group of serine protease according to Siezen et al., Protein Engng. 4 (1991 ) 719-737 and Siezen et al. Protein Science 6 (1997) 501 -523. The subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family. The term "protease activity" means a proteolytic activity (EC 3.4). Proteases usably in detergents are mainly endopeptidases (EC 3.4.21 ). There are several protease activity types: The three main activity types are: trypsin-like where there is cleavage of amide substrates following Arg or Lys at P1 , chymotrypsin-like where cleavage occurs following one of the hydrophobic amino acids at P1 , and elastase-like with cleavage following an Ala at P1. For purposes of the present invention, protein activity, such as protease activity is determined according to the procedure described in the Examples section below. In one aspect, the subtilase variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the enzyme activity of the mature polypeptide of the parent enzyme. In one particular aspect the subtilase variants of the present invention have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% of the protease activity of the polypeptide of SEQ ID NO: 1.
The term "protease activity" means a proteolytic activity (EC 3.4). Proteases of the invention are endopeptidases (EC 3.4.21 ). There are several protease activity types: The three main activity types are: trypsin-like where there is cleavage of amide substrates following Arg or Lys at P1 , chymotrypsin-like where cleavage occurs following one of the hydrophobic amino acids at P1 , and elastase-like with cleavage following an Ala at P1 . For purposes of the present invention, protease activity is determined according to the Suc-AAPF-pNA activity assay described in "Materials and Methods" herein. The subtilase variants of the present invention preferably have at least 20%, e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, and at least 100% of the protease activity of the polypeptide of SEQ ID NO: 1 .
The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity". For purposes of the present invention, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
(Identical Residues x 100)/(Length of Alignment - Total Number of Gaps in Alignment). For purposes of the present invention, the sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, supra), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
(Identical Deoxyribonucleotides x 100)/(Length of Alignment - Total Number of Gaps in Alignment).
The term "substantially pure variant" means a preparation that contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polypeptide material with which it is natively or recombinantly associated. Preferably, the variant is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation. The variants of the present invention are preferably in a substantially pure form. This can be accomplished, for example, by preparing the variant by well-known recombinant methods or by classical purification methods.
The term "substantially pure polynucleotide" means a polynucleotide preparation free of other extraneous or unwanted nucleotides and in a form suitable for use within genetically engineered polypeptide production systems. Thus, a substantially pure polynucleotide contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polynucleotide material with which it is natively or recombinantly associated. A substantially pure polynucleotide may, however, include naturally occurring 5'- and 3'- untranslated regions, such as promoters and terminators. It is preferred that the substantially pure polynucleotide is at least 90% pure, e.g., at least 92% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, and at least 99.5% pure by weight. The polynucleotides of the present invention are preferably in a substantially pure form.
The term "textile" means any textile material including yarns, yarn intermediates, fibers, non-woven materials, natural materials, synthetic materials, as well as fabrics made of these materials such as garments, cloths and other articles. When the term fabric or garment is used it is intended to include the broader term textiles as well.
The term "variant" means a polypeptide having protease activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions compared to the parent protease. A substitution means replacement of the amino acid occupying a position with a different amino acid; a deletion means removal of the amino acid occupying a position; and an insertion means adding one or more (e.g. several) amino acids, e.g. 1 , 2, 3, 4 or 5 amino acids adjacent to and immediately following the amino acid occupying a position. The term subtilase variant means a variant of a subtilase parent i.e. a subtilase variant and is a subtilase which comprises alterations i.e., a substitution, insertion, and/or deletion, at one or more (e.g., several) positions compared to the parent subtilase. The term "wash performance" is used as an enzyme's ability to remove stains present on the object to be cleaned during e.g. wash, such as laundry or hard surface cleaning. The improvement in the wash performance may be quantified by calculating the so-called intensity value (Int) defined in AMSA assay, as described in Materials and Methods section.
The term "wild-type subtilase" means a protease expressed by a naturally occurring organism, such as a bacterium, archaea, yeast, fungus, plant or animal found in nature. An example of a wild-type subtilase is Savinase i.e. amino acid 1 to 269 of SEQ ID NO 1 or BPN' i.e. amino acid 1 to 275 of SEQ ID NO: 2.
Conventions for Designation of Variants
For purposes of the present invention, the polypeptide (ΒΡΝ') disclosed in SEQ ID NO: 2 is used to determine the corresponding amino acid residue in another protease. The amino acid sequence of another protease is aligned with the mature polypeptide disclosed in SEQ ID NO: 2, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the polypeptide disclosed in SEQ ID NO: 2 is determined using the Needleman- Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or later. The parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
Identification of the corresponding amino acid residue in another protease can be determined by an alignment of multiple polypeptide sequences using several computer programs including, but not limited to, MUSCLE (multiple sequence comparison by log- expectation; version 3.5 or later; Edgar, 2004, Nucleic Acids Research 32: 1792-1797), MAFFT (version 6.857 or later; Katoh and Kuma, 2002, Nucleic Acids Research 30: 3059-3066; Katoh et al., 2005, Nucleic Acids Research 33: 51 1 -518; Katoh and Toh, 2007, Bioinformatics 23: 372- 374; Katoh et al., 2009, Methods in Molecular Biology 537:_39-64; Katoh and Toh, 2010, Bioinformatics 26:_1899-1900), and EMBOSS EMMA employing ClustalW (1 .83 or later; Thompson et al., 1994, Nucleic Acids Research 22: 4673-4680), using their respective default parameters.
When the other enzyme has diverged from the mature polypeptide of SEQ ID NO: 2 such that traditional sequence-based comparison fails to detect their relationship (Lindahl and Elofsson, 2000, J. Mol. Biol. 295: 613-615), other pairwise sequence comparison algorithms can be used. Greater sensitivity in sequence-based searching can be attained using search programs that utilize probabilistic representations of polypeptide families (profiles) to search databases. For example, the PSI-BLAST program generates profiles through an iterative database search process and is capable of detecting remote homologs (Atschul et al., 1997, Nucleic Acids Res. 25: 3389-3402). Even greater sensitivity can be achieved if the family or superfamily for the polypeptide has one or more representatives in the protein structure databases. Programs such as GenTHREADER (Jones, 1999, J. Mol. Biol. 287: 797-815; McGuffin and Jones, 2003, Bioinformatics 19: 874-881 ) utilize information from a variety of sources (PSI-BLAST, secondary structure prediction, structural alignment profiles, and solvation potentials) as input to a neural network that predicts the structural fold for a query sequence. Similarly, the method of Gough et al., 2000, J. Mol. Biol. 313: 903-919, can be used to align a sequence of unknown structure with the superfamily models present in the SCOP database. These alignments can in turn be used to generate homology models for the polypeptide, and such models can be assessed for accuracy using a variety of tools developed for that purpose.
For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of proteins have been structurally aligned, and those alignments are accessible and downloadable. Two or more protein structures can be aligned using a variety of algorithms such as the distance alignment matrix (Holm and Sander, 1998, Proteins 33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998, Protein Engineering 1 1 : 739-747), and implementation of these algorithms can additionally be utilized to query structure databases with a structure of interest in order to discover possible structural homologs (e.g., Holm and Park, 2000, Bioinformatics 16: 566-567).
In describing the variants of the present invention, the nomenclature described below is adapted for ease of reference. The accepted lUPAC single letter or three letter amino acid abbreviation is employed.
Substitutions. For an amino acid substitution, the following nomenclature is used: Original amino acid, position, substituted amino acid. Accordingly, the substitution of Histidine at position 226 with alanine is designated as "His226Ala" or Ή226Α". Multiple mutations may be separated by addition marks ("+"), e.g., "Ne205Arg + Leu217Phe" or "I205R + L217F", representing substitutions at positions 205 and 217 of isoleucine (I) with arginine (R) and leucine (L) with phenylalanine (F), respectively. In the context of present application substitutions are usually indicated with the amino acid present in Savinase (SEQ ID NO 1 ) at a position corresponding to the position of BPN' (SEQ ID NO 2). As described in "parent protease" various parent proteases are suitable for making the variants disclosed. It will be clear to the skilled artisan that the amino acid substituted i.e. the preceding amino acid may be different from those of Savinase (SEQ ID NO 1 ) if the variants is made from another parent. This could be shown by an X representing any amino acid indicating that any original amino acid at the position may be substituted. For example, X9E means that any amino acid residue at position 9 other than E is substituted with E.
Deletions. For an amino acid deletion, the following nomenclature is used: Original amino acid, position, *. Accordingly, the deletion of glycine at position 195 is designated as "Gly195*" or "G195*". Multiple deletions are separated by addition marks ("+"), e.g., "Gly195* + Ser9*" or "G195* + S9*".
Insertions: The insertion of an additional amino acid residue such as e.g. a lysine after G195 may be indicated by: Gly195Glyl_ys or G195GK. Alternatively insertion of an additional amino acid residue such as lysine after G195 may be indicated by: *195aK. When more than one amino acid residue is inserted, such as e.g. a Lys and Ala after G195 this may be indicated as: Gly195Glyl_ysAla or G195GKA. In such cases, the inserted amino acid residue(s) may also be numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s), in this example: *195aK *195bA. In the above example, the sequences 194 to 196 would thus be:
194 195 196
Savinase A - G - L
194 195 195a 195b 196
Variant A - G - K - A - L
In cases where a substitution and an insertion occur at the same position, this may be indicated as S99SD+S99A or in short S99AD. The same modification may also be indicated as S99A + *99aD.
In cases where an amino acid residue identical to the existing amino acid residue is inserted, it is clear that degeneracy in the nomenclature arises. If for example a glycine is inserted after the glycine in the above example this would be indicated by G195GG or *195GaG. The same actual change could just as well be indicated as A194AG or *194aG for the change from:
194 195 196
Savinase A - G - L
To:
194 195 195a 196
Variant A - G - G - L
194 194a 195 196
Such instances will be apparent to the skilled person and the indication G195GG and corresponding indications for this type of insertions are thus meant to comprise such equivalent degenerate indications.
Multiple alterations: Variants comprising multiple alterations are separated by addition marks ("+"), e.g., "Arg170Tyr+Gly195Glu" or "R170Y+G195E" representing a substitution of arginine and glycine at positions 170 and 195 with tyrosine and glutamic acid, respectively. Alternatively multiple alterations may be separated be space or a comma e.g. R170Y G195E or R170Y, G195E respectively.
Different alterations: Where different alterations can be introduced at a position, the different alterations are separated by a comma, e.g., "Arg170Tyr,Glu" represents a substitution of arginine at position 170 with tyrosine or glutamic acid. Thus, "Tyr167Gly,Ala + Arg170Gly,Ala" designates the following variants:
"Tyr167Gly+Arg170Gly", "Tyr167Gly+Arg170Ala", "Tyr167Ala+Arg170Gly", and "Tyr167Ala+Arg170Ala".
Alternatively different alterations or optional substitutions may be indicated in brackets e.g. Arg170[Tyr, Gly] or Arg170{Tyr, Gly} or in short R170 [Y,G] or R170 {Y, G}.
Numbering of amino acid positions/residues
Unless otherwise indicated, the amino acid numbering used herein corresponds to the amino acid sequence of subtilase BPN' (BASBPN). The amino acid sequence of subtilisin BPN' is the sequence of amino acids 1 to 275 of SEQ ID NO: 2 (Siezen et al., 1991 , Protein Eng. 4: 719-737).
Table 1 of WO 89/06279 shows the alignment of the mature polypeptide of the subtilase BPN' (BASBPN) sequence (sequence c in table 1 ) and the mature polypeptide of subtilisin 309 from B. Lentus, also known as Savinase®, (BLSAVI) (sequence a in table 1 ). Detailed Description of the Invention
The present invention relates to subtilase variants with improved stability compared to its parent subtilase. A particular preferred aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to its parent subtilase. Preferably the subtilase variants according to the invention have at least 25% improved stability when measured as described in the accelerated storage stability assay in Example 3 herein compared to a subtilase with SEQ ID NO 1 . A preferred aspect of the invention relates to variants of a subtilase parent, i.e. "subtilase variants" having protease activity and having at least 25% improved stability compared to the parent subtilase when measured as described in the accelerated storage stability assay in Example 3, wherein the subtilase variant comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Each of the above single mutations increase the stability compared to the parent subtilase. Thus introducing any of the above substitutions in a subtilase parent provide increased stability.
As mentioned, each of the single mutations increase the stability compared to the parent subtilase adding two, three, four etc. of these mutations increase the stability even further as could be seen in Example 4. Thus a preferred aspect of the invention relates to variants of a subtilase parent wherein the subtilase variant has at least 25% improved stability compared to the parent subtilase, wherein the subtilase variant comprises two or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
The parent protease is preferably selected from proteases with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to any of the polypeptides comprising the amino acid sequence SEQ ID NO: 1 ,SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12.
The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ I D NO: 1 . The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 2. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 3. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 4. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 5. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 6. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 7, The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 8. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 9. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 10. The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 1 1 . The subtilase variant is preferably selected from subtilase variants with at least 60% identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to the polypeptide comprising the amino acid sequence SEQ ID NO: 12.
One aspect of the invention relates to variants of a subtilase parent wherein the subtilase variant has at least 25% improved stability compared to the parent subtilase, wherein the subtilase variant comprises two or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 60 % identity, such as at least 65%, at least 70%, at least 75%, at least 80%, at least 81 %, at least 82%, at least 83%, at least 84%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, but less than 100% identity to a polypeptide with SEQ ID NO: 1 ,SEQ I D NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12.
One preferred aspect of the invention relates to subtilase variants having protease activity and having at least 50% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Another preferred aspect of the invention relates to subtilase variants having protease activity and having at least 75% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Another preferred aspect of the invention relates to subtilase variants having protease activity and having at least 100% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Another preferred aspect of the invention relates to subtilase variants having protease activity and having at least 25%, such as at least 30%, such as at least 35% such as at least 40%, such as at least 45%, such as at least 50%, such as at least 55%, such as at least 60%, such as at least 65%, such as at least 70%, such as at least 75%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 100%, such as at least 105%, such as at least 1 10%, such as at least 1 15% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Improved stability is in this context measured by the improvement factor as described in example 4 herein. Decrease in activity during incubation with detergent was assumed to be exponential. Half lifes (T½) were found from linear regression of Log(Activity) versus incubation time (0, 1 -4 and 20-25 hours), and half life improvement factors (T½ IF) were calculated as half life of subtilase variant relative to half life of the reference enzyme. The reference enzyme in example 3 is Savinase (SEQ ID NO 1 ) with N76D mutation (SEQ ID NO 3). The reference enzyme in examples 5 and 6 is SEQ ID NO 8. The reference enzyme is preferably the parent subtilase in that way the contribution of each mutation can be measured. The term improved stability is in this context the improvement factor as calculated above indicated as a percent improvement. Thus 25 % improvement corresponds to an improvement factor of 1 .25 and so forth.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 1 comprises one or more, preferably two or more of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 1 .
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 2 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 2 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 2.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 3 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 3 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 3.
A preferred aspect relates to subtilase variants having protease activity, wherein the subtilase comprises the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191 N, A194D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261 D, N261 C, N261 E, N261 L, N261 M, N261 R, N261V, N261W, N261Y, N261 F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
Another aspect of the invention relates to subtilase variants having protease activity, comprising the substitution N76D and one or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191 N, A194D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261 D, N261 C, N261 E, N261 L, N261 M, N261 R, N261V, N261W, N261Y, N261 F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1.
Another aspect of the invention relates to subtilase variants having protease activity, comprising the substitution N76D and two or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191 N, A194D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261 D, N261 C, N261 E, N261 L, N261 M, N261 R, N261V, N261W, N261Y, N261 F, L262Y, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1. One preferred aspect of the invention relates to subtilase variants having protease activity, comprising the substitution N76D and one or more, preferably two or more substitutions selected from the group consisting of Q2R, W6I, I8C, I8H, N18S, S49T, G53A, G53L, G61 D, S78N, V104P, V104T, V104Y, V149Q, S161Y, I 162L, A194D, A194E, V205L, Y209L, M222A, P225S, V244H, N248H, T255Q, T260A, N261 R and L262Y, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1 .
Another preferred aspect of the invention relates to subtilase variants having protease activity, comprising the substitution N76D and one or more, preferably two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261 W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1 .
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 4 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 4 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 4.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 5 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 5 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 5.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 6 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 6 comprises, one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 6.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 7 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 7 comprises, one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H 120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 7.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 8 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 8.
One preferred aspect of the invention relates to subtilase variants having protease activity, wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more substitutions selected from the group consisting of S3V, S3Y, S9M, P40E, N43E, N43D, R45E, H120I, H120D, A133E, Q182E, S188T, V205I, Q206E, S212D, N218D, A228S, Q236E, Q245R,S259D, L262Y and A270G, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 8.
Another preferred aspect of the invention relates to subtilase variants having protease activity, wherein the subtilase variant compared to SEQ ID NO 8 comprises one or more, preferably two or more, substitutions selected from the group consisting of S3V, S3Y, S9M, S9C, S9D, S9E, S9Q, P40E, N43E, N43D, N43A, N43C, N43L, N43R, N43W, R45E, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120D, H120I, H120T, H120V, P129D, A133E, V147W, V149C, 149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182E,Q182C, Q182E, N185C, N185E, S188T, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, N218D, M222C, M222R, P225A, A228S, Q236E, Q245R, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262Y, L262C, L262E, L262Q and A270G, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1 .
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 9 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 9 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H 120I, H 120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 9.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 10 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 10 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 10.
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 1 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 1 1 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, ΤΊ 58Ε, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 1 1 .
One aspect of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 12 when measured in the accelerated storage stability assay in Example 3 as described herein and wherein the subtilase variant compared to SEQ ID NO 12 comprises one or more, preferably two or more, of substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I 1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261W, Y262C, Y262E and Y262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has at least 80 % identity to SEQ ID NO: 12.
In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the mature polypeptide of the parent subtilase or to the polypeptide of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12. In a preferred embodiment, the subtilase variant has improved stability, in particular improved storage stability, and on par or improved wash performance compared to the polypeptide of the parent subtilase, to the polypeptide of SEQ ID NO: 1 SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
In one embodiment, the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay in Example 3 herein, wherein the subtilase variant comprise one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is
a) a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of the parent subtilase; or
b) a polypeptide that is encoded by a polynucleotide having at least 60% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
In an embodiment, the subtilase variant has at least 65% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 70% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 75% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 80% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 85% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 90% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 93% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 95% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 96% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 97% but less than 100% sequence identity to the mature polypeptide of the parent subtilase. In an embodiment, the subtilase variant has at least 98% but less than 100% sequence identity to the mature polypeptide of the parent subtilase.
In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 65% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 70% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 75% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 80% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 85% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 90% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 93% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 95% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 96% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 97% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase. In an embodiment, the subtilase variant is encoded by a polynucleotide that has at least 98% but less than 100% sequence identity to the mature polypeptide coding sequence of the parent subtilase.
In one aspect, the total number of alterations in the subtilase variant compared to the parent subtilase is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations. In another aspect, total number of alterations in the parent subtilase is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
The parent subtilase may be any subtilase. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 1 . In one aspect the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 2. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 3. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 4. In one aspect, the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 5. In one aspect, the parent subtilase is amino acids 1 to 270 of SEQ ID NO: 6. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 7. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 8. In one aspect, the parent subtilase is amino acids 1 to 269 of SEQ ID NO: 9. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 10. In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 1 1 . In one aspect, the parent subtilase is amino acids 1 to 275 of SEQ ID NO: 12.
One embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more, preferably two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO 1 ;
In an embodiment, the subtilase variant has at least 65% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1. In an embodiment, the subtilase variant has at least 70% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 75% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 80% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 85% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 90% but less than 100% sequence identity to the polypeptide of SEQ I D NO: 1 . In an embodiment, the subtilase variant has at least 93% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 95% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 96% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 97% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 . In an embodiment, the subtilase variant has at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1.
In one aspect, the total number of alterations in the polypeptide of SEQ ID NO: 1 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations. In another aspect, total number of alterations in the polypeptide of SEQ ID NO: 1 is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
In one embodiment, the subtilase variant has improved stability, in particular improved in storage stability, compared to the polypeptide of SEQ ID NO: 1 . In a preferred embodiment, the subtilase variant has improved stability, in particular improved in wash stability, and/or on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 .
In one embodiment, the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID N0:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more substitutions selected from the group consisting of X9C, 9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, 1201, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, 185E, 188C, 188D, 188E, 191 N, 204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261 W, X261Y, X261 F, X262C, X262E and X262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12;
In an embodiment, the subtilase variant has at least 65%, such as at least 70 %, such as at least 75 % , such as at least 80 % , such as at least 81 %, such as at least 82 %, such as at least 83 %, such as at least 84 %, such as at least 85 %, such as at least 86 %, such as at least 87 %, such as at least 88 %, such as at least 89 %, such as at least 90 % , such as at least 91 % , such as at least 92 % , such as at least 93 % , such as at least 94 % , such as at least 95 %, such as at least 96 % , such as at least 97 % , such as at least 98 % , such as at least 99%but less than 100% sequence identity to any of the polypeptides comprising the amino acid sequences of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
In one aspect, the total number of alterations in any of the parent polypeptides selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations. In another aspect, total number of alterations in any of the parent polypeptides selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 and SEQ ID NO:12 is 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 alterations.
In one embodiment, the subtilase variant has improved stability, in particular improved in storage stability, compared to any of the polypeptides with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12. In one embodiment, the subtilase variant has improved stability, in particular improved in wash stability, and/or on par or improved wash performance compared to any of the polypeptides with SEQ ID NO:2, SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
In one particular embodiment, the parent subtilase is any of the subtilases SEQ ID NO 1 ,
SEQ ID NO:2, SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 and stabilizing mutations any of the particular preferred selected from the following substitutions S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261 C, N261 E, N261 L, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q. Each of these mutations provides significantly improved stability. As mentioned the inventors found that adding two, three, four, five, six, seven or even more of the stabilizing mutations increases the stabilizing effect even further. Thus a particular preferred embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase parent when measured in the accelerated storage stability assay in Example 3 herein wherein the subtilase variant comprise two or more, substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261 C, N261 E, N261 L, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% but less than 100% sequence identity to the parent subtilase, wherein the parent protease is selected from SEQ ID NO 1 , SEQ I D NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 and SEQ ID NO:12.
Even more particular preferred stabilizing mutations are selected from the following substitutions S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E. Thus another preferred embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the parent subtilase when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise one or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2, wherein subtilase variant is a polypeptide that has at least 60% identity to the parent protease and wherein the parent protease is selected from SEQ ID NO 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 and SEQ ID NO:12.
In one aspect of the invention, the subtilase variant comprises or consists of one or more, preferably two or more, of the substitutions in table 1 , wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one aspect of the invention, the subtilase variant comprises or consists of one or more, preferably two or more of the substitutions in table 1 , wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1 . In one aspect of the invention, the subtilase variant comprises an amino acid sequence that comprises one or more, preferably two or more, substitution(s) in comparison to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12, wherein the substitution(s) is/are selected from the substitutions of table 1 and wherein the positions correspond to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12. In a preferred embodiment, the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 or to any of the polypeptides of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
Table 1 : Subtilase Variants SEQ ID NO 1 , SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID
NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
NO:1 1 or SEQ ID NO:12 + one or more mutation(s) listed below
Figure imgf000032_0001
172 A Q191 N S256A
172 V N204D S256C
S78D N204V S256D
V104F V205I S256V
A114V Q206C S256Y
G1 15T Q206E S259D
G1 15W Q206I T260E
H120I Q206K T260P
H120T Q206T N261 C
H120V Q206V N261 E
P129D Q206W N261 L
V147W Q206L N261 M
V149C Y209W N261V
V149N S212A N261Y
A158E S212D N261 F
G160D S212G N261W
G160P S212N L262C
S161 C S216I L262E
S161 E S216T L262Q
In one embodiment, the parent subtilase is the subtilase having the amino acid sequence of SEQ ID NO: 1 . Thus in one embodiment, the subtilase variant comprises or consists of the substitution S9C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S9D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S9Q in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N43A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution N43C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N43L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N43R in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N43W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution I72A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution I72V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S78D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution V104F in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
G1 15T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution G1 15W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution H120I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution H120T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution H120V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution P129D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution V147W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
V149C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution V149N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution A158E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution G160D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution G160P in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
S161 C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S161 E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S163A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S163D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution Q182C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q182E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N185C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
N185E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S188C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S188D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S188E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q191 N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
N204D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N204V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution V205I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution Q206E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206K in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Q206L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
S212A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S212D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S212G in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S212N in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution S216I in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S216T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S216V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution L217C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution L217M in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N218T in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution M222C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution M222R in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
P225A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution T255C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution T255E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S256A in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution S256C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S256D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S256V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
S256Y in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution S259D in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution T260E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution T260P in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261 C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
N261 E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261 L in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261 M in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261V in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution N261W in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261Y in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution N261 F in the polypeptide of SEQ ID NO: 1 , wherein each position corresponds to the position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution L262C in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution L262E in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution L262Q in the polypeptide of SEQ ID NO: 1 , wherein the position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In a preferred embodiment of the invention, the variant is a polypeptide having the substitutions according to the invention and having an amino acid sequence which is at least 60 % identical to SEQ ID NO 1. Thus in one embodiment, the subtilase variant comprises or consists of the substitution S9C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide having at least 60% such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1.
In one embodiment, the subtilase variant comprises or consists of the substitution S9D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S9E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S9Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N43A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N43C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N43L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N43R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N43W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution I72A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution I72V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S78D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
V104F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
A1 14V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
G1 15T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
G1 15W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution H120I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least
80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution H120T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 . In one embodiment, the subtilase variant comprises or consists of the substitution H120V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution P129D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution V147W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution V149C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution V149N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution A158E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution G160D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution G160P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S161 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S161 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence In one embodiment, the subtilase variant comprises or consists of the substitution S163A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S163D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution Q182C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution Q182E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N185C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N185E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S188C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S188D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S188E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution Q191 N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N204D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N204V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution V205I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206K, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution
Q206V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 . In one embodiment, the subtilase variant comprises or consists of the substitution Q206W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution Q206L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution Y209W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S212A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S212D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S212G, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S212N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S216I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S216T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S216V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution L217C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution L217M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N218T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution M222C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution M222R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution P225A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution T255C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution T255E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S256A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S256C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S256D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S256V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 . In one embodiment, the subtilase variant comprises or consists of the substitution S256Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution S259D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution T260E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution T260P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution N261 F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1.
In one embodiment, the subtilase variant comprises or consists of the substitution L262C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution L262E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution L262Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2, and wherein the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to the amino acid sequence with SEQ ID NO: 1 .
In one embodiment, the subtilase variant comprises or consists of the substitution X9C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X9D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X9E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X9Q in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X43A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X43C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X43L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X43R in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X43W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X72A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X72V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X78D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X104F in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X1 14V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X1 15T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X1 15W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X120I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution X120T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X120V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X129D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X147W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X149C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X149N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X158E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X160D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X160P in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X161 C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X161 E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X163A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X163D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X182C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X182E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution X185C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X185E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X188C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X188D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X188E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X191 N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X204D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X204V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X205I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206K in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X206L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X209W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X212A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X212D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X212G in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X212N in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X216I in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution X216T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X216V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X217C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X217M in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X218T in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X222C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X222R in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X225A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X255C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X255E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X256A in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X256C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X256D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X256V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X256Y in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2. In one embodiment, the subtilase variant comprises or consists of the substitution X259D in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X260E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X260P in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261 C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261 E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261 L in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X261 M in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution
X261 V in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261 W in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261Y in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X261 F in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X262C in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X262E in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant comprises or consists of the substitution X262Q in any of the polypeptides of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of SEQ ID NO: 2.
In another preferred embodiment of the invention the variant is a polypeptide having the substitutions according to the invention and having an amino acid sequence which is at least 60 % identical to SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution S9C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2..
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X9Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2..
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X43W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X72A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X72V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X78D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D N0:6, SEQ ID N0:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12 comprises or consists of the substitution X104F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 14V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 15T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X1 15W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X120V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X129D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X147W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X149C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X149N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X158E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X160D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X160P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X161 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X161 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X163A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X163D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X182C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X182E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X185C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X185E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X188E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X191 N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X204D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X204V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X205I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206K, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X206L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X209W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212G, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X212N, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216I, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X216V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X217C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ I D NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X217M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X218T, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X222C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X222R, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X225A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ I D NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X255C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X255E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256A, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X256Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X259D, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X260E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X260P, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ I D NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 L, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 M, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261V, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261W, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261Y, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X261 F, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ I D NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262C, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262E, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one embodiment, the subtilase variant is a polypeptide having at least 60%, such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95% sequence identity to any of the amino acid sequences with SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein the subtilase variant compared to any of SEQ ID NO: 2, SEQ ID NO:3, SEQ I D NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ I D NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises or consists of the substitution X262Q, wherein the position corresponds to the corresponding position of SEQ ID NO: 2.
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C,E,I,K,T,V, L or W preferably with L, C or W. In another aspect, the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 1 (ΒΡΝ' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2 is substituted with C, E or Q preferably with E or C. In another aspect, the variant comprises or consists of the substitution L262E or L262C in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A In another aspect, the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted with C, D, E or Q preferably with E. In another aspect, the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted with L or W preferably with W. In another aspect, the variant comprises or consists of the substitution Y209W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 212 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 212 of the polypeptide of SEQ ID NO: 2 is substituted with A, D, G or N preferably with D, G or N. In another aspect, the variant comprises or consists of the substitution S212D, S212G or S212N in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, L, M V, W, Y or F preferably with W. In another aspect, the variant comprises or consists of the substitution N261 W in the polypeptide of SEQ ID NO: 1 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 206 of the polypeptide of SEQ ID NO: 2 is substituted with C,E,I,K,T,V, L or W preferably with L, C or W. In another aspect, the variant comprises or consists of the substitution Q206L, Q206W or Q206C in the polypeptide of SEQ ID NO: 2 (ΒΡΝ' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 262 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 262 of the polypeptide of SEQ ID NO 2 is substituted with C, E or Q preferably with E or C. In another aspect, the variant comprises or consists of the substitution Y262E or Y262C in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 225 of the polypeptide of SEQ ID NO: 2 is substituted with A. In another aspect, the variant comprises or consists of the substitution P225A in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 9 of the polypeptide of SEQ ID NO: 2 is substituted with C, D, E or Q preferably with E. In another aspect, the variant comprises or consists of the substitution S9E in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 209 of the polypeptide of SEQ ID NO: 2 is substituted with W. In another aspect, the variant comprises or consists of the substitution L209W in the polypeptide of SEQ ID NO: 2 (BPN' numbering).
In one preferred aspect of the invention, the subtilase variants of the invention comprises or consists of a substitution at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2. In another preferred aspect, the amino acid at a position corresponding to position 261 of the polypeptide of SEQ ID NO: 2 is substituted with C, E, L, M, V, W or Y preferably with W. In another aspect, the variant comprises or consists of the substitution F261 W in the polypeptide of SEQ ID NO: 2 (BPN' numbering)
The inventors have shown that each of the mutations selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q provides a stabilizing effect to a subtilase protease. This stabilizing effect is increased when more stabilizing mutations are added.
Thus, another aspect of the invention relates to subtilase variants having protease activity, wherein the variant comprises two of the substitutions selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
Another preferred embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43C, N43R, I72A, G1 15W, H120V, P129D, A158E, G160D, G160P, Q182E, Q191 N, N204D, N204V, V205I, Q206C, Q206I, Q206V, Q206W, Q206L, Y209W, S212D, S212G, S212N, S216V, L217C, L217M, N218T, P225A, S256C, S256D, S259D, T260E, N261 C, N261 E, N261 L, N261V, N261Y, N261 W, L262C, L262E and L262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1
Another preferred embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to the subtilase with SEQ ID NO: 1 when measured in the accelerated storage stability assay in Example 3 herein wherein the variant comprise two or more substitutions selected from the group consisting of S9E, N43R, H120V, Q182E, Q191 N, N204D, V205I, Q206L, Y209W, S212G, S216V, S256D, S259D, N261 E, N261W and L262E, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1 In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ ID NO: 1 or to the polypeptide of SEQ ID NO: 2. In a preferred embodiment, the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 or to the polypeptide of SEQ ID NO: 2.
In one aspect of the invention, the subtilase variant comprises or consists of one or more of the substitutions set in table 2, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide that has at least 60% identity to the amino acid sequence of SEQ ID NO: 1 . In one aspect of the invention, the subtilase variant comprises an amino acid sequence that comprises one or more substitution(s) in comparison to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ I D NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 1 1 or SEQ ID NO: 12, wherein the substitution(s) is/are selected from one or more of the substitutions sets of table 2 and wherein the positions correspond to the corresponding position of the polypeptide of SEQ ID NO: 2.
Table 2: Subtilase Variants SEQ ID NO 1 , SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID
NO:1 1 or SEQ ID NO:12 + one or more mutation(s) listed below
S9C+N43A S9C+N43C S9C+N43L S9C+N43R
S9C+N43W S9C+I72A S9C+I72V S9C+S78D
S9C+V104F S9C+A1 14V S9C+G1 15T S9C+G1 15W
S9C+H120I S9C+H120T S9C+H120V S9C+P129D
S9C+V147W S9C+V149C S9C+V149N S9C+A158E
S9C+G160D S9C+G160P S9C+S161 C S9C+S161 E
S9C+S163A S9C+S163D S9C+Q182C S9C+Q182E
S9C+N185C S9C+N185E S9C+S188C S9C+S188D
S9C+S188E S9C+Q191 N S9C+N204D S9C+N204V
S9C+V205I S9C+Q206C S9C+Q206E S9C+Q206I
S9C+Q206K S9C+Q206T S9C+Q206V S9C+Q206W
S9C+Q206L S9C+Y209W S9C+S212A S9C+S212D
S9C+S212G S9C+S212N S9C+S216I S9C+S216T
S9C+S216V S9C+L217C S9C+L217M S9C+N218T
S9C+M222C S9C+M222R S9C+P225A S9C+T255C
S9C+T255E S9C+S256A S9C+S256C S9C+S256D
S9C+S256V S9C+S256Y S9C+S259D S9C+T260E
S9C+T260P S9C+N261 C S9C+N261 E S9C+N261 L
S9C+N261 M S9C+N261V S9C+N261Y S9C+N261 F
S9C+N261W S9C+L262C S9C+L262E S9C+L262Q
S9D+N43A S9D+N43C S9D+N43L S9D+N43R
S9D+N43W S9D+I72A S9D+I72V S9D+S78D
S9D+V104F S9D+A1 14V S9D+G1 15T S9D+G1 15W
S9D+H120I S9D+H120T S9D+H120V S9D+P129D
S9D+V147W S9D+V149C S9D+V149N S9D+A158E S9D+G160D S9D+G160P S9D+S161 C S9D+S161 E
S9D+S163A S9D+S163D S9D+Q182C S9D+Q182E
S9D+N185C S9D+N185E S9D+S188C S9D+S188D
S9D+S188E S9D+Q191 N S9D+N204D S9D+N204V
S9D+V205I S9D+Q206C S9D+Q206E S9D+Q206I
S9D+Q206K S9D+Q206T S9D+Q206V S9D+Q206W
S9D+Q206L S9D+Y209W S9D+S212A S9D+S212D
S9D+S212G S9D+S212N S9D+S216I S9D+S216T
S9D+S216V S9D+L217C S9D+L217M S9D+N218T
S9D+M222C S9D+M222R S9D+P225A S9D+T255C
S9D+T255E S9D+S256A S9D+S256C S9D+S256D
S9D+S256V S9D+S256Y S9D+S259D S9D+T260E
S9D+T260P S9D+N261 C S9D+N261 E S9D+N261 L
S9D+N261 M S9D+N261V S9D+N261Y S9D+N261 F
S9D+N261W S9D+L262C S9D+L262E S9D+L262Q
S9E+N43A S9E+N43C S9E+N43L S9E+N43R
S9E+N43W S9E+I72A S9E+I72V S9E+S78D
S9E+V104F S9E+A1 14V S9E+G1 15T S9E+G1 15W
S9E+H120I S9E+H120T S9E+H 120V S9E+P129D
S9E+V147W S9E+V149C S9E+V149N S9E+A158E
S9E+G160D S9E+G160P S9E+S161 C S9E+S161 E
S9E+S163A S9E+S163D S9E+Q182C S9E+Q182E
S9E+N185C S9E+N 185E S9E+S188C S9E+S188D
S9E+S188E S9E+Q191 N S9E+N204D S9E+N204V
S9E+V205I S9E+Q206C S9E+Q206E S9E+Q206I
S9E+Q206K S9E+Q206T S9E+Q206V S9E+Q206W
S9E+Q206L S9E+Y209W S9E+S212A S9E+S212D
S9E+S212G S9E+S212N S9E+S216I S9E+S216T
S9E+S216V S9E+L217C S9E+L217M S9E+N218T
S9E+M222C S9E+M222R S9E+P225A S9E+T255C
S9E+T255E S9E+S256A S9E+S256C S9E+S256D
S9E+S256V S9E+S256Y S9E+S259D S9E+T260E
S9E+T260P S9E+N261 C S9E+N261 E S9E+N261 L
S9E+N261 M S9E+N261V S9E+N261Y S9E+N261 F
S9E+N261W S9E+L262C S9E+L262E S9E+L262Q
S9Q+N43A S9Q+N43C S9Q+N43L S9Q+N43R
S9Q+N43W S9Q+I72A S9Q+I72V S9Q+S78D
S9Q+V104F S9Q+A1 14V S9Q+G1 15T S9Q+G1 15W
S9Q+H120I S9Q+H120T S9Q+H 120V S9Q+P129D
S9Q+V147W S9Q+V149C S9Q+V149N S9Q+A158E
S9Q+G160D S9Q+G160P S9Q+S161 C S9Q+S161 E
S9Q+S163A S9Q+S163D S9Q+Q182C S9Q+Q182E
S9Q+N185C S9Q+N 185E S9Q+S188C S9Q+S188D
S9Q+S188E S9Q+Q191 N S9Q+N204D S9Q+N204V
S9Q+V205I S9Q+Q206C S9Q+Q206E S9Q+Q206I
S9Q+Q206K S9Q+Q206T S9Q+Q206V S9Q+Q206W
S9Q+Q206L S9Q+Y209W S9Q+S212A S9Q+S212D
S9Q+S212G S9Q+S212N S9Q+S216I S9Q+S216T
S9Q+S216V S9Q+L217C S9Q+L217M S9Q+N218T
S9Q+M222C S9Q+M222R S9Q+P225A S9Q+T255C
S9Q+T255E S9Q+S256A S9Q+S256C S9Q+S256D
S9Q+S256V S9Q+S256Y S9Q+S259D S9Q+T260E
S9Q+T260P S9Q+N261 C S9Q+N261 E S9Q+N261 L
S9Q+N261 M S9Q+N261V S9Q+N261Y S9Q+N261 F S9Q+N261W S9Q+L262C S9Q+L262E S9Q+L262Q
N43A+I72A N43A+I72V N43A+S78D N43A+V104F
N43A+A1 14V N43A+G1 15T N43A+G1 15W N43A+H120I
N43A+H120T N43A+H 120V N43A+P129D N43A+V147W
N43A+V149C N43A+V149N N43A+A158E N43A+G160D
N43A+G160P N43A+S161 C N43A+S161 E N43A+S163A
N43A+S163D N43A+Q182C N43A+Q182E N43A+N185C
N43A+N 185E N43A+S188C N43A+S188D N43A+S188E
N43A+Q191 N N43A+N204D N43A+N204V N43A+V205I
N43A+Q206C N43A+Q206E N43A+Q206I N43A+Q206K
N43A+Q206T N43A+Q206V N43A+Q206W N43A+Q206L
N43A+Y209W N43A+S212A N43A+S212D N43A+S212G
N43A+S212N N43A+S216I N43A+S216T N43A+S216V
N43A+L217C N43A+L217M N43A+N218T N43A+M222C
N43A+M222R N43A+P225A N43A+T255C N43A+T255E
N43A+S256A N43A+S256C N43A+S256D N43A+S256V
N43A+S256Y N43A+S259D N43A+T260E N43A+T260P
N43A+N261 C N43A+N261 E N43A+N261 L N43A+N261 M
N43A+N261V N43A+N261Y N43A+N261 F N43A+N261W
N43A+L262C N43A+L262E N43A+L262Q N43C+I72A
N43C+I72V N43C+S78D N43C+V104F N43C+A1 14V
N43C+G1 15T N43C+G1 15W N43C+H120I N43C+H120T
N43C+H120V N43C+P129D N43C+V147W N43C+V149C
N43C+V149N N43C+A158E N43C+G160D N43C+G160P
N43C+S161 C N43C+S161 E N43C+S163A N43C+S163D
N43C+Q182C N43C+Q182E N43C+N185C N43C+N185E
N43C+S188C N43C+S188D N43C+S188E N43C+Q191 N
N43C+N204D N43C+N204V N43C+V205I N43C+Q206C
N43C+Q206E N43C+Q206I N43C+Q206K N43C+Q206T
N43C+Q206V N43C+Q206W N43C+Q206L N43C+Y209W
N43C+S212A N43C+S212D N43C+S212G N43C+S212N
N43C+S216I N43C+S216T N43C+S216V N43C+L217C
N43C+L217M N43C+N218T N43C+M222C N43C+M222R
N43C+P225A N43C+T255C N43C+T255E N43C+S256A
N43C+S256C N43C+S256D N43C+S256V N43C+S256Y
N43C+S259D N43C+T260E N43C+T260P N43C+N261 C
N43C+N261 E N43C+N261 L N43C+N261 M N43C+N261V
N43C+N261Y N43C+N261 F N43C+N261W N43C+L262C
N43C+L262E N43C+L262Q N43L+I72A N43L+I72V
N43L+S78D N43L+V104F N43L+A1 14V N43L+G1 15T
N43L+G1 15W N43L+H120I N43L+H120T N43L+H120V
N43L+P129D N43L+V147W N43L+V149C N43L+V149N
N43L+A158E N43L+G160D N43L+G160P N43L+S161 C
N43L+S161 E N43L+S163A N43L+S163D N43L+Q182C
N43L+Q182E N43L+N185C N43L+N185E N43L+S188C
N43L+S188D N43L+S188E N43L+Q191 N N43L+N204D
N43L+N204V N43L+V205I N43L+Q206C N43L+Q206E
N43L+Q206I N43L+Q206K N43L+Q206T N43L+Q206V
N43L+Q206W N43L+Q206L N43L+Y209W N43L+S212A
N43L+S212D N43L+S212G N43L+S212N N43L+S216I
N43L+S216T N43L+S216V N43L+L217C N43L+L217M
N43L+N218T N43L+M222C N43L+M222R N43L+P225A
N43L+T255C N43L+T255E N43L+S256A N43L+S256C
N43L+S256D N43L+S256V N43L+S256Y N43L+S259D N43L+T260E N43L+T260P N43L+N261 C N43L+N261 E
N43L+N261 L N43L+N261 M N43L+N261V N43L+N261Y
N43L+N261 F N43L+N261W N43L+L262C N43L+L262E
N43L+L262Q N43R+I72A N43R+I72V N43R+S78D
N43R+V104F N43R+A1 14V N43R+G1 15T N43R+G1 15W
N43R+H120I N43R+H120T N43R+H120V N43R+P129D
N43R+V147W N43R+V149C N43R+V149N N43R+A158E
N43R+G160D N43R+G160P N43R+S161 C N43R+S161 E
N43R+S163A N43R+S163D N43R+Q182C N43R+Q182E
N43R+N185C N43R+N185E N43R+S188C N43R+S188D
N43R+S188E N43R+Q191 N N43R+N204D N43R+N204V
N43R+V205I N43R+Q206C N43R+Q206E N43R+Q206I
N43R+Q206K N43R+Q206T N43R+Q206V N43R+Q206W
N43R+Q206L N43R+Y209W N43R+S212A N43R+S212D
N43R+S212G N43R+S212N N43R+S216I N43R+S216T
N43R+S216V N43R+L217C N43R+L217M N43R+N218T
N43R+M222C N43R+M222R N43R+P225A N43R+T255C
N43R+T255E N43R+S256A N43R+S256C N43R+S256D
N43R+S256V N43R+S256Y N43R+S259D N43R+T260E
N43R+T260P N43R+N261 C N43R+N261 E N43R+N261 L
N43R+N261 M N43R+N261V N43R+N261Y N43R+N261 F
N43R+N261W N43R+L262C N43R+L262E N43R+L262Q
N43W+I72A N43W+I72V N43W+S78D N43W+V104F
N43W+A1 14V N43W+G1 15T N43W+G1 15W N43W+H120I
N43W+H120T N43W+H120V N43W+P129D N43W+V147W
N43W+V149C N43W+V149N N43W+A158E N43W+G160D
N43W+G160P N43W+S161 C N43W+S161 E N43W+S163A
N43W+S163D N43W+Q182C N43W+Q182E N43W+N185C
N43W+N185E N43W+S188C N43W+S188D N43W+S188E
N43W+Q191 N N43W+N204D N43W+N204V N43W+V205I
N43W+Q206C N43W+Q206E N43W+Q206I N43W+Q206K
N43W+Q206T N43W+Q206V N43W+Q206W N43W+Q206L
N43W+Y209W N43W+S212A N43W+S212D N43W+S212G
N43W+S212N N43W+S216I N43W+S216T N43W+S216V
N43W+L217C N43W+L217M N43W+N218T N43W+M222C
N43W+M222R N43W+P225A N43W+T255C N43W+T255E
N43W+S256A N43W+S256C N43W+S256D N43W+S256V
N43W+S256Y N43W+S259D N43W+T260E N43W+T260P
N43W+N261 C N43W+N261 E N43W+N261 L N43W+N261 M
N43W+N261V N43W+N261Y N43W+N261 F N43W+N261W
N43W+L262C N43W+L262E N43W+L262Q I72A+S78D
I72A+V104F I72A+A1 14V I72A+G1 15T I72A+G1 15W
I72A+H120I I72A+H120T I72A+H120V I72A+P129D
I72A+V147W I72A+V149C I72A+V149N I72A+A158E
I72A+G160D I72A+G160P I72A+S161 C I72A+S161 E
I72A+S163A I72A+S163D I72A+Q182C I72A+Q182E
I72A+N185C I72A+N185E I72A+S188C I72A+S188D
I72A+S188E I72A+Q191 N I72A+N204D I72A+N204V
I72A+V205I I72A+Q206C I72A+Q206E I72A+Q206I
I72A+Q206K I72A+Q206T I72A+Q206V I72A+Q206W
I72A+Q206L I72A+Y209W I72A+S212A I72A+S212D
I72A+S212G I72A+S212N I72A+S216I I72A+S216T
I72A+S216V I72A+L217C I72A+L217M I72A+N218T
I72A+M222C I72A+M222R I72A+P225A I72A+T255C I72A+T255E I72A+S256A I72A+S256C I72A+S256D
I72A+S256V I72A+S256Y I72A+S259D I72A+T260E
I72A+T260P I72A+N261 C I72A+N261 E I72A+N261 L
I72A+N261 M I72A+N261V I72A+N261Y I72A+N261 F
I72A+N261W I72A+L262C I72A+L262E I72A+L262Q
I72V+S78D I72V+V104F I72V+A1 14V I72V+G1 15T
I72V+G1 15W I72V+H120I I72V+H120T I72V+H120V
I72V+P129D I72V+V147W I72V+V149C I72V+V149N
I72V+A158E I72V+G160D I72V+G160P I72V+S161 C
I72V+S161 E I72V+S163A I72V+S163D I72V+Q182C
I72V+Q182E I72V+N185C I72V+N185E I72V+S188C
I72V+S188D I72V+S188E I72V+Q191 N I72V+N204D
I72V+N204V I72V+V205I I72V+Q206C I72V+Q206E
I72V+Q206I I72V+Q206K I72V+Q206T I72V+Q206V
I72V+Q206W I72V+Q206L I72V+Y209W I72V+S212A
I72V+S212D I72V+S212G I72V+S212N I72V+S216I
I72V+S216T I72V+S216V I72V+L217C I72V+L217M
I72V+N218T I72V+M222C I72V+M222R I72V+P225A
I72V+T255C I72V+T255E I72V+S256A I72V+S256C
I72V+S256D I72V+S256V I72V+S256Y I72V+S259D
I72V+T260E I72V+T260P I72V+N261 C I72V+N261 E
I72V+N261 L I72V+N261 M I72V+N261V I72V+N261Y
I72V+N261 F I72V+N261W I72V+L262C I72V+L262E
I72V+L262Q S78D+V104F S78D+A1 14V S78D+G1 15T
S78D+G1 15W S78D+H120I S78D+H120T S78D+H 120V
S78D+P129D S78D+V147W S78D+V149C S78D+V149N
S78D+A158E S78D+G160D S78D+G160P S78D+S161 C
S78D+S161 E S78D+S163A S78D+S163D S78D+Q182C
S78D+Q182E S78D+N185C S78D+N 185E S78D+S188C
S78D+S188D S78D+S188E S78D+Q191 N S78D+N204D
S78D+N204V S78D+V205I S78D+Q206C S78D+Q206E
S78D+Q206I S78D+Q206K S78D+Q206T S78D+Q206V
S78D+Q206W S78D+Q206L S78D+Y209W S78D+S212A
S78D+S212D S78D+S212G S78D+S212N S78D+S216I
S78D+S216T S78D+S216V S78D+L217C S78D+L217M
S78D+N218T S78D+M222C S78D+M222R S78D+P225A
S78D+T255C S78D+T255E S78D+S256A S78D+S256C
S78D+S256D S78D+S256V S78D+S256Y S78D+S259D
S78D+T260E S78D+T260P S78D+N261 C S78D+N261 E
S78D+N261 L S78D+N261 M S78D+N261V S78D+N261Y
S78D+N261W S78D+L262C S78D+L262E S78D+L262Q
V104F+A1 14V V104F+G1 15T V104F+G1 15W V104F+H120I
V104F+H120T V104F+H120V V104F+P129D V104F+V147W
V104F+V149C V104F+V149N V104F+A158E V104F+G160D
V104F+G160P V104F+S161 C V104F+S161 E V104F+S163A
V104F+S163D V104F+Q182C V104F+Q182E V104F+N185C
V104F+N185E V104F+S188C V104F+S188D V104F+S188E
V104F+Q191 N V104F+N204D V104F+N204V V104F+V205I
V104F+Q206C V104F+Q206E V104F+Q206I V104F+Q206K
V104F+Q206T V104F+Q206V V104F+Q206W V104F+Q206L
V104F+Y209W V104F+S212A V104F+S212D V104F+S212G
V104F+S212N V104F+S216I V104F+S216T V104F+S216V
V104F+L217C V104F+L217M V104F+N218T V104F+M222C
V104F+M222R V104F+P225A V104F+T255C V104F+T255E V104F+S256A V104F+S256C V104F+S256D V104F+S256V
V104F+S256Y V104F+S259D V104F+T260E V104F+T260P
V104F+N261C V104F+N261E V104F+N261L V104F+N261M
V104F+N261V V104F+N261Y V104F+N261W V104F+L262C
V104F+L262E V104F+L262Q A114V+G115T A114V+G115W
A114V+H120I A114V+H120T A114V+H120V A114V+P129D
A114V+V147W A114V+V149C A114V+V149N A114V+A158E
A114V+G160D A114V+G160P A114V+S161C A114V+S161E
A114V+S163A A114V+S163D A114V+Q182C A114V+Q182E
A114V+N185C A114V+N185E A114V+S188C A114V+S188D
A114V+S188E A114V+Q191N A114V+N204D A114V+N204V
A114V+V205I A114V+Q206C A114V+Q206E A114V+Q206I
A114V+Q206K A114V+Q206T A114V+Q206V A114V+Q206W
A114V+Q206L A114V+Y209W A114V+S212A A114V+S212D
A114V+S212G A114V+S212N A114V+S216I A114V+S216T
A114V+S216V A114V+L217C A114V+L217M A114V+N218T
A114V+M222C A114V+M222R A114V+P225A A114V+T255C
A114V+T255E A114V+S256A A114V+S256C A114V+S256D
A114V+S256V A114V+S256Y A114V+S259D A114V+T260E
A114V+T260P A114V+N261C A114V+N261E A114V+N261L
A114V+N261M A114V+N261V A114V+N261Y A114V+N261W
A114V+L262C A114V+L262E A114V+L262Q G115T+H120I
G115T+H120T G115T+H120V G115T+P129D G115T+V147W
G115T+V149C G115T+V149N G115T+A158E G115T+G160D
G115T+G160P G115T+S161C G115T+S161E G115T+S163A
G115T+S163D G115T+Q182C G115T+Q182E G115T+N185C
G115T+N185E G115T+S188C G115T+S188D G115T+S188E
G115T+Q191N G115T+N204D G115T+N204V G115T+V205I
G115T+Q206C G115T+Q206E G115T+Q206I G115T+Q206K
G115T+Q206T G115T+Q206V G115T+Q206W G115T+Q206L
G115T+Y209W G115T+S212A G115T+S212D G115T+S212G
G115T+S212N G115T+S216I G115T+S216T G115T+S216V
G115T+L217C G115T+L217M G115T+N218T G115T+M222C
G115T+M222R G115T+P225A G115T+T255C G115T+T255E
G115T+S256A G115T+S256C G115T+S256D G115T+S256V
G115T+S256Y G115T+S259D G115T+T260E G115T+T260P
G115T+N261C G115T+N261E G115T+N261L G115T+N261M
G115T+N261V G115T+N261Y G115T+N261W G115T+L262C
G115T+L262E G115T+L262Q G115W+H120I G115W+H120T
G115W+H120V G115W+P129D G115W+V147W G115W+V149C
G115W+V149N G115W+A158E G115W+G160D G115W+G160P
G115W+S161C G115W+S161E G115W+S163A G115W+S163D
G115W+Q182C G115W+Q182E G115W+N185C G115W+N185E
G115W+S188C G115W+S188D G115W+S188E G115W+Q191N
G115W+N204D G115W+N204V G115W+V205I G115W+Q206C
G115W+Q206E G115W+Q206I G115W+Q206K G115W+Q206T
G115W+Q206V G115W+Q206W G115W+Q206L G115W+Y209W
G115W+S212A G115W+S212D G115W+S212G G115W+S212N
G115W+S216I G115W+S216T G115W+S216V G115W+L217C
G115W+L217M G115W+N218T G115W+M222C G115W+M222R
G115W+P225A G115W+T255C G115W+T255E G115W+S256A
G115W+S256C G115W+S256D G115W+S256V G115W+S256Y
G115W+S259D G115W+T260E G115W+T260P G115W+N261C
G115W+N261E G115W+N261L G115W+N261M G115W+N261V G1 15W+N261Y G1 15W+N261W G1 15W+L262C G1 15W+L262E
G1 15W+L262Q H120I+P129D H120I+V147W H120I+V149C
H120I+V149N H120I+A158E H120I+G160D H120I+G160P
H120I+S161 C H120I+S161 E H120I+S163A H120I+S163D
H120I+Q182C H120I+Q182E H120I+N185C H120I+N185E
H120I+S188C H120I+S188D H120I+S188E H120I+Q191 N
H120I+N204D H120I+N204V H120I+V205I H120I+Q206C
H120I+Q206E H120I+Q206I H120I+Q206K H120I+Q206T
H120I+Q206V H120I+Q206W H120I+Q206L H120I+Y209W
H120I+S212A H120I+S212D H120I+S212G H120I+S212N
H120I+S216I H120I+S216T H120I+S216V H120I+L217C
H120I+L217M H120I+N218T H120I+M222C H120I+M222R
H120I+P225A H120I+T255C H120I+T255E H120I+S256A
H120I+S256C H120I+S256D H120I+S256V H120I+S256Y
H120I+S259D H120I+T260E H120I+T260P H120I+N261 C
H120I+N261 E H120I+N261 L H120I+N261 M H120I+N261V
H120I+N261Y H120I+N261W H120I+L262C H120I+L262E
H120I+L262Q H120T+P129D H120T+V147W H120T+V149C
H120T+V149N H120T+A158E H120T+G160D H120T+G160P
H120T+S161 C H120T+S161 E H120T+S163A H120T+S163D
H120T+Q182C H120T+Q182E H120T+N185C H120T+N 185E
H120T+S188C H120T+S188D H120T+S188E H120T+Q191 N
H120T+N204D H120T+N204V H120T+V205I H120T+Q206C
H120T+Q206E H120T+Q206I H120T+Q206K H120T+Q206T
H120T+Q206V H120T+Q206W H120T+Q206L H120T+Y209W
H120T+S212A H120T+S212D H120T+S212G H120T+S212N
H120T+S216I H120T+S216T H120T+S216V H120T+L217C
H120T+L217M H120T+N218T H120T+M222C H120T+M222R
H120T+P225A H120T+T255C H120T+T255E H120T+S256A
H120T+S256C H120T+S256D H120T+S256V H120T+S256Y
H120T+S259D H120T+T260E H120T+T260P H120T+N261 C
H120T+N261 E H120T+N261 L H120T+N261 M H120T+N261V
H120T+N261Y H120T+N261W H120T+L262C H120T+L262E
H120T+L262Q H120V+P129D H120V+V147W H120V+V149C
H120V+V149N H120V+A158E H120V+G160D H120V+G160P
H120V+S161 C H120V+S161 E H120V+S163A H120V+S163D
H120V+Q182C H120V+Q182E H120V+N185C H120V+N185E
H120V+S188C H120V+S188D H120V+S188E H120V+Q191 N
H120V+N204D H120V+N204V H120V+V205I H120V+Q206C
H120V+Q206E H120V+Q206I H120V+Q206K H120V+Q206T
H120V+Q206V H120V+Q206W H120V+Q206L H120V+Y209W
H120V+S212A H120V+S212D H120V+S212G H120V+S212N
H120V+S216I H120V+S216T H120V+S216V H120V+L217C
H120V+L217M H120V+N218T H120V+M222C H120V+M222R
H120V+P225A H120V+T255C H120V+T255E H120V+S256A
H120V+S256C H120V+S256D H120V+S256V H120V+S256Y
H120V+S259D H120V+T260E H120V+T260P H120V+N261 C
H120V+N261 E H120V+N261 L H120V+N261 M H120V+N261V
H120V+N261Y H120V+N261W H120V+L262C H120V+L262E
H120V+L262Q P129D+V147W P129D+V149C P129D+V149N
P129D+A158E P129D+G160D P129D+G160P P129D+S161 C
P129D+S161 E P129D+S163A P129D+S163D P129D+Q182C
P129D+Q182E P129D+N185C P129D+N185E P129D+S188C
P129D+S188D P129D+S188E P129D+Q191 N P129D+N204D P129D+N204V P129D+V205I P129D+Q206C P129D+Q206E
P129D+Q206I P129D+Q206K P129D+Q206T P129D+Q206V
P129D+Q206W P129D+Q206L P129D+Y209W P129D+S212A
P129D+S212D P129D+S212G P129D+S212N P129D+S216I
P129D+S216T P129D+S216V P129D+L217C P129D+L217M
P129D+N218T P129D+M222C P129D+M222R P129D+P225A
P129D+T255C P129D+T255E P129D+S256A P129D+S256C
P129D+S256D P129D+S256V P129D+S256Y P129D+S259D
P129D+T260E P129D+T260P P129D+N261 C P129D+N261 E
P129D+N261 L P129D+N261 M P129D+N261V P129D+N261Y
P129D+N261W P129D+L262C P129D+L262E P129D+L262Q
V147W+V149C V147W+V149N V147W+A158E V147W+G160D
V147W+G160P V147W+S161 C V147W+S161 E V147W+S163A
V147W+S163D V147W+Q182C V147W+Q182E V147W+N185C
V147W+N185E V147W+S188C V147W+S188D V147W+S188E
V147W+Q191 N V147W+N204D V147W+N204V V147W+V205I
V147W+Q206C V147W+Q206E V147W+Q206I V147W+Q206K
V147W+Q206T V147W+Q206V V147W+Q206W V147W+Q206L
V147W+Y209W V147W+S212A V147W+S212D V147W+S212G
V147W+S212N V147W+S216I V147W+S216T V147W+S216V
V147W+L217C V147W+L217M V147W+N218T V147W+M222C
V147W+M222R V147W+P225A V147W+T255C V147W+T255E
V147W+S256A V147W+S256C V147W+S256D V147W+S256V
V147W+S256Y V147W+S259D V147W+T260E V147W+T260P
V147W+N261 C V147W+N261 E V147W+N261 L V147W+N261 M
V147W+N261V V147W+N261Y V147W+N261W V147W+L262C
V147W+L262E V147W+L262Q V149C+A158E V149C+G160D
V149C+G160P V149C+S161 C V149C+S161 E V149C+S163A
V149C+S163D V149C+Q182C V149C+Q182E V149C+N185C
V149C+N185E V149C+S188C V149C+S188D V149C+S188E
V149C+Q191 N V149C+N204D V149C+N204V V149C+V205I
V149C+Q206C V149C+Q206E V149C+Q206I V149C+Q206K
V149C+Q206T V149C+Q206V V149C+Q206W V149C+Q206L
V149C+Y209W V149C+S212A V149C+S212D V149C+S212G
V149C+S212N V149C+S216I V149C+S216T V149C+S216V
V149C+L217C V149C+L217M V149C+N218T V149C+M222C
V149C+M222R V149C+P225A V149C+T255C V149C+T255E
V149C+S256A V149C+S256C V149C+S256D V149C+S256V
V149C+S256Y V149C+S259D V149C+T260E V149C+T260P
V149C+N261 C V149C+N261 E V149C+N261 L V149C+N261 M
V149C+N261V V149C+N261Y V149C+N261W V149C+L262C
V149C+L262E V149C+L262Q V149N+A158E V149N+G160D
V149N+G160P V149N+S161 C V149N+S161 E V149N+S163A
V149N+S163D V149N+Q182C V149N+Q182E V149N+N185C
V149N+N185E V149N+S188C V149N+S188D V149N+S188E
V149N+Q191 N V149N+N204D V149N+N204V V149N+V205I
V149N+Q206C V149N+Q206E V149N+Q206I V149N+Q206K
V149N+Q206T V149N+Q206V V149N+Q206W V149N+Q206L
V149N+Y209W V149N+S212A V149N+S212D V149N+S212G
V149N+S212N V149N+S216I V149N+S216T V149N+S216V
V149N+L217C V149N+L217M V149N+N218T V149N+M222C
V149N+M222R V149N+P225A V149N+T255C V149N+T255E
V149N+S256A V149N+S256C V149N+S256D V149N+S256V
V149N+S256Y V149N+S259D V149N+T260E V149N+T260P V149N+N261C V149N+N261E V149N+N261L V149N+N261M
V149N+N261V V149N+N261Y V149N+N261W V149N+L262C
V149N+L262E V149N+L262Q A158E+G160D A158E+G160P
A158E+S161C A158E+S161E A158E+S163A A158E+S163D
A158E+Q182C A158E+Q182E A158E+N185C A158E+N185E
A158E+S188C A158E+S188D A158E+S188E A158E+Q191N
A158E+N204D A158E+N204V A158E+V205I A158E+Q206C
A158E+Q206E A158E+Q206I A158E+Q206K A158E+Q206T
A158E+Q206V A158E+Q206W A158E+Q206L A158E+Y209W
A158E+S212A A158E+S212D A158E+S212G A158E+S212N
A158E+S216I A158E+S216T A158E+S216V A158E+L217C
A158E+L217M A158E+N218T A158E+M222C A158E+M222R
A158E+P225A A158E+T255C A158E+T255E A158E+S256A
A158E+S256C A158E+S256D A158E+S256V A158E+S256Y
A158E+S259D A158E+T260E A158E+T260P A158E+N261C
A158E+N261E A158E+N261L A158E+N261M A158E+N261V
A158E+N261Y A158E+N261W A158E+L262C A158E+L262E
A158E+L262Q G160D+S161C G160D+S161E G160D+S163A
G160D+S163D G160D+Q182C G160D+Q182E G160D+N185C
G160D+N185E G160D+S188C G160D+S188D G160D+S188E
G160D+Q191N G160D+N204D G160D+N204V G160D+V205I
G160D+Q206C G160D+Q206E G160D+Q206I G160D+Q206K
G160D+Q206T G160D+Q206V G160D+Q206W G160D+Q206L
G160D+Y209W G160D+S212A G160D+S212D G160D+S212G
G160D+S212N G160D+S216I G160D+S216T G160D+S216V
G160D+L217C G160D+L217M G160D+N218T G160D+M222C
G160D+M222R G160D+P225A G160D+T255C G160D+T255E
G160D+S256A G160D+S256C G160D+S256D G160D+S256V
G160D+S256Y G160D+S259D G160D+T260E G160D+T260P
G160D+N261C G160D+N261E G160D+N261L G160D+N261M
G160D+N261V G160D+N261Y G160D+N261W G160D+L262C
G160D+L262E G160D+L262Q G160P+S161C G160P+S161E
G160P+S163A G160P+S163D G160P+Q182C G160P+Q182E
G160P+N185C G160P+N185E G160P+S188C G160P+S188D
G160P+S188E G160P+Q191N G160P+N204D G160P+N204V
G160P+V205I G160P+Q206C G160P+Q206E G160P+Q206I
G160P+Q206K G160P+Q206T G160P+Q206V G160P+Q206W
G160P+Q206L G160P+Y209W G160P+S212A G160P+S212D
G160P+S212G G160P+S212N G160P+S216I G160P+S216T
G160P+S216V G160P+L217C G160P+L217M G160P+N218T
G160P+M222C G160P+M222R G160P+P225A G160P+T255C
G160P+T255E G160P+S256A G160P+S256C G160P+S256D
G160P+S256V G160P+S256Y G160P+S259D G160P+T260E
G160P+T260P G160P+N261C G160P+N261E G160P+N261L
G160P+N261M G160P+N261V G160P+N261Y G160P+N261W
G160P+L262C G160P+L262E G160P+L262Q S161C+S163A
S161C+S163D S161C+Q182C S161C+Q182E S161C+N185C
S161C+N185E S161C+S188C S161C+S188D S161C+S188E
S161C+Q191N S161C+N204D S161C+N204V S161C+V205I
S161C+Q206C S161C+Q206E S161C+Q206I S161C+Q206K
S161C+Q206T S161C+Q206V S161C+Q206W S161C+Q206L
S161C+Y209W S161C+S212A S161C+S212D S161C+S212G
S161C+S212N S161C+S216I S161C+S216T S161C+S216V
S161C+L217C S161C+L217M S161C+N218T S161C+M222C S161C+M222R S161C+P225A S161C+T255C S161C+T255E
S161C+S256A S161C+S256C S161C+S256D S161C+S256V
S161C+S256Y S161C+S259D S161C+T260E S161C+T260P
S161C+N261C S161C+N261E S161C+N261L S161C+N261M
S161C+N261V S161C+N261Y S161C+N261W S161C+L262C
S161C+L262E S161C+L262Q S161E+S163A S161E+S163D
S161E+Q182C S161E+Q182E S161E+N185C S161E+N185E
S161E+S188C S161E+S188D S161E+S188E S161E+Q191N
S161E+N204D S161E+N204V S161E+V205I S161E+Q206C
S161E+Q206E S161E+Q206I S161E+Q206K S161E+Q206T
S161E+Q206V S161E+Q206W S161E+Q206L S161E+Y209W
S161E+S212A S161E+S212D S161E+S212G S161E+S212N
S161E+S216I S161E+S216T S161E+S216V S161E+L217C
S161E+L217M S161E+N218T S161E+M222C S161E+M222R
S161E+P225A S161E+T255C S161E+T255E S161E+S256A
S161E+S256C S161E+S256D S161E+S256V S161E+S256Y
S161E+S259D S161E+T260E S161E+T260P S161E+N261C
S161E+N261E S161E+N261L S161E+N261M S161E+N261V
S161E+N261Y S161E+N261W S161E+L262C S161E+L262E
S161E+L262Q S163A+Q182C S163A+Q182E S163A+N185C
S163A+N185E S163A+S188C S163A+S188D S163A+S188E
S163A+Q191N S163A+N204D S163A+N204V S163A+V205I
S163A+Q206C S163A+Q206E S163A+Q206I S163A+Q206K
S163A+Q206T S163A+Q206V S163A+Q206W S163A+Q206L
S163A+Y209W S163A+S212A S163A+S212D S163A+S212G
S163A+S212N S163A+S216I S163A+S216T S163A+S216V
S163A+L217C S163A+L217M S163A+N218T S163A+M222C
S163A+M222R S163A+P225A S163A+T255C S163A+T255E
S163A+S256A S163A+S256C S163A+S256D S163A+S256V
S163A+S256Y S163A+S259D S163A+T260E S163A+T260P
S163A+N261C S163A+N261E S163A+N261L S163A+N261M
S163A+N261V S163A+N261Y S163A+N261W S163A+L262C
S163A+L262E S163A+L262Q S163D+Q182C S163D+Q182E
S163D+N185C S163D+N185E S163D+S188C S163D+S188D
S163D+S188E S163D+Q191N S163D+N204D S163D+N204V
S163D+V205I S163D+Q206C S163D+Q206E S163D+Q206I
S163D+Q206K S163D+Q206T S163D+Q206V S163D+Q206W
S163D+Q206L S163D+Y209W S163D+S212A S163D+S212D
S163D+S212G S163D+S212N S163D+S216I S163D+S216T
S163D+S216V S163D+L217C S163D+L217M S163D+N218T
S163D+M222C S163D+M222R S163D+P225A S163D+T255C
S163D+T255E S163D+S256A S163D+S256C S163D+S256D
S163D+S256V S163D+S256Y S163D+S259D S163D+T260E
S163D+T260P S163D+N261C S163D+N261E S163D+N261L
S163D+N261M S163D+N261V S163D+N261Y S163D+N261W
S163D+L262C S163D+L262E S163D+L262Q Q182C+N185C
Q182C+N185E Q182C+S188C Q182C+S188D Q182C+S188E
Q182C+Q191N Q182C+N204D Q182C+N204V Q182C+V205I
Q182C+Q206C Q182C+Q206E Q182C+Q206I Q182C+Q206K
Q182C+Q206T Q182C+Q206V Q182C+Q206W Q182C+Q206L
Q182C+Y209W Q182C+S212A Q182C+S212D Q182C+S212G
Q182C+S212N Q182C+S216I Q182C+S216T Q182C+S216V
Q182C+L217C Q182C+L217M Q182C+N218T Q182C+M222C
Q182C+M222R Q182C+P225A Q182C+T255C Q182C+T255E Q182C+S256A Q182C+S256C Q182C+S256D Q182C+S256V
Q182C+S256Y Q182C+S259D Q182C+T260E Q182C+T260P
Q182C+N261 C Q182C+N261 E Q182C+N261 L Q182C+N261 M
Q182C+N261V Q182C+N261Y Q182C+N261W Q182C+L262C
Q182C+L262E Q182C+L262Q Q182E+N185C Q182E+N 185E
Q182E+S188C Q182E+S188D Q182E+S188E Q182E+Q191 N
Q182E+N204D Q182E+N204V Q182E+V205I Q182E+Q206C
Q182E+Q206E Q182E+Q206I Q182E+Q206K Q182E+Q206T
Q182E+Q206V Q182E+Q206W Q182E+Q206L Q182E+Y209W
Q182E+S212A Q182E+S212D Q182E+S212G Q182E+S212N
Q182E+S216I Q182E+S216T Q182E+S216V Q182E+L217C
Q182E+L217M Q182E+N218T Q182E+M222C Q182E+M222R
Q182E+P225A Q182E+T255C Q182E+T255E Q182E+S256A
Q182E+S256C Q182E+S256D Q182E+S256V Q182E+S256Y
Q182E+S259D Q182E+T260E Q182E+T260P Q182E+N261 C
Q182E+N261 E Q182E+N261 L Q182E+N261 M Q182E+N261V
Q182E+N261Y Q182E+N261W Q182E+L262C Q182E+L262E
Q182E+L262Q N185C+S188C N185C+S188D N185C+S188E
N185C+Q191 N N185C+N204D N185C+N204V N185C+V205I
N185C+Q206C N185C+Q206E N185C+Q206I N185C+Q206K
N185C+Q206T N185C+Q206V N185C+Q206W N185C+Q206L
N185C+Y209W N185C+S212A N185C+S212D N185C+S212G
N185C+S212N N185C+S216I N185C+S216T N185C+S216V
N185C+L217C N185C+L217M N185C+N218T N185C+M222C
N185C+M222R N185C+P225A N185C+T255C N185C+T255E
N185C+S256A N185C+S256C N185C+S256D N185C+S256V
N185C+S256Y N185C+S259D N185C+T260E N185C+T260P
N185C+N261 C N185C+N261 E N185C+N261 L N185C+N261 M
N185C+N261V N185C+N261Y N185C+N261W N185C+L262C
N185C+L262E N185C+L262Q N185E+S188C N185E+S188D
N185E+S188E N185E+Q191 N N185E+N204D N185E+N204V
N185E+V205I N185E+Q206C N185E+Q206E N185E+Q206I
N185E+Q206K N185E+Q206T N185E+Q206V N185E+Q206W
N185E+Q206L N185E+Y209W N185E+S212A N185E+S212D
N185E+S212G N185E+S212N N185E+S216I N185E+S216T
N185E+S216V N185E+L217C N185E+L217M N185E+N218T
N185E+M222C N185E+M222R N185E+P225A N185E+T255C
N185E+T255E N185E+S256A N185E+S256C N185E+S256D
N185E+S256V N185E+S256Y N185E+S259D N185E+T260E
N185E+T260P N185E+N261 C N185E+N261 E N185E+N261 L
N185E+N261 M N185E+N261V N185E+N261Y N185E+N261W
N185E+L262C N185E+L262E N185E+L262Q S188C+Q191 N
S188C+N204D S188C+N204V S188C+V205I S188C+Q206C
S188C+Q206E S188C+Q206I S188C+Q206K S188C+Q206T
S188C+Q206V S188C+Q206W S188C+Q206L S188C+Y209W
S188C+S212A S188C+S212D S188C+S212G S188C+S212N
S188C+S216I S188C+S216T S188C+S216V S188C+L217C
S188C+L217M S188C+N218T S188C+M222C S188C+M222R
S188C+P225A S188C+T255C S188C+T255E S188C+S256A
S188C+S256C S188C+S256D S188C+S256V S188C+S256Y
S188C+S259D S188C+T260E S188C+T260P S188C+N261 C
S188C+N261 E S188C+N261 L S188C+N261 M S188C+N261V
S188C+N261Y S188C+N261W S188C+L262C S188C+L262E
S188C+L262Q S188D+Q191 N S188D+N204D S188D+N204V S188D+V205I S188D+Q206C S188D+Q206E S188D+Q206I
S188D+Q206K S188D+Q206T S188D+Q206V S188D+Q206W
S188D+Q206L S188D+Y209W S188D+S212A S188D+S212D
S188D+S212G S188D+S212N S188D+S216I S188D+S216T
S188D+S216V S188D+L217C S188D+L217M S188D+N218T
S188D+M222C S188D+M222R S188D+P225A S188D+T255C
S188D+T255E S188D+S256A S188D+S256C S188D+S256D
S188D+S256V S188D+S256Y S188D+S259D S188D+T260E
S188D+T260P S188D+N261C S188D+N261E S188D+N261L
S188D+N261M S188D+N261V S188D+N261Y S188D+N261W
S188D+L262C S188D+L262E S188D+L262Q S188E+Q191N
S188E+N204D S188E+N204V S188E+V205I S188E+Q206C
S188E+Q206E S188E+Q206I S188E+Q206K S188E+Q206T
S188E+Q206V S188E+Q206W S188E+Q206L S188E+Y209W
S188E+S212A S188E+S212D S188E+S212G S188E+S212N
S188E+S216I S188E+S216T S188E+S216V S188E+L217C
S188E+L217M S188E+N218T S188E+M222C S188E+M222R
S188E+P225A S188E+T255C S188E+T255E S188E+S256A
S188E+S256C S188E+S256D S188E+S256V S188E+S256Y
S188E+S259D S188E+T260E S188E+T260P S188E+N261C
S188E+N261E S188E+N261L S188E+N261M S188E+N261V
S188E+N261Y S188E+N261W S188E+L262C S188E+L262E
S188E+L262Q Q191N+N204D Q191N+N204V Q191N+V205I
Q191N+Q206C Q191N+Q206E Q191N+Q206I Q191N+Q206K
Q191N+Q206T Q191N+Q206V Q191N+Q206W Q191N+Q206L
Q191N+Y209W Q191N+S212A Q191N+S212D Q191N+S212G
Q191N+S212N Q191N+S216I Q191N+S216T Q191N+S216V
Q191N+L217C Q191N+L217M Q191N+N218T Q191N+M222C
Q191N+M222R Q191N+P225A Q191N+T255C Q191N+T255E
Q191N+S256A Q191N+S256C Q191N+S256D Q191N+S256V
Q191N+S256Y Q191N+S259D Q191N+T260E Q191N+T260P
Q191N+N261C Q191N+N261E Q191N+N261L Q191N+N261M
Q191N+N261V Q191N+N261Y Q191N+N261W Q191N+L262C
Q191N+L262E Q191N+L262Q N204D+V205I N204D+Q206C
N204D+Q206E N204D+Q206I N204D+Q206K N204D+Q206T
N204D+Q206V N204D+Q206W N204D+Q206L N204D+Y209W
N204D+S212A N204D+S212D N204D+S212G N204D+S212N
N204D+S216I N204D+S216T N204D+S216V N204D+L217C
N204D+L217M N204D+N218T N204D+M222C N204D+M222R
N204D+P225A N204D+T255C N204D+T255E N204D+S256A
N204D+S256C N204D+S256D N204D+S256V N204D+S256Y
N204D+S259D N204D+T260E N204D+T260P N204D+N261C
N204D+N261E N204D+N261L N204D+N261M N204D+N261V
N204D+N261Y N204D+N261W N204D+L262C N204D+L262E
N204D+L262Q N204V+V205I N204V+Q206C N204V+Q206E
N204V+Q206I N204V+Q206K N204V+Q206T N204V+Q206V
N204V+Q206W N204V+Q206L N204V+Y209W N204V+S212A
N204V+S212D N204V+S212G N204V+S212N N204V+S216I
N204V+S216T N204V+S216V N204V+L217C N204V+L217M
N204V+N218T N204V+M222C N204V+M222R N204V+P225A
N204V+T255C N204V+T255E N204V+S256A N204V+S256C
N204V+S256D N204V+S256V N204V+S256Y N204V+S259D
N204V+T260E N204V+T260P N204V+N261C N204V+N261E
N204V+N261L N204V+N261M N204V+N261V N204V+N261Y N204V+N261W N204V+L262C N204V+L262E N204V+L262Q
V205I+Q206C V205I+Q206E V205I+Q206I V205I+Q206K
V205I+Q206T V205I+Q206V V205I+Q206W V205I+Q206L
V205I+Y209W V205I+S212A V205I+S212D V205I+S212G
V205I+S212N V205I+S216I V205I+S216T V205I+S216V
V205I+L217C V205I+L217M V205I+N218T V205I+M222C
V205I+M222R V205I+P225A V205I+T255C V205I+T255E
V205I+S256A V205I+S256C V205I+S256D V205I+S256V
V205I+S256Y V205I+S259D V205I+T260E V205I+T260P
V205I+N261 C V205I+N261 E V205I+N261 L V205I+N261 M
V205I+N261V V205I+N261Y V205I+N261W V205I+L262C
V205I+L262E V205I+L262Q Q206C+Y209W Q206C+S212A
Q206C+S212D Q206C+S212G Q206C+S212N Q206C+S216I
Q206C+S216T Q206C+S216V Q206C+L217C Q206C+L217M
Q206C+N218T Q206C+M222C Q206C+M222R Q206C+P225A
Q206C+T255C Q206C+T255E Q206C+S256A Q206C+S256C
Q206C+S256D Q206C+S256V Q206C+S256Y Q206C+S259D
Q206C+T260E Q206C+T260P Q206C+N261 C Q206C+N261 E
Q206C+N261 L Q206C+N261 M Q206C+N261V Q206C+N261Y
Q206C+N261W Q206C+L262C Q206C+L262E Q206C+L262Q
Q206E+Y209W Q206E+S212A Q206E+S212D Q206E+S212G
Q206E+S212N Q206E+S216I Q206E+S216T Q206E+S216V
Q206E+L217C Q206E+L217M Q206E+N218T Q206E+M222C
Q206E+M222R Q206E+P225A Q206E+T255C Q206E+T255E
Q206E+S256A Q206E+S256C Q206E+S256D Q206E+S256V
Q206E+S256Y Q206E+S259D Q206E+T260E Q206E+T260P
Q206E+N261 C Q206E+N261 E Q206E+N261 L Q206E+N261 M
Q206E+N261V Q206E+N261Y Q206E+N261W Q206E+L262C
Q206E+L262E Q206E+L262Q Q206I+Y209W Q206I+S212A
Q206I+S212D Q206I+S212G Q206I+S212N Q206I+S216I
Q206I+S216T Q206I+S216V Q206I+L217C Q206I+L217M
Q206I+N218T Q206I+M222C Q206I+M222R Q206I+P225A
Q206I+T255C Q206I+T255E Q206I+S256A Q206I+S256C
Q206I+S256D Q206I+S256V Q206I+S256Y Q206I+S259D
Q206I+T260E Q206I+T260P Q206I+N261 C Q206I+N261 E
Q206I+N261 L Q206I+N261 M Q206I+N261V Q206I+N261Y
Q206I+N261W Q206I+L262C Q206I+L262E Q206I+L262Q
Q206K+Y209W Q206K+S212A Q206K+S212D Q206K+S212G
Q206K+S212N Q206K+S216I Q206K+S216T Q206K+S216V
Q206K+L217C Q206K+L217M Q206K+N218T Q206K+M222C
Q206K+M222R Q206K+P225A Q206K+T255C Q206K+T255E
Q206K+S256A Q206K+S256C Q206K+S256D Q206K+S256V
Q206K+S256Y Q206K+S259D Q206K+T260E Q206K+T260P
Q206K+N261 C Q206K+N261 E Q206K+N261 L Q206K+N261 M
Q206K+N261V Q206K+N261Y Q206K+N261W Q206K+L262C
Q206K+L262E Q206K+L262Q Q206T+Y209W Q206T+S212A
Q206T+S212D Q206T+S212G Q206T+S212N Q206T+S216I
Q206T+S216T Q206T+S216V Q206T+L217C Q206T+L217M
Q206T+N218T Q206T+M222C Q206T+M222R Q206T+P225A
Q206T+T255C Q206T+T255E Q206T+S256A Q206T+S256C
Q206T+S256D Q206T+S256V Q206T+S256Y Q206T+S259D
Q206T+T260E Q206T+T260P Q206T+N261 C Q206T+N261 E
Q206T+N261 L Q206T+N261 M Q206T+N261V Q206T+N261Y
Q206T+N261W Q206T+L262C Q206T+L262E Q206T+L262Q Q206V+Y209W Q206V+S212A Q206V+S212D Q206V+S212G
Q206V+S212N Q206V+S216I Q206V+S216T Q206V+S216V
Q206V+L217C Q206V+L217M Q206V+N218T Q206V+M222C
Q206V+M222R Q206V+P225A Q206V+T255C Q206V+T255E
Q206V+S256A Q206V+S256C Q206V+S256D Q206V+S256V
Q206V+S256Y Q206V+S259D Q206V+T260E Q206V+T260P
Q206V+N261 C Q206V+N261 E Q206V+N261 L Q206V+N261 M
Q206V+N261V Q206V+N261Y Q206V+N261W Q206V+L262C
Q206V+L262E Q206V+L262Q Q206W+Y209W Q206W+S212A
Q206W+S212D Q206W+S212G Q206W+S212N Q206W+S216I
Q206W+S216T Q206W+S216V Q206W+L217C Q206W+L217M
Q206W+N218T Q206W+M222C Q206W+M222R Q206W+P225A
Q206W+T255C Q206W+T255E Q206W+S256A Q206W+S256C
Q206W+S256D Q206W+S256V Q206W+S256Y Q206W+S259D
Q206W+T260E Q206W+T260P Q206W+N261 C Q206W+N261 E
Q206W+N261 L Q206W+N261 M Q206W+N261V Q206W+N261Y
Q206W+N261W Q206W+L262C Q206W+L262E Q206W+L262Q
Q206L+Y209W Q206L+S212A Q206L+S212D Q206L+S212G
Q206L+S212N Q206L+S216I Q206L+S216T Q206L+S216V
Q206L+L217C Q206L+L217M Q206L+N218T Q206L+M222C
Q206L+M222R Q206L+P225A Q206L+T255C Q206L+T255E
Q206L+S256A Q206L+S256C Q206L+S256D Q206L+S256V
Q206L+S256Y Q206L+S259D Q206L+T260E Q206L+T260P
Q206L+N261 C Q206L+N261 E Q206L+N261 L Q206L+N261 M
Q206L+N261V Q206L+N261Y Q206L+N261W Q206L+L262C
Q206L+L262E Q206L+L262Q Y209W+S212A Y209W+S212D
Y209W+S212G Y209W+S212N Y209W+S216I Y209W+S216T
Y209W+S216V Y209W+L217C Y209W+L217M Y209W+N218T
Y209W+M222C Y209W+M222R Y209W+P225A Y209W+T255C
Y209W+T255E Y209W+S256A Y209W+S256C Y209W+S256D
Y209W+S256V Y209W+S256Y Y209W+S259D Y209W+T260E
Y209W+T260P Y209W+N261 C Y209W+N261 E Y209W+N261 L
Y209W+N261 M Y209W+N261V Y209W+N261Y Y209W+N261W
Y209W+L262C Y209W+L262E Y209W+L262Q S212A+S216I
S212A+S216T S212A+S216V S212A+L217C S212A+L217M
S212A+N218T S212A+M222C S212A+M222R S212A+P225A
S212A+T255C S212A+T255E S212A+S256A S212A+S256C
S212A+S256D S212A+S256V S212A+S256Y S212A+S259D
S212A+T260E S212A+T260P S212A+N261 C S212A+N261 E
S212A+N261 L S212A+N261 M S212A+N261V S212A+N261Y
S212A+N261W S212A+L262C S212A+L262E S212A+L262Q
S212D+S216I S212D+S216T S212D+S216V S212D+L217C
S212D+L217M S212D+N218T S212D+M222C S212D+M222R
S212D+P225A S212D+T255C S212D+T255E S212D+S256A
S212D+S256C S212D+S256D S212D+S256V S212D+S256Y
S212D+S259D S212D+T260E S212D+T260P S212D+N261 C
S212D+N261 E S212D+N261 L S212D+N261 M S212D+N261V
S212D+N261Y S212D+N261W S212D+L262C S212D+L262E
S212D+L262Q S212G+S216I S212G+S216T S212G+S216V
S212G+L217C S212G+L217M S212G+N218T S212G+M222C
S212G+M222R S212G+P225A S212G+T255C S212G+T255E
S212G+S256A S212G+S256C S212G+S256D S212G+S256V
S212G+S256Y S212G+S259D S212G+T260E S212G+T260P
S212G+N261 C S212G+N261 E S212G+N261 L S212G+N261 M S212G+N261V S212G+N261Y S212G+N261W S212G+L262C
S212G+L262E S212G+L262Q S212N+S216I S212N+S216T
S212N+S216V S212N+L217C S212N+L217M S212N+N218T
S212N+M222C S212N+M222R S212N+P225A S212N+T255C
S212N+T255E S212N+S256A S212N+S256C S212N+S256D
S212N+S256V S212N+S256Y S212N+S259D S212N+T260E
S212N+T260P S212N+N261 C S212N+N261 E S212N+N261 L
S212N+N261 M S212N+N261V S212N+N261Y S212N+N261W
S212N+L262C S212N+L262E S212N+L262Q S216I+L217C
S216I+L217M S216I+N218T S216I+M222C S216I+M222R
S216I+P225A S216I+T255C S216I+T255E S216I+S256A
S216I+S256C S216I+S256D S216I+S256V S216I+S256Y
S216I+S259D S216I+T260E S216I+T260P S216I+N261 C
S216I+N261 E S216I+N261 L S216I+N261 M S216I+N261V
S216I+N261Y S216I+N261W S216I+L262C S216I+L262E
S216I+L262Q S216T+L217C S216T+L217M S216T+N218T
S216T+M222C S216T+M222R S216T+P225A S216T+T255C
S216T+T255E S216T+S256A S216T+S256C S216T+S256D
S216T+S256V S216T+S256Y S216T+S259D S216T+T260E
S216T+T260P S216T+N261 C S216T+N261 E S216T+N261 L
S216T+N261 M S216T+N261V S216T+N261Y S216T+N261W
S216T+L262C S216T+L262E S216T+L262Q S216V+L217C
S216V+L217M S216V+N218T S216V+M222C S216V+M222R
S216V+P225A S216V+T255C S216V+T255E S216V+S256A
S216V+S256C S216V+S256D S216V+S256V S216V+S256Y
S216V+S259D S216V+T260E S216V+T260P S216V+N261 C
S216V+N261 E S216V+N261 L S216V+N261 M S216V+N261V
S216V+N261Y S216V+N261W S216V+L262C S216V+L262E
S216V+L262Q L217C+N218T L217C+M222C L217C+M222R
L217C+P225A L217C+T255C L217C+T255E L217C+S256A
L217C+S256C L217C+S256D L217C+S256V L217C+S256Y
L217C+S259D L217C+T260E L217C+T260P L217C+N261 C
L217C+N261 E L217C+N261 L L217C+N261 M L217C+N261V
L217C+N261Y L217C+N261W L217C+L262C L217C+L262E
L217C+L262Q L217M+N218T L217M+M222C L217M+M222R
L217M+P225A L217M+T255C L217M+T255E L217M+S256A
L217M+S256C L217M+S256D L217M+S256V L217M+S256Y
L217M+S259D L217M+T260E L217M+T260P L217M+N261 C
L217M+N261 E L217M+N261 L L217M+N261 M L217M+N261V
L217M+N261Y L217M+N261W L217M+L262C L217M+L262E
L217M+L262Q N218T+M222C N218T+M222R N218T+P225A
N218T+T255C N218T+T255E N218T+S256A N218T+S256C
N218T+S256D N218T+S256V N218T+S256Y N218T+S259D
N218T+T260E N218T+T260P N218T+N261 C N218T+N261 E
N218T+N261 L N218T+N261 M N218T+N261V N218T+N261Y
N218T+N261W N218T+L262C N218T+L262E N218T+L262Q
M222C+P225A M222C+T255C M222C+T255E M222C+S256A
M222C+S256C M222C+S256D M222C+S256V M222C+S256Y
M222C+S259D M222C+T260E M222C+T260P M222C+N261 C
M222C+N261 E M222C+N261 L M222C+N261 M M222C+N261V
M222C+N261Y M222C+N261W M222C+L262C M222C+L262E
M222C+L262Q M222R+P225A M222R+T255C M222R+T255E
M222R+S256A M222R+S256C M222R+S256D M222R+S256V
M222R+S256Y M222R+S259D M222R+T260E M222R+T260P M222R+N261C M222R+N261E M222R+N261L M222R+N261M
M222R+N261V M222R+N261Y M222R+N261W M222R+L262C
M222R+L262E M222R+L262Q P225A+T255C P225A+T255E
P225A+S256A P225A+S256C P225A+S256D P225A+S256V
P225A+S256Y P225A+S259D P225A+T260E P225A+T260P
P225A+N261C P225A+N261E P225A+N261L P225A+N261M
P225A+N261V P225A+N261Y P225A+N261W P225A+L262C
P225A+L262E P225A+L262Q T255C+S256A T255C+S256C
T255C+S256D T255C+S256V T255C+S256Y T255C+S259D
T255C+T260E T255C+T260P T255C+N261C T255C+N261E
T255C+N261L T255C+N261M T255C+N261V T255C+N261Y
T255C+N261W T255C+L262C T255C+L262E T255C+L262Q
T255E+S256A T255E+S256C T255E+S256D T255E+S256V
T255E+S256Y T255E+S259D T255E+T260E T255E+T260P
T255E+N261C T255E+N261E T255E+N261L T255E+N261M
T255E+N261V T255E+N261Y T255E+N261W T255E+L262C
T255E+L262E T255E+L262Q S256A+S259D S256A+T260E
S256A+T260P S256A+N261C S256A+N261E S256A+N261L
S256A+N261M S256A+N261V S256A+N261Y S256A+N261W
S256A+L262C S256A+L262E S256A+L262Q S256C+S259D
S256C+T260E S256C+T260P S256C+N261C S256C+N261E
S256C+N261L S256C+N261M S256C+N261V S256C+N261Y
S256C+N261W S256C+L262C S256C+L262E S256C+L262Q
S256D+S259D S256D+T260E S256D+T260P S256D+N261C
S256D+N261E S256D+N261L S256D+N261M S256D+N261V
S256D+N261Y S256D+N261W S256D+L262C S256D+L262E
S256D+L262Q S256V+S259D S256V+T260E S256V+T260P
S256V+N261C S256V+N261E S256V+N261L S256V+N261M
S256V+N261V S256V+N261Y S256V+N261W S256V+L262C
S256V+L262E S256V+L262Q S256Y+S259D S256Y+T260E
S256Y+T260P S256Y+N261C S256Y+N261E S256Y+N261L
S256Y+N261M S256Y+N261V S256Y+N261Y S256Y+N261W
S256Y+L262C S256Y+L262E S256Y+L262Q S259D+T260E
S259D+T260P S259D+N261C S259D+N261E S259D+N261L
S259D+N261M S259D+N261V S259D+N261Y S259D+N261W
S259D+L262C S259D+L262E S259D+L262Q T260E+N261C
T260E+N261E T260E+N261L T260E+N261M T260E+N261V
T260E+N261Y T260E+N261W T260E+L262C T260E+L262E
T260E+L262Q T260P+N261C T260P+N261E T260P+N261L
T260P+N261M T260P+N261V T260P+N261Y T260P+N261W
T260P+L262C T260P+L262E T260P+L262Q N261C+L262C
N261C+L262E N261C+L262Q N261E+L262C N261E+L262E
N261E+L262Q N261L+L262C N261L+L262E N261L+L262Q
N261M+L262C N261M+L262E N261M+L262Q N261V+L262C
N261V+L262E N261V+L262Q N261Y+L262C N261Y+L262E
N261Y+L262Q
In another aspect of the invention, the subtilase variant of the invention comprises three of the substitutions selected from the list consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A114V, G115T, G115W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161C, S161E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the parent subtilase. In a preferred embodiment, the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance compared to the parent protease.
Preferred variants includes variants which compared to any of SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 comprises the following mutations:
N76D+S9E+L262E
N76D+P225A+S259D
N76D+S212D+P225A
N76D+N43R+L262E
N76D+S212D+S259D
N76D+Q206C+Y209W
N76D+V205I+Q206L
N76D+P131 *+S212D
N76D+P131 *+S259D
N76D+V205I+Q206I
N76D+G160P+S161 E
N76D+N204D+Q206L
N76D+V205I+Q206V
N76D+A194P+Q206E
N76D+P131 *+P225A
N76D+N204D+Q206I
N76D+N204D+V205I
N76D+N204D+Q206V
N76D+N204D+Q206W
N76D+N261 W+L262E
N76D+N261 L+L262E
N76D+G160P+S161Y
N76D+N261 E+L262E N76D+N261V+L262E
N76D+Q206L+Y209W
N76D+N261Y+L262E
N76D+V205I+Q206W
N76D+G160D+S161 E
N76D+V205I+Q206E
N76D+Q206L+S256D
N76D+G1 15T+H120T
N76D+G160D+S161Y
N76D+N18S+V205I
N76D+A194P+M222S
N76D+Y209W+S256D
N76D+N18S+Q206E
N76D+Y209W+S256C
N76D+G1 15T+H120V
N76D+T255E+S256D
N76D+G1 15T+H120I
N76D+T255Q+S256D,
N76D +*99aE +S212D +N261 D N76D +T255E +S256Y +T260E
N76D +T255E +S256Y +T260P
N76D +T255Q +S256Y +T260E
N76D +T255Q +S256Y +T260P
N76D +T255E +S256A +T260P N76D +T255Q +S256A +T260E
N76D +T255Q +S256A +T260P
N76D +A158E +G160D +S161 E
N76D +A158E +G160D +S161 H
N76D +A158E +G160D +S161Y N76D +A158E +G160P +S161 E
N76D +A158E +G160P +S161 H
N76D +A158E +G160P +S161Y
N76D +N204D +V205I +Q206I
N76D +N204D +V205I +Q206L N76D +N204D +V205I +Q206V
N76D +N204D +V205I +Q206W
N76D +N204D +V205L +Q206I N76D +N204D +V205L +Q206L
N76D +N204D +V205L +Q206V
N76D +N204D +V205L +Q206W
N76D +T255E +S256D +T260E N76D +T255E +S256D +T260P
N76D +T255Q +S256D +T260E
N76D +T255Q +S256D +T260P
N76D +P129D +A158E +Q191 N
N76D +P129D +G160D +S161 E N76D +P129D +G160D +S161 H
N76D +P129D +G160D +S161Y
N76D +P129D +G160P +S161 H
N76D +G160P +S161Y +Q191 N
S9E +N43R +N76D +L262E
S9E +N76D +S212D +S259D
N43R +N76D +S212D +S259D
S9E +N76D +S212D +N261 D
S9E +N76D +S212D +N261 D
N76D +S212D +S259D +N261 D S9E +G61 E +N76D +L262E
G61 E +N76D +Q206L +L262E
N76D +*99aE +G195E +K235L
N76D +*99aE +H 120D +G195E
S9E +N76D +*99aE +L262E
N76D +*99aE +H 120D +K235L
N76D +*99aE +A194P +Q206E
N43R +N76D +*99aE +L262E
N18S +N76D +V205I +Q206E
N76D +Q206C +Y209W +S256D N76D +Q206L +Y209W +S256D
N76D +Q206L +Y209W +S256C
G61 E +N76D +A194P +V205I +Q206E
S9E +N43R +N76D +A194P +L262E
S9E +N43R +N76D +S212D +S259D S9E +N43R +G61 E +N76D +L262E
S9E +N76D +Q206L +Y209W +S256D
G61 E +N76D +Q206L +Y209W +S256D S9E +G61 E +N76D +Q206L +Y209W
N76D +*99aE +S212D +S259D
N76D +*99aE +P131 * +S259D
S9E +N76D +*99aE +S212D +S259D
N43R +N76D +*99aE +S212D +S259D
S9E +N76D +*99aE +S212D +N261 D
S212D +N76D +*99aE +P131 *
*35aD +N76D +H120D +G195E +*275aF
N43R +N76D +Q206L +Y209W +S256D
N76D +*99aE +H120D +G195E +K235L
N76D +*99aE +Q206L +Y209W +S256D
N76D +*99aE +Q206L +Y209W +S256D
S9E +N43R +N76D +*99aE +L262E
N76D +A158E +G160D +S161 E +Q191 N N76D +P129D +A158E +G160D +S161 E
N76D +P129D +A158E +G160D +S161 E
N76D +P129D +A158E +G160D +S161 E
N76D +P129D +A158E +G160D +S161 E
N76D +A158E +G160D +S161 H +Q191 N N76D +P129D +A158E +G160D +S161 H
N76D +A158E +G160D +S161Y +Q191 N
N76D +P129D +A158E +G160D +S161Y
N76D +A158E +G160P +S161 E +Q191 N
N76D +P129D +A158E +G160P +S161 E N76D +P129D +A158E +G160P +S161Y
N76D +N204D +V205I +Q206I +S216V
N76D +N204D +V205I +Q206L +S216V
N76D +Q182E +N204D +V205I +Q206L
N76D +S99D +H120N +P131 * +Q206E +S212D N76D +S99D +H120N +P131 * +A194P +Q206E
N76D +S99D +H120N +P131T +A194P +Q206E
A15T +N76D +H120N +P131 * +V205I +Q206E
A15T +N76D +H120I +P131 T +V205I +Q206E
S9E +N43R +N76D +Q206H +S212D +S259D *35aD +N76D +H120D +G195E +K235L +*275aR
S9E +G61 E +N76D +Q206L +Y209W +S256D
S9E +N43R +I72A +N76D +A194P +L262E S9E +N43R +N76D +Q206L +Y209W +S256D
S9E +N43R +N76D +*99aE +A194P +L262E
S9E +N43R +N76D +*99aE +S212D +S259D
N76D +P129D +A158E +G160D +S161 E +Q191 N
N76D +P129D +A158E +G160D +S161 H +Q191 N
N76D +P129D +A158E +G160D +S161Y +Q191 N
N76D +P129D +A158E +G160P +S161 E +Q191 N
N76D +P129D +A158E +G160P +S161 H +Q191 N
N76D +Q182E +N204D +V205I +Q206I +S216V
N76D +Q182E +N204D +V205I +Q206L +S216V
35aD +N76D +H120D +G195E +K235L +*275aH
S9R +A15T +N76D +A194P +Q206E +Q245R +N261 D
S9R +A15T +G61 E +N76D +A194P +Q245R +N261 D
S9E +N43R +N76D +A158E +G160P +A194P +L262E
S9E +N43R +N76D +*99aE +Q206H +S212D +S259D
S9E +N43R +N76D +P131 * +Q206L +Y209W +S256D
S9E +N43R +I72A +N76D +A158E +G160P +A194P +L262E
35aD +N76D +H120D +G195E +K235L +*275aH +*275bH
A15T +G61 D +N76D +S99D +H120N +P131 * +Q206E +S212D
S9R +A15T +N76D +S99D +A194P +V205I +Q206E +Q245R +N261 D
*35aD +N76D +H120D +G195E +K235L +*275aH +*275bH +*275cH
A15T +N76D +S99D +H120D +A194P +V205I +S212D +Q245R +N261 D
T58Y +N76D +S99D +H120N +P131 * +A194P +Q206E +S212D +S259D
A15T +N76D +S99D +H120N +A194P +Q206E +Q245R +N261 D +L262Y
S9E +N43R +I72A +N76D +A158E +G160P +A194P +L262E +*275aH +*275bH
A15T +G61 D +N76D +H120I +P131 * +A194P +Q206L +S212D +Q245R +S259D
A15T +G61 D +N76D +H120I +P131 * +A194P +Q206V +S212D +Q245R +S259D
S9E +N43R +I72A +N76D +Q137H +S141 H +R145H +A158E +G160P +A194P +L262E, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2.
In another aspect of the invention, the subtilase variant of the invention comprises four or five or six or seven or eight of the substitutions selected from the list consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved storage stability, compared to the polypeptide of SEQ I D NO: 1 or to the polypeptide of SEQ ID NO: 2. In a preferred embodiment, the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 or to the polypeptide of SEQ ID NO: 2.
A particular embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2, wherein the variant comprises any of the further mutations selected from the list consisting of Q2R, W6L,W6I, I8C,I8H, S9R A15T, N 18S, S24H, *35aD, A48H, S49T, G53A, G53L, T58Y, G61 E, G61 D, N76D, S99D, *99aE,V104P, V104T, V104Y, N1 17H, H120N, H120D, P131 *, Q137H, S141 H, R145H V149Q, S161Y, I 162L, N184D, A194P, A194D, A194E, V205L, M222N, P225S, K235L, N238H, V244H, N248H, T255Q, T260A, N261 D, N261 R, *275aR, *275aF, *275aH, *275bH and *275cH.
The subtilase variants may further comprise one or more substitutions selected from the group consisting of S3T, V4I, A15T, S24G,S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E,Q245K and Q245R (numbering according to SEQ ID NO: 2).
Thus in further embodiments of the invention, the subtilase variant described in table 1 and 2 further comprises or consists of one or more of the substitutions S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R in the polypeptide of SEQ ID NO: 1 ,SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12, wherein each position corresponds to the corresponding position of the polypeptide of SEQ ID NO: 2. In one embodiment, the subtilase variant has improved stability, in particular improved in storage stability, compared to the parent subtilase or compared to the polypeptide of SEQ ID NO: 1 .
A particular embodiment of the invention relates to subtilase variants having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO 1 when measured as described in the accelerated storage stability assay in Example 3 herein wherein the subtilase variants comprises one or more of the substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2, wherein the variant comprises any of the further mutations selected from the list consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of one of the substitutions S9C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S9D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R(numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S9E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S9Q and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N43A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N43C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N43L and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N43R and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N43W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution I72A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution I72V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S78D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution A1 14V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution G1 15T and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution G1 15W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitutionH120l and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 4).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution H120T and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution H120V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution V147W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution V149C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution V149N and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution A158E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution G160D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution G160P and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S161 C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S161 E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S163A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S163D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q182C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q182E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N185C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N185E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q188C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q188D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q188E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q191 N and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N204D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N204V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution V205I and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206I and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206K and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206T and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Q206L and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution Y209W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S212A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S212D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S212G and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S212N and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S216I and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S216T and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S216V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution M222C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q, S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution M222R and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution P225A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution T255C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution T255E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S256A and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S256C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S256D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S256V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S256Y and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution S259D and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution T260E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution T260P and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261 C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261 E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 , S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261 L and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261 M and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261V and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261W and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261Y and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution N261 F and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution L262C and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution L262E and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In one embodiment of the invention, the subtilase variant comprises or consists of the substitution L262Q and one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
The amino acid changes may be of a minor nature, that is conservative amino acid substitutions or insertions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of 1 -30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
Examples of conservative substitutions are within the groups of basic amino acids
(arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagine), hydrophobic amino acids (leucine, isoleucine and valine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, threonine and methionine). Amino acid substitutions that do not generally alter specific activity are known in the art and are described, for example, by H. Neurath and R.L. Hill, 1979, In, The Proteins, Academic Press, New York. Common substitutions are Ala/Ser, Val/lle, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/lle, LeuA al, Ala/Glu, and Asp/Gly.
Alternatively, the amino acid changes are of such a nature that the physico-chemical properties of the polypeptides are altered. For example, amino acid changes may improve thermal stability of the polypeptide, alter the substrate specificity, change the pH optimum, and the like.
Essential amino acids in a polypeptide can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham and Wells, 1989, Science 244: 1081 -1085). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for protease activity to identify amino acid residues that are critical to the activity of the molecule. See also, Hilton et at., 1996, J. Biol. Chem. 271 : 4699-4708. The active site of the enzyme or other biological interaction can also be determined by physical analysis of structure, as determined by such techniques as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, in conjunction with mutation of putative contact site amino acids. See, for example, de Vos et al., 1992, Science 255: 306-312; Smith et al., 1992, J. Mol. Biol. 224: 899-904; Wlodaver et al., 1992, FEBS Lett. 309: 59-64. For BPN' (SEQ ID NO: 2) the catalytic triad comprising the amino acids S221 , H64, and D32 is essential for protease activity of the enzyme.
The subtilase variants may consist of 150 to 350, e.g., 175 to 330, 200 to 310, 220 to 300, 240 to 290, 260 to 280 or 269, 270, 271 , 272, 273, 274 or 275 amino acids.
In an embodiment, the subtilase variant has improved stability, in particular improved in storage stability, compared to the parent enzyme wherein in storage stability is measured using the 'accelerated storage stability assay" as described in the Materials and Methods Example 3 herein. In an embodiment, the subtilase variant has improved stability, in particular improved in storage stability, compared to the polypeptide of SEQ ID NO: 1 wherein in stability is measured using the 'accelerated storage stability assay' as described in the Materials and Methods section herein.
In an embodiment, the subtilase variant has improved stability, in particular improved in wash stability, and on par or improved wash performance compared to the parent enzyme wherein in wash stability is measured using the 'in wash stability assay' and wash performance is measured using the Automatic Mechanical Stress Assay (AMSA) for laundry as described in the Materials and Methods section herein. In an embodiment, the subtilase variant has improved stability, in particular improved storage stability, and on par or improved wash performance compared to the polypeptide of SEQ ID NO: 1 wherein storage stability is measured using the 'accelerated storage stability assay' and wash performance is measured using the Automatic Mechanical Stress Assay (AMSA) for laundry as described in "Materials and Methods" section herein.
Parent protease
The parent or the precursor protease may be any subtilase or preferred any subtilisin as defined below. The amino acid sequences of the subtilases can be aligned to identify corresponding amino acids in a given sequence. As mentioned above SEQ ID NO 2 (ΒΡΝ') is used for numbering. However, the parent or precursor protease maybe any subtilase thus as described in "convention for designating variants" the amino acid at a given position maybe different among various subtilases it will be clear to the person skilled in the art that for example the following mutation V205I in the context of the present invention do not require that it's the amino acid valine which is replaced by isoleucine or leucine. Thus the mutations according to the invention maybe written as follows: X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261 W, X261Y, X261 F, X262C, X262E and X262Q, where X is any amino acid which may be present in the parent subtilase or the start or precursor subtilase It will be clear that if the parent, precursor or starting protease already comprises e.g. I at position corresponding to positions 205 of SEQ ID NO 2 this will not be substituted.
Enzymes cleaving the amide linkages in protein substrates are classified as proteases, or (interchangeably) peptidases (see Walsh, 1979, Enzymatic Reaction Mechanisms. W.H. Freeman and Company, San Francisco, Chapter 3).
Serine proteases
A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site (White, Handler and Smith, 1973 "Principles of Biochemistry," Fifth Edition, McGraw-Hill Book Company, NY, pp. 271 -272).
The bacterial serine proteases have molecular weights in the 20,000 to 45,000 Dalton range. They are inhibited by diisopropylfluorophosphate. They hydrolyze simple terminal esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 1 1 .0 (for review, see Priest (1977) Bacteriological Rev. 41 :71 1 - 753). Subtilases
A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al. (1991 ), Protein Eng. 4:719-737 and Siezen et al. (1997), Protein Science 6:501 -523. They are defined by homology analysis of more than 170 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously often defined as a serine protease produced by Gram-positive bacteria or fungi, and according to Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases has been determined. For a more detailed description of such subtilases and their amino acid sequences reference is made to Siezen et al. (1997).
Subtilisins
A subgroup of the subtilases is the subtilisins which are serine proteases from the family S8, in particular from the subfamily S8A, as defined by the MEROPS database (http://merops.sanger.ac. uk/cgi-bin/famsum?family=S8).
BPN' and Savinase have the MEROPS numbers S08.034 and S08.003, respectively.
Parent subtilase
The term "parent subtilase" describes a subtilase defined according to Siezen et al. (1997), Protein Science 6:501 -523. For further details see description of "Subtilases" above. A parent subtilase may also be a subtilase isolated from a natural source, wherein subsequent modifications (such as replacement(s) of the amino acid side chain(s), substitution(s), deletion(s) and/or insertion(s)) have been made while retaining the characteristic of a subtilase. Furthermore, a parent subtilase may be a subtilase which has been prepared by the DNA shuffling technique, such as described by J.E. Ness et al. (1999) Nature Biotechnology, 17:893- 896.
Alternatively, the term "parent subtilase" may be termed "precursor subtilase" and the term is used to describe the starting protease into which mutations are made to obtain the variant of the invention. The parent subtilase is preferably of the subtilisin subgroups.
One subgroup of the subtilases, I-S1 or "true" subtilisins, comprises the "classical" subtilisins, such as subtilisin 168 (BSS168), subtilisin BPN', subtilisin Carlsberg (ALCALASE®, NOVOZYMES A/S), and subtilisin DY (BSSDY). BPN' is subtilisin BPN' from B. amyloliquefaciens, BPN' has the amino acid sequence SEQ ID NO: 2. A further subgroup of the subtilases, I-S2 or high alkaline subtilisins, is recognized by Siezen et al. (supra). Sub-group I- S2 proteases are described as highly alkaline subtilisins and comprises enzymes such as subtilisin PB92 (BAALKP) (MAXACAL®, Genencor International Inc.), subtilisin 147 (BLS147) (ESPERASE®, Novozymes A/S), alkaline elastase YaB (BSEYAB) and subtilisin 309 (SAVINASE®, Novozymes A/S) having the amino acid sequence SEQ ID NO 1 . Preferably the parent subtilase is selected from any of the proteases having the amino acid sequences SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
For reference, table 3 below gives a list of some acronyms for various subtilases mentioned herein. For further acronyms, see Siezen et al. (1991 and 1997).
Table 3: Acronyms of various subtilases
Figure imgf000126_0001
Homologous subtilase sequences
The homology between two amino acid sequences is in this context described by the parameter "identity" for purposes of the present invention, the degree of identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm as described above in "convention for designating variants". The output from the routine is besides the amino acid alignment the calculation of the "Percent Identity" between the two sequences.
Based on this description it is routine for a person skilled in the art to identify suitable homologous subtilases, which can be modified according to the invention.
The parent protease may be a polypeptide having at least 60% sequence identity to the polypeptide of SEQ ID NO: 1 .
Preferably the parent subtilase is selected from any of the proteases having at least 60% sequence identity to any of the amino acid sequences SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID N0:7, SEQ ID N0:8, SEQ ID N0:9, SEQ ID NO:10, SEQ ID N0:1 1 or SEQ ID NO:12.
In an aspect, the parent has a sequence identity to the polypeptide of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which have protease activity. In one aspect, the amino acid sequence of the parent differs by up to 10 amino acids, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10, from any of the polypeptides of SEQ ID NO: 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 1 .
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ
ID NO: 2.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 3.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 4.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 5.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 6.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ
ID NO: 7.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 8.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 9.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 10.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ ID NO: 1 1.
In another aspect, the parent comprises or consists of the amino acid sequence of SEQ
ID NO: 12. The polypeptide may be a hybrid polypeptide in which a region of one polypeptide is fused at the N-terminus or the C-terminus of a region of another polypeptide.
The parent subtilase may be obtained from microorganisms of any genus. For purposes of the present invention, the term "obtained from" as used herein in connection with a given source shall mean that the parent encoded by a polynucleotide is produced by the source or by a strain in which the polynucleotide from the source has been inserted. In one aspect, the parent is secreted extracellularly.
The parent may be a bacterial protease. For example, the parent may be a Gram- positive bacterial polypeptide such as a Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, or Streptomyces protease, or a Gram-negative bacterial polypeptide such as a Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, llyobacter, Neisseria, Pseudomonas, Salmonella, or Ureaplasma protease.
In one aspect, the parent is a Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis, or Bacillus thuringiensis protease
In one aspect, the parent is a Bacillus amyloliquefaciens protease, e.g., the protease of SEQ ID NO: 2.
In another aspect, the parent is a Bacillus lentus or a bacillus clausii protease, e.g., the protease of SEQ ID NO: 1 .
Strains of these species are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL).
The parent may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) or DNA samples obtained directly from natural materials (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms and DNA directly from natural habitats are well known in the art. A polynucleotide encoding a parent may then be obtained by similarly screening a genomic DNA or cDNA library of another microorganism or mixed DNA sample. Once a polynucleotide encoding a parent has been detected with the probe(s), the polynucleotide can be isolated or cloned by utilizing techniques that are known to those of ordinary skill in the art (see, e.g., Sambrook et ai, 1989, supra). Preparation of Variants
The present invention also relates to methods for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a parent subtilase one or more substitutions selected from the group S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V,
G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 1 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D,
G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E,
N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 2 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261W, N261 F, Y262C, Y262E and Y262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 3 one or more substitutions selected from the group consisting Q2R, W6I, I8C, I8H, S9C, S9D, S9E, S9Q, N18S, N43A, N43C, N43L, N43R, N43W, S49T, G53A, G53L, G61 D, I72A, I72V, S78D, S78N, V104F, V104P, V104T, V104Y, A1 14V, G1 15T, G1 15W, H 120I, H120T, H120V, P129D, V147W, V149C, V149N, V149Q, A158E, G160D, G160P, S161 C, S161Y, S161 E, I 162L, S163A, S163D, Q182C, Q182E, N184D, N185C, N185E, S188C, S188D, S188E, Q191 N, A194D, A194E, N204D, N204V, V205I, V205L, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, Y209L, Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222N, M222R, P225A, P225S, V244H, N248H, T255C, T255E, T255Q, S256A, S256C, S256D, S256V, S256Y, S259D, T260A, T260E, T260P, N261 D, N261 C, N261 E, N261 L, N261 M, N261 R, N261V, N261W, N261Y, N261 F, L262Y, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 4 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 5 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 6 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 7 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C,
N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising: (a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 8 one or more substitutions selected from the group consisting S3V, S3Y, S9M, S9C, S9D, S9E, S9Q, P40E, N43E, N43D, N43A, N43C, N43L, N43R, N43W, R45E, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120D, H120I, H120T, H120V, P129D, A133E, V147W, V149C, 149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182E, Q182C, Q182E, N185C, N185E, S188T, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, N218D, M222C, M222R, P225A, A228S, Q236E, Q245R, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262Y, L262C, L262E, L262Q and A270G, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 9 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 10 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261 V, F261Y, F261 W, Y262C, Y262E and Y262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and (b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 1 1 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, K43A, K43C,
K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, ΤΊ 58Ε, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261 W, Y262C, Y262E and Y262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
Another aspect of the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
(a) introducing into a subtilase having the amino acid sequence with SEQ ID NO 12 one or more substitutions selected from the group consisting S9C, S9D, S9E, S9Q, K43A, K43C, K43L, K43R, K43W, V72A, S78D, Y104F, A1 14V, I 1 15T, I1 15W, D120I, D120T, D120V, P129D, V147W, V149C, V149N, T158E, G160D, G160P, S161 C, S161 E, S163A, S163D, S182C, S182E, Q185C, Q185E, S188C, S188D, S188E, S191 N, S204D, S204V, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L, L209W, N212A, N212D, N212G, A216I, A216T, A216V, Y217C, Y217M, N218T, M222C, M222R, P225A, T255C, T255E, K256A, K256C, K256D, K256V, K256Y, S260E, S260P, F261 C, F261 E, F261 L, F261 M, F261V, F261Y, F261 W, Y262C, Y262E and Y262Q, wherein the position corresponds to the position of SEQ ID NO: 2, and
(b) recovering the variant.
The parent protease subtilase is preferably selected from SEQ ID NO 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 , SEQ ID NO:12.
In an embodiment, the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
a) introducing into a parent subtilase having the amino acid sequence with SEQ ID NO 1 one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of the mature polypeptide of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide that has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide with SEQ ID NO 1 ;
b) recovering the variant.
In an embodiment, the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
a) introducing into a parent subtilase having the amino acid sequence with SEQ ID NO 1 two or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of the mature polypeptide of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide that has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide with SEQ ID NO 1 ;
b) recovering the variant.
In an embodiment, the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
a) introducing into a parent subtilase having the amino acid sequence with SEQ ID
NO 1 three or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of the mature polypeptide of SEQ ID NO: 2 and wherein the subtilase variant is a polypeptide that has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide with SEQ ID NO 1 ;
b) recovering the variant.
The subtilase variants may further comprise one or more substitutions (e.g. several) selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
In an embodiment, the invention relates to a method for obtaining a subtilase variant having protease activity, comprising:
a) introducing into a parent subtilase with SEQ ID NO 1 , SEQ ID NO:2, SEQ ID
NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 one or more substitutions selected from the group consisting of X9C, 9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, 1201, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, 185E, 188C, 188D, 188E, 191 N, 204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261 W, X261Y, X261 F, X262C, X262E and X262Q (numbering according to SEQ ID NO: 2), wherein the subtilase variant is a polypeptide having at least 60%, SEQ ID NO 1 ;
b) introducing one or more additional mutations selected from the group consisting of X3T, X4I, X15T, X24G, X24R, X68A, X99D, X99E, X101 R, X101 K, X101 N, X101 M, X101 E, X101 D, X101 L, X101 I, X103A, X104I, X128A, X128L, X128S, X129N, X129Q, X130A, X199M, X217Y, X217D, X217E, X217Q, X218D, X218E, X245K and X245R (numbering according to SEQ ID NO: 2)
c) recovering the variant.
The variants can be prepared using any mutagenesis procedure known in the art, such as site-directed mutagenesis, synthetic gene construction, semi-synthetic gene construction, random mutagenesis, shuffling, etc.
Site-directed mutagenesis is a technique in which one or more (e.g., several) mutations are introduced at one or more defined sites in a polynucleotide encoding the parent. Site-directed mutagenesis can be accomplished in vitro by PCR involving the use of oligonucleotide primers containing the desired mutation. Site-directed mutagenesis can also be performed in vitro by cassette mutagenesis involving the cleavage by a restriction enzyme at a site in the plasmid comprising a polynucleotide encoding the parent and subsequent ligation of an oligonucleotide containing the mutation in the polynucleotide. Usually the restriction enzyme that digests the plasmid and the oligonucleotide is the same, permitting sticky ends of the plasmid and the insert to ligate to one another. See, e.g., Scherer and Davis, 1979, Proc. Natl. Acad. Sci. USA 76: 4949-4955; and Barton et al., 1990, Nucleic Acids Res. 18: 7349-4966.
Site-directed mutagenesis can also be accomplished in vivo by methods known in the art. See, e.g., U.S. Patent Application Publication No. 2004/0171 154; Storici et al., 2001 , Nature Biotechnol. 19: 773-776; Kren et al., 1998, Nat. Med. 4: 285-290; and Calissano and Macino, 1996, Fungal Genet. Newslett. 43: 15-16.
Any site-directed mutagenesis procedure can be used in the present invention. There are many commercial kits available that can be used to prepare variants.
Synthetic gene construction entails in vitro synthesis of a designed polynucleotide molecule to encode a polypeptide of interest. Gene synthesis can be performed utilizing a number of techniques, such as the multiplex microchip-based technology described by Tian et al. (2004, Nature 432: 1050-1054) and similar technologies wherein oligonucleotides are synthesized and assembled upon photo-programmable microfluidic chips.
Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241 : 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413; or WO 95/22625. Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991 , Biochemistry 30: 10832-10837; U.S. Patent No. 5,223,409; WO 92/06204) and region-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Ner ei a/., 1988, DNA 7: 127).
Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness et al., 1999, Nature Biotechnology 17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.
Semi-synthetic gene construction is accomplished by combining aspects of synthetic gene construction, and/or site-directed mutagenesis, and/or random mutagenesis, and/or shuffling. Semi-synthetic construction is typified by a process utilizing polynucleotide fragments that are synthesized, in combination with PCR techniques. Defined regions of genes may thus be synthesized de novo, while other regions may be amplified using site-specific mutagenic primers, while yet other regions may be subjected to error-prone PCR or non-error prone PCR amplification. Polynucleotide subsequences may then be shuffled.
Polynucleotides
The present invention also relates to polynucleotides encoding a variant of the present invention.
Nucleic Acid Constructs
The present invention also relates to nucleic acid constructs comprising a polynucleotide encoding a variant of the present invention operably linked to one or more control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
The polynucleotide may be manipulated in a variety of ways to provide for expression of a variant. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.
The control sequence may be a promoter, a polynucleotide which is recognized by a host cell for expression of the polynucleotide. The promoter contains transcriptional control sequences that mediate the expression of the variant. The promoter may be any polynucleotide that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
Examples of suitable promoters for directing transcription of the nucleic acid constructs of the present invention in a bacterial host cell are the promoters obtained from the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus licheniformis penicillinase gene (penP), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus subtilis levansucrase gene (sacB), Bacillus subtilis xylA and xylB genes, Bacillus thuringiensis crylllA gene (Agaisse and Lereclus, 1994, Molecular Microbiology 13: 97-107), E. coli lac operon, E. coli trc promoter (Egon et al., 1988, Gene 69: 301 -315), Streptomyces coelicolor agarase gene {dagA), and prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. USA 75: 3727-3731 ), as well as the tac promoter (DeBoer et al., 1983, Proc. Natl. Acad. Sci. USA 80: 21 -25). Further promoters are described in "Useful proteins from recombinant bacteria" in Gilbert et al., 1980, Scientific American 242: 74-94; and in Sambrook et al., 1989, supra. Examples of tandem promoters are disclosed in WO 99/43835. The control sequence may also be a transcription terminator, which is recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3'-terminus of the polynucleotide encoding the variant. Any terminator that is functional in the host cell may be used.
Preferred terminators for bacterial host cells are obtained from the genes for Bacillus clausii alkaline protease {aprH), Bacillus licheniformis alpha-amylase (amyL), and Escherichia coli ribosomal RNA (rrnB).
The control sequence may also be an mRNA stabilizer region downstream of a promoter and upstream of the coding sequence of a gene which increases expression of the gene.
Examples of suitable mRNA stabilizer regions are obtained from a Bacillus thuringiensis crylllA gene (WO 94/25612) and a Bacillus subtilis SP82 gene (Hue et ai, 1995, Journal of Bacteriology 177: 3465-3471 ).
The control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a variant and directs the variant into the cell's secretory pathway. The 5'-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the coding sequence that encodes the variant. Alternatively, the 5'-end of the coding sequence may contain a signal peptide coding sequence that is foreign to the coding sequence. A foreign signal peptide coding sequence may be required where the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, a foreign signal peptide coding sequence may simply replace the natural signal peptide coding sequence in order to enhance secretion of the variant. However, any signal peptide coding sequence that directs the expressed variant into the secretory pathway of a host cell may be used.
Effective signal peptide coding sequences for bacterial host cells are the signal peptide coding sequences obtained from the genes for Bacillus NCIB 1 1837 maltogenic amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus alpha-amylase, Bacillus stearothermophilus neutral proteases {nprT, nprS, nprM), and Bacillus subtilis prsA. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57: 109-137.
The control sequence may also be a propeptide coding sequence that encodes a propeptide positioned at the N-terminus of a variant. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding sequence may be obtained from the genes for Bacillus subtilis alkaline protease {aprE), Bacillus subtilis neutral protease {nprT), Myceliophthora thermophila laccase (WO 95/33836), Rhizomucor miehei aspartic proteinase, and Saccharomyces cerevisiae alpha-factor. Where both signal peptide and propeptide sequences are present, the propeptide sequence is positioned next to the N-terminus of the variant and the signal peptide sequence is positioned next to the N-terminus of the propeptide sequence.
It may also be desirable to add regulatory sequences that regulate expression of the variant relative to the growth of the host cell. Examples of regulatory systems are those that cause expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems include the lac, tac, and trp operator systems.
Expression Vectors
The present invention also relates to recombinant expression vectors comprising a polynucleotide encoding a variant of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleotide and control sequences may be joined together to produce a recombinant expression vector that may include one or more convenient restriction sites to allow for insertion or substitution of the polynucleotide encoding the variant at such sites. Alternatively, the polynucleotide may be expressed by inserting the polynucleotide or a nucleic acid construct comprising the polynucleotide into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression.
The recombinant expression vector may be any vector (e.g., a plasmid or virus) that can be conveniently subjected to recombinant DNA procedures and can bring about expression of the polynucleotide. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may be a linear or closed circular plasmid.
The vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one that when introduced into the host cell is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. Furthermore, a single vector or plasmid or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon, may be used.
The vector preferably contains one or more selectable markers that permit easy selection of transformed, transfected, transduced, or the like cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers are Bacillus licheniformis or Bacillus subtilis dal genes, or markers that confer antibiotic resistance such as ampicillin, chloramphenicol, kanamycin, neomycin, spectinomycin or tetracycline resistance.
The vector preferably contains an element(s) that permits integration of the vector into the host cell's genome or autonomous replication of the vector in the cell independent of the genome.
For integration into the host cell genome, the vector may rely on the polynucleotide's sequence encoding the variant or any other element of the vector for integration into the genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides for directing integration by homologous recombination into the genome of the host cell at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs, and 800 to 10,000 base pairs, which have a high degree of sequence identity to the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding polynucleotides. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.
For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. The origin of replication may be any plasmid replicator mediating autonomous replication that functions in a cell. The term "origin of replication" or "plasmid replicator" means a polynucleotide that enables a plasmid or vector to replicate in vivo.
Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, and pACYC184 permitting replication in E. coli, and pUB1 10, pE194, pTA1060, and ρΑΜβΙ permitting replication in Bacillus.
More than one copy of a polynucleotide of the present invention may be inserted into a host cell to increase production of a variant. An increase in the copy number of the polynucleotide can be obtained by integrating at least one additional copy of the sequence into the host cell genome or by including an amplifiable selectable marker gene with the polynucleotide where cells containing amplified copies of the selectable marker gene, and thereby additional copies of the polynucleotide, can be selected for by cultivating the cells in the presence of the appropriate selectable agent.
The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra). Host Cells
The present invention also relates to recombinant host cells, comprising a polynucleotide encoding a variant of the present invention operably linked to one or more control sequences that direct the production of a variant of the present invention. A construct or vector comprising a polynucleotide is introduced into a host cell so that the construct or vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector as described earlier. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of a host cell will to a large extent depend upon the gene encoding the variant and its source.
The host cell may be any cell useful in the recombinant production of a variant, e.g., a prokaryote or a eukaryote.
The prokaryotic host cell may be any Gram-positive or Gram-negative bacterium. Gram- positive bacteria include, but are not limited to, Bacillus, Clostridium, Enterococcus, Geobacillus, Lactobacillus, Lactococcus, Oceanobacillus, Staphylococcus, Streptococcus, and Streptomyces. Gram-negative bacteria include, but are not limited to, Campylobacter, E. coli, Flavobacterium, Fusobacterium, Helicobacter, llyobacter, Neisseria, Pseudomonas, Salmonella, and Ureaplasma.
The bacterial host cell may be any Bacillus cell including, but not limited to, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus brevis, Bacillus circulans, Bacillus clausii, Bacillus coagulans, Bacillus firmus, Bacillus lautus, Bacillus lentus, Bacillus licheniformis, Bacillus megaterium, Bacillus pumilus, Bacillus stearothermophilus, Bacillus subtilis, and Bacillus thuringiensis cells.
The bacterial host cell may also be any Streptococcus cell including, but not limited to, Streptococcus equisimilis, Streptococcus pyogenes, Streptococcus uberis, and Streptococcus equi subsp. Zooepidemicus cells.
The bacterial host cell may also be any Streptomyces cell, including, but not limited to, Streptomyces achromogenes, Streptomyces avermitilis, Streptomyces coelicolor, Streptomyces griseus, and Streptomyces lividans cells.
The introduction of DNA into a Bacillus cell may be effected by protoplast transformation (see, e.g., Chang and Cohen, 1979, Mol. Gen. Genet. 168: 1 1 1 -1 15), competent cell transformation (see, e.g., Young and Spizizen, 1961 , J. Bacteriol. 81 : 823-829, or Dubnau and Davidoff-Abelson, 1971 , J. Mol. Biol. 56: 209-221 ), electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6: 742-751 ), or conjugation (see, e.g., Koehler and Thorne, 1987, J. Bacteriol. 169: 5271 -5278). The introduction of DNA into an E. coli cell may be effected by protoplast transformation (see, e.g., Hanahan, 1983, J. Mol. Biol. 166: 557-580) or electroporation (see, e.g., Dower et al, 1988, Nucleic Acids Res. 16: 6127-6145). The introduction of DNA into a Streptomyces cell may be effected by protoplast transformation, electroporation (see, e.g., Gong et al., 2004, Folia Microbiol. (Praha) 49: 399-405), conjugation (see, e.g., Mazodier et al., 1989, J. Bacteriol. 171 : 3583-3585), or transduction (see, e.g., Burke et al., 2001 , Proc. Natl. Acad. Sci. USA 98: 6289-6294). The introduction of DNA into a Pseudomonas cell may be effected by electroporation (see, e.g., Choi et al., 2006, J. Microbiol. Methods 64: 391 -397), or conjugation (see, e.g., Pinedo and Smets, 2005, Appl. Environ. Microbiol. 71 : 51 -57). The introduction of DNA into a Streptococcus cell may be effected by natural competence (see, e.g., Perry and Kuramitsu, 1981 , Infect. Immun. 32: 1295-1297), protoplast transformation (see, e.g., Catt and Jollick, 1991 , Microbios 68: 189-207), electroporation (see, e.g., Buckley et al., 1999, Appl. Environ. Microbiol. 65: 3800-3804) or conjugation (see, e.g., Clewell, 1981 , Microbiol. Rev. 45: 409-436). However, any method known in the art for introducing DNA into a host cell can be used.
Methods of Production
The present invention also relates to methods of producing a variant, comprising: (a) cultivating a host cell of the present invention under conditions suitable for expression of the variant; and (b) recovering the variant.
The host cells are cultivated in a nutrient medium suitable for production of the variant using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, or small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the variant to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art. Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the variant is secreted into the nutrient medium, the variant can be recovered directly from the medium. If the variant is not secreted, it can be recovered from cell lysates.
The variant may be detected using methods known in the art that are specific for the variants with protease activity. These detection methods include, but are not limited to, use of specific antibodies, formation of an enzyme product, or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the variant.
The variant may be recovered using methods known in the art. For example, the variant may be recovered from the nutrient medium by conventional procedures including, but not limited to, collection, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.
The variant may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, Janson and Ryden, editors, VCH Publishers, New York, 1989) to obtain substantially pure variants.
In an alternative aspect, the variant is not recovered, but rather a host cell of the present invention expressing the variant is used as a source of the variant.
Compositions
In one certain aspect, the subtilase variants according to the invention have improved wash performance compared to the parent enzyme or compared to a subtilase with SEQ ID NO 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 wherein wash performance is measured using the Automatic Mechanical Stress Assay (AMSA) for laundry as described in the Materials and Methods section herein.
In another certain aspect, the variants according to the invention have improved stability, preferably improved storage stability, compared to the parent enzyme or compared to a protease with SEQ ID NO 1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO: 12, wherein storage stability is measured using the 'accelerated storage stability assay' as described in the Materials and Methods section herein.
Thus, in a preferred embodiment the composition is a detergent composition, and one aspect of the invention relates to the use of a detergent composition comprising a variant according to the invention in a cleaning process such as laundry or hard surface cleaning.
The choice of additional components is within the skill of the artisan and includes conventional ingredients, including the exemplary non-limiting components set forth below. The choice of components may include, for fabric care, the consideration of the type of fabric to be cleaned, the type and/or degree of soiling, the temperature at which cleaning is to take place, and the formulation of the detergent product. Although components mentioned below are categorized by general header according to a particular functionality, this is not to be construed as a limitation, as a component may comprise additional functionalities as will be appreciated by the person skilled in the art.
In one embodiment of the present invention, the subtilase variant of the present invention may be added to a detergent composition in an amount corresponding to 0.01 -200 mg of enzyme protein per liter of wash liqour, preferably 0.05-50 mg of enzyme protein per liter of wash liqour, in particular 0.1 -10 mg of enzyme protein per liter of wash liqour. A composition for use in automatic dishwash (ADW), for example, may include 0.0001 %- 50%, such as 0.001 %-30%, such as 0.01 %-20%, such as 0.5-15% of enzyme protein by weight of the composition.
A composition for use in laundry granulation, for example, may include 0.0001 %-50%, such as 0.001 %-20%, such as 0.01 %-10%, such as 0.05%-5% of enzyme protein by weight of the composition.
A composition for use in laundry liquid, for example, may include 0.0001 %-10%, such as 0.001 -7%, such as 0.1 %-5% of enzyme protein by weight of the composition.
The enzymes such as the subtilase variant of the invention may be stabilized using conventional stabilizing agents, e.g., a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid, and the composition may be formulated as described in, for example, WO 92/19709 and WO 92/19708 or the variants according to the invention may be stabilized using peptide aldehydes or ketones such as described in WO 2005/105826 and WO 2009/1 18375.
A variant of the present invention may also be incorporated in the detergent formulations disclosed in WO 97/07202, which is hereby incorporated by reference.
Surfactants
The detergent composition may comprise one or more surfactants, which may be anionic and/or cationic and/or non-ionic and/or semi-polar and/or zwitterionic, or a mixture thereof. In a particular embodiment, the detergent composition includes a mixture of one or more nonionic surfactants and one or more anionic surfactants. The surfactant(s) is typically present at a level of from about 0.1 % to 60% by weight, such as about 1 % to about 40%, or about 3% to about 20%, or about 3% to about 10%. The surfactant(s) is chosen based on the desired cleaning application, and includes any conventional surfactant(s) known in the art. Any surfactant known in the art for use in detergents may be utilized.
When included therein, the detergent will usually contain from about 1 % to about 40% by weight, such as from about 5% to about 30%, including from about 5% to about 15%, or from about 20% to about 25% of an anionic surfactant. Non-limiting examples of anionic surfactants include sulfates and sulfonates, in particular, linear alkylbenzenesulfonat.es (LAS), isomers of LAS, branched alkylbenzenesulfonat.es (BABS), phenylalkanesulfonat.es, alpha-olefinsulfonates (AOS), olefin sulfonates, alkene sulfonates, alkane-2,3-diylbis(sulfates), hydroxyalkanesulfonat.es and disulfonates, alkyl sulfates (AS) such as sodium dodecyl sulfate (SDS), fatty alcohol sulfates (FAS), primary alcohol sulfates (PAS), alcohol ethersulfates (AES or AEOS or FES, also known as alcohol ethoxysulfates or fatty alcohol ether sulfates), secondary alkanesulfonates (SAS), paraffin sulfonates (PS), ester sulfonates, sulfonated fatty acid glycerol esters, alpha-sulfo fatty acid methyl esters (alpha-SFMe or SES) including methyl ester sulfonate (MES), alkyl- or alkenylsuccinic acid, dodecenyl/tetradecenyl succinic acid (DTSA), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic acid or soap, and combinations thereof.
When included therein, the detergent will usually contain from about 0% to about 10% by weight of a cationic surfactant. Non-limiting examples of cationic surfactants include alklydimethylethanolamine quat (ADMEAQ), cetyltrimethylammonium bromide (CTAB), dimethyldistearylammonium chloride (DSDMAC), and alkylbenzyldimethylammonium, alkyl quaternary ammonium compounds, alkoxylated quaternary ammonium (AQA) compounds, and combinations thereof.
When included therein, the detergent will usually contain from about 0.2% to about
40% by weight of a non-ionic surfactant, for example from about 0.5% to about 30%, in particular from about 1 % to about 20%, from about 3% to about 10%, such as from about 3% to about 5%, or from about 8% to about 12%. Non-limiting examples of non-ionic surfactants include alcohol ethoxylates (AE or AEO), alcohol propoxylates, propoxylated fatty alcohols (PFA), alkoxylated fatty acid alkyl esters, such as ethoxylated and/or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (APE), nonylphenol ethoxylates (NPE), alkylpolyglycosides (APG), alkoxylated amines, fatty acid monoethanolamides (FAM), fatty acid diethanolamides (FADA), ethoxylated fatty acid monoethanolamides (EFAM), propoxylated fatty acid monoethanolamides (PFAM), polyhydroxy alkyl fatty acid amides, or /V-acyl /V-alkyl derivatives of glucosamine (glucamides, GA, or fatty acid glucamide, FAGA), as well as products available under the trade names SPAN and TWEEN, and combinations thereof.
When included therein, the detergent will usually contain from about 0% to about 10% by weight of a semipolar surfactant. Non-limiting examples of semipolar surfactants include amine oxides (AO) such as alkyldimethylamineoxide, /V-(coco alkyl)-/V,/V-dimethylamine oxide and /V-(tallow-alkyl)-/V,/V-bis(2-hydroxyethyl)amine oxide, fatty acid alkanolamides and ethoxylated fatty acid alkanolamides, and combinations thereof.
When included therein, the detergent will usually contain from about 0% to about 10% by weight of a zwitterionic surfactant. Non-limiting examples of zwitterionic surfactants include betaine, alkyldimethylbetaine, sulfobetaine, and combinations thereof. Hydrotropes
A hydrotrope is a compound that solubilises hydrophobic compounds in aqueous solutions (or oppositely, polar substances in a non-polar environment). Typically, hydrotropes have both hydrophilic and a hydrophobic character (so-called amphiphilic properties as known from surfactants); however the molecular structure of hydrotropes generally do not favor spontaneous self-aggregation, see e.g. review by Hodgdon and Kaler (2007), Current Opinion in Colloid & Interface Science 12: 121 -128. Hydrotropes do not display a critical concentration above which self-aggregation occurs as found for surfactants and lipids forming miceller, lamellar or other well defined meso-phases. Instead, many hydrotropes show a continuous-type aggregation process where the sizes of aggregates grow as concentration increases. However, many hydrotropes alter the phase behavior, stability, and colloidal properties of systems containing substances of polar and non-polar character, including mixtures of water, oil, surfactants, and polymers. Hydrotropes are classically used across industries from pharma, personal care, food, to technical applications. Use of hydrotropes in detergent compositions allow for example more concentrated formulations of surfactants (as in the process of compacting liquid detergents by removing water) without inducing undesired phenomena such as phase separation or high viscosity.
The detergent may contain 0-5% by weight, such as about 0.5 to about 5%, or about 3% to about 5%, of a hydrotrope. Any hydrotrope known in the art for use in detergents may be utilized. Non-limiting examples of hydrotropes include sodium benzene sulfonate, sodium p- toluene sulfonate (STS), sodium xylene sulfonate (SXS), sodium cumene sulfonate (SCS), sodium cymene sulfonate, amine oxides, alcohols and polyglycolethers, sodium hydroxynaphthoate, sodium hydroxynaphthalene sulfonate, sodium ethylhexyl sulfate, and combinations thereof.
Builders and Co-Builders
The detergent composition may contain about 0-65% by weight, such as about 5% to about 45% of a detergent builder or co-builder, or a mixture thereof. In a dish wash deteregent, the level of builder is typically 40-65%, particularly 50-65%. The builder and/or co-builder may particularly be a chelating agent that forms water-soluble complexes with Ca and Mg. Any builder and/or co-builder known in the art for use in laundry detergents may be utilized. Non- limiting examples of builders include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (STP or STPP), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (e.g., SKS-6 from Hoechst), ethanolamines such as 2-aminoethan-1 -ol (MEA), diethanolamine (DEA, also known as iminodiethanol), triethanolamine (TEA, also known as 2,2',2"-nitrilotriethanol), and carboxymethyl inulin (CMI), and combinations thereof.
The detergent composition may also contain 0-20% by weight, such as about 5% to about 10%, of a detergent co-builder, or a mixture thereof. The detergent composition may include include a co-builder alone, or in combination with a builder, for example a zeolite builder. Non-limiting examples of co-builders include homopolymers of polyacrylates or copolymers thereof, such as poly(acrylic acid) (PAA) or copoly(acrylic acid/maleic acid) (PAA/PMA). Further non-limiting examples include citrate, chelators such as aminocarboxylates, aminopolycarboxylates and phosphonates, and alkyl- or alkenylsuccinic acid. Additional specific examples include 2,2',2"-nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), iminodisuccinic acid (IDS), ethylenediamine-/V,/V'- disuccinic acid (EDDS), methylglycinediacetic acid (MGDA), glutamic acid-N,N-diacetic acid (GLDA), 1 -hydroxyethane-1 ,1 -diphosphonic acid (HEDP), ethylenediaminetetra- (methylenephosphonic acid) (EDTMPA), diethylenetriaminepentakis(methylenephosphonic acid) (DTPMPA or DTMPA), /V-(2-hydroxyethyl)iminodiacetic acid (EDG), aspartic acid-/V-monoacetic acid (ASMA), aspartic acid-/V,/V-diacetic acid (ASDA), aspartic acid-/V-monopropionic acid (ASMP), iminodisuccinic acid (IDA), /V-(2-sulfomethyl)-aspartic acid (SMAS), /V-(2-sulfoethyl)- aspartic acid (SEAS), /V-(2-sulfomethyl)-glutamic acid (SMGL), /V-(2-sulfoethyl)-glutamic acid (SEGL), /V-methyliminodiacetic acid (Ml DA), a-alanine-/V, /V-diacetic acid (a-ALDA), serine-/V, N- diacetic acid (SEDA), isoserine-/V, /V-diacetic acid (ISDA), phenylalanine-/V, /V-diacetic acid (PHDA), anthranilic acid-/V, /V-diacetic acid (ANDA), sulfanilic acid-/V, /V-diacetic acid (SLDA) , taurine-/V, /V-diacetic acid (TUDA) and sulfomethyl-/V, /V-diacetic acid (SMDA), N-{2- hydroxyethyl)-ethylidenediamine-/V, N', /V-triacetate (HEDTA), diethanolglycine (DEG), diethylenetriamine penta(methylenephosphonic acid) (DTPMP), aminotris(methylenephosphonic acid) (ATMP), and combinations and salts thereof. Further exemplary builders and/or co- builders are described in, e.g., WO 09/102854, US 5977053 Bleaching Systems
The detergent may contain 0-50% by weight, such as about 0.1 % to about 25%, of a bleaching system. Any bleaching system known in the art for use in laundry detergents may be utilized. Suitable bleaching system components include bleaching catalysts, photobleaches, bleach activators, sources of hydrogen peroxide such as sodium percarbonate and sodium perborates, preformed peracids and mixtures thereof. Suitable preformed peracids include, but are not limited to, peroxycarboxylic acids and salts, percarbonic acids and salts, perimidic acids and salts, peroxymonosulfuric acids and salts, for example, Oxone (R), and mixtures thereof. Non-limiting examples of bleaching systems include peroxide-based bleaching systems, which may comprise, for example, an inorganic salt, including alkali metal salts such as sodium salts of perborate (usually mono- or tetra-hydrate), percarbonate, persulfate, perphosphate, persilicate salts, in combination with a peracid-forming bleach activator. The term bleach activator is meant herein as a compound which reacts with peroxygen bleach like hydrogen peroxide to form a peracid. The peracid thus formed constitutes the activated bleach. Suitable bleach activators to be used herein include those belonging to the class of esters amides, imides or anhydrides. Suitable examples are tetracetylethylene diamine (TAED), sodium 4- [(3,5,5-trimethylhexanoyl)oxy]benzene sulfonate (ISONOBS), diperoxy dodecanoic acid, 4- (dodecanoyloxy)benzenesulfonate (LOBS), 4-(decanoyloxy)benzenesulfonate, 4- (decanoyloxy)benzoate (DOBS), 4-(nonanoyloxy)-benzenesulfonate (NOBS), and/or those disclosed in W098/17767. A particular family of bleach activators of interest was disclosed in EP624154 and particulary preferred in that family is acetyl triethyl citrate (ATC). ATC or a short chain triglyceride like triacetin has the advantage that it is environmental friendly as it eventually degrades into citric acid and alcohol. Furthermore acetyl triethyl citrate and triacetin has a good hydrolytical stability in the product upon storage and it is an efficient bleach activator. Finally ATC provides a good building capacity to the laundry additive.
Bleach catalysts and boosters
The bleaching system may also include a bleach catalyst or booster.
Some non-limiting examples of bleach catalysts that may be used in the compositions of the present invention include manganese oxalate, manganese acetate, manganese-collagen, cobalt-amine catalysts and manganese triazacyclononane (MnTACN) catalysts; particularly preferred are complexes of manganese with 1 ,4,7-trimethyl-1 ,4,7-triazacyclononane (Me3- TACN) or 1 , 2,4, 7-tetramethyl-1 ,4,7-triazacyclononane (Me4-TACN), in particular Me3-TACN, such as the dinuclear manganese complex [(Me3-TACN)Mn(0)3Mn(Me3-TACN)](PF6)2, and [2,2',2"-nitrilotris(ethane-1 ,2-diylazanylylidene-KN-methanylylidene)triphenolato- K30]manganese(lll). The bleach catalysts may also be other metal compounds, such as iron or cobalt complexes.
Alternatively, the bleaching system may comprise peroxyacids of, for example, the amide, imide, or sulfone type. The bleaching system may also comprise peracids such as 6- (phthalimido)peroxyhexanoic acid (PAP). The bleaching system may also include a bleach catalyst. In some embodiments the bleach component may be an organic catalyst selected from the group consisting of organic catalysts having the following formulae:
Figure imgf000148_0001
(iii) and mixtures thereof; wherein each R1 is independently a branched alkyl group containing from 9 to 24 carbons or linear alkyl group containing from 1 1 to 24 carbons, preferably each R1 is independently a branched alkyl group containing from 9 to 18 carbons or linear alkyl group containing from 1 1 to 18 carbons, more preferably each R1 is independently selected from the group consisting of 2-propylheptyl, 2-butyloctyl, 2-pentylnonyl, 2-hexyldecyl, n-dodecyl, n-tetradecyl, n-hexadecyl, n-octadecyl, iso-nonyl, iso-decyl, iso-tridecyl and iso- pentadecyl. Other exemplary bleaching systems are described, e.g. in WO2007/087258, WO2007/087244, WO2007/087259 and WO2007/087242. Suitable photobleaches may for example be sulfonated zinc phthalocyanine
Polymers
The detergent may contain 0-10% by weight, such as 0.5-5%, 2-5%, 0.5-2% or 0.2-1 % of a polymer. Any polymer known in the art for use in detergents may be utilized. The polymer may function as a co-builder as mentioned above, or may provide antiredeposition, fiber protection, soil release, dye transfer inhibition, grease cleaning and/or anti-foaming properties. Some polymers may have more than one of the above-mentioned properties and/or more than one of the below-mentioned motifs. Exemplary polymers include (carboxymethyl)cellulose (CMC), polyvinyl alcohol) (PVA), poly(vinylpyrrolidone) (PVP), poly(ethyleneglycol) or poly(ethylene oxide) (PEG), ethoxylated poly(ethyleneimine), carboxymethyl inulin (CMI), and polycarboxylates such as PAA, PAA/PMA, poly-aspartic acid, and lauryl methacrylate/acrylic acid copolymers , hydrophobically modified CMC (HM-CMC) and silicones, copolymers of terephthalic acid and oligomeric glycols, copolymers of poly(ethylene terephthalate) and poly(oxyethene terephthalate) (PET-POET), PVP, poly(vinylimidazole) (PVI), poly(vinylpyridine-/V-oxide) (PVPO or PVPNO) and polyvinylpyrrolidone-vinylimidazole (PVPVI). Further exemplary polymers include sulfonated polycarboxylates, polyethylene oxide and polypropylene oxide (PEO-PPO) and diquaternium ethoxy sulfate. Other exemplary polymers are disclosed in, e.g., WO 2006/130575. Salts of the above-mentioned polymers are also contemplated.
Fabric hueing agents
The detergent compositions of the present invention may also include fabric hueing agents such as dyes or pigments, which when formulated in detergent compositions can deposit onto a fabric when the fabric is contacted with a wash liquor comprising the detergent compositions and thus altering the tint of the fabric through absorption/reflection of visible light. Fluorescent whitening agents emit at least some visible light. In contrast, fabric hueing agents alter the tint of a surface as they absorb at least a portion of the visible light spectrum. Suitable fabric hueing agents include dyes and dye-clay conjugates, and may also include pigments. Suitable dyes include small molecule dyes and polymeric dyes. Suitable small molecule dyes include small molecule dyes selected from the group consisting of dyes falling into the Colour Index (C.I.) classifications of Direct Blue, Direct Red, Direct Violet, Acid Blue, Acid Red, Acid Violet, Basic Blue, Basic Violet and Basic Red, or mixtures thereof, for example as described in WO2005/03274, WO2005/03275, WO2005/03276 and EP1876226 (hereby incorporated by reference). The detergent composition preferably comprises from about 0.00003 wt% to about 0.2 wt%, from about 0.00008 wt% to about 0.05 wt%, or even from about 0.0001 wt% to about 0.04 wt% fabric hueing agent. The composition may comprise from 0.0001 wt% to 0.2 wt% fabric hueing agent, this may be especially preferred when the composition is in the form of a unit dose pouch. Suitable hueing agents are also disclosed in, e.g. WO 2007/087257 and WO2007/087243.
Additional Enzymes
The detergent additive as well as the detergent composition may comprise one or more (additional) enzymes such as a protease, lipase, cutinase, an amylase, carbohydrase, cellulase, pectinase, mannanase, arabinase, galactanase, xylanase, oxidase, e.g., a laccase, and/or peroxidase. In general, the properties of the selected enzyme(s) should be compatible with the selected detergent, (i.e., pH-optimum, compatibility with other enzymatic and non-enzymatic ingredients, etc.), and the enzyme(s) should be present in effective amounts.
Cellulases
Suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Bacillus, Pseudomonas, Humicola, Fusarium, Thielavia, Acremonium, e.g., the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum disclosed in US 4,435,307, US 5,648,263, US 5,691 ,178, US 5,776,757 and WO 89/09259.
Especially suitable cellulases are the alkaline or neutral cellulases having color care benefits. Examples of such cellulases are cellulases described in EP 0 495 257, EP 0 531 372, WO 96/1 1262, WO 96/29397, WO 98/08940. Other examples are cellulase variants such as those described in WO 94/07998, EP 0 531 315, US 5,457,046, US 5,686,593, US 5,763,254, WO 95/24471 , WO 98/12307 and PCT/DK98/00299.
Example of cellulases exhibiting endo-beta-1 ,4-glucanase activity (EC 3.2.1.4) are those having described in WO02/099091.
Other examples of cellulases include the family 45 cellulases described in W096/29397, and especially variants thereof having substitution, insertion and/or deletion at one or more of the positions corresponding to the following positions in SEQ ID NO: 8 of WO 02/099091 : 2, 4, 7, 8, 10, 13, 15, 19, 20, 21 , 25, 26, 29, 32, 33, 34, 35, 37, 40, 42, 42a, 43, 44, 48, 53, 54, 55, 58, 59, 63, 64, 65, 66, 67, 70, 72, 76, 79, 80, 82, 84, 86, 88, 90, 91 , 93, 95, 95d, 95h, 95j, 97, 100, 101 , 102, 103, 1 13, 1 14, 1 17, 1 19, 121 , 133, 136, 137, 138, 139, 140a, 141 , 143a, 145, 146, 147, 150e, 150j, 151 , 152, 153, 154, 155, 156, 157, 158, 159, 160c, 160e, 160k, 161 , 162, 164, 165, 168, 170, 171 , 172, 173, 175, 176, 178, 181 , 183, 184, 185, 186, 188, 191 , 192, 195, 196, 200, and/or 20, preferably selected among P19A, G20K, Q44K, N48E, Q1 19H or Q146 R.
Commercially available cellulases include Celluzyme™, and Carezyme™ (Novozymes A/S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation). Proteases
The detergent composition may include additional proteases. Suitable additional proteases include those of bacterial, fungal, plant, viral or animal origin e.g. vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. It may be an alkaline protease, such as a serine protease or a metalloprotease. A serine protease may for example be of the S1 family, such as trypsin, or the S8 family such as subtilisin. A metalloproteases protease may for example be a thermolysin from e.g. family M4 or other metalloprotease such as those from M5, M7 or M8 families. The term "subtilases" refers to a sub-group of serine protease according to Siezen et al., Protein Engng. 4 (1991 ) 719-737 and Siezen et al. Protein Science 6 (1997) 501 -523. Serine proteases are a subgroup of proteases characterized by having a serine in the active site, which forms a covalent adduct with the substrate. The subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family.
Examples of subtilases are those derived from Bacillus such as Bacillus lentus, B. alkalophilus, B. subtilis, B. amyloliquefaciens, Bacillus pumilus and Bacillus gibsonii described in; US7262042 and WO09/021867, and subtilisin lentus, subtilisin Novo, subtilisin Carlsberg, , subtilisin BPN', subtilisin 309, subtilisin 147 and subtilisin 168 described in WO89/06279 and protease PD138 described in (WO93/18140). Other useful proteases may be those described WO01/016285, WO02/026024 and WO02/016547. Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO89/06270, W094/25583 and WO05/040372, and the chymotrypsin proteases derived from Cellulomonas described in WO05/052161 and WO05/052146.
A further preferred protease is the alkaline protease from Bacillus lentus DSM 5483, as described for example in W095/23221 , and variants thereof which are described in WO92/21760, W095/23221 , EP1921 147 and EP1921 148.
Examples of metalloproteases are the neutral metalloprotease as described in WO07/044993 (Genencor Int.) such as those derived from Bacillus amyloliquefaciens.
Examples of useful proteases are the variants described in: W092/19729, WO96/034946, WO98/201 15, WO98/201 16, WO99/01 1768, WO01/44452, WO03/006602, WO04/03186, WO04/041979, WO07/006305, W01 1/036263, W01 1/036264, especially the variants with substitutions in one or more of the following positions: 3, 4, 9, 15, 27, 36, 57, 68, 76, 87, 95, 96, 97, 98, 99, 100, 101 , 102, 103, 104, 106, 1 18, 120, 123, 128, 129, 130, 160, 167, 170, 194, 195, 199, 205, 206, 217, 218, 222, 224, 232, 235, 236, 245, 248, 252 and 274 using the BPN' numbering. More preferred the subtilase variants may comprise the mutations: S3T, V4I, S9R, A15T, K27R, *36D, V68A, N76D, N87S,R, *97E, A98S, S99G,D,A, S99AD, S101 G,M,R S103A, V104I,Y,N, S106A, G1 18V,R, H120D,N, N123S, S128L, P129Q, S130A, G160D, Y167A, R170S, A194P, G195E, V199M, V205I, L217D, N218D, M222S, A232V, K235L, Q236H, Q245R, N252K, T274A (using BPN' numbering).
Suitable commercially available protease enzymes include those sold under the trade names Alcalase®, DuralaseTm, DurazymTm, Relase®, Relase® Ultra, Savinase®, Savinase® Ultra, Primase®, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Ovozyme®, Coronase®, Coronase® Ultra, Neutrase®, Everlase® and Esperase® (Novozymes A/S), those sold under the tradename Maxatase®, Maxacal®, Maxapem®, Purafect®, Purafect Prime®, Purafect MA®, Purafect Ox®, Purafect OxP®, Puramax®, Properase®, FN2®, FN3® , FN4®, Excellase®, Eraser® , Ultimase®, Opticlean® and Optimase® (Danisco/DuPont), Axapem™ (Gist-Brocases N.V.), BLAP (sequence shown in Figure 29 of US5352604) and variants hereof (Henkel AG) and KAP (Bacillus alkalophilus subtilisin) from Kao.
Lipases and Cutinases
Suitable lipases and cutinases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from Thermomyces, e.g. from T. lanuginosus (previously named Humicola lanuginosa) as described in EP258068 and EP305216, cutinase from Humicola, e.g. H. insolens (WO96/13580), lipase from strains of Pseudomonas (some of these now renamed to Burkholderia), e.g. P. alcaligenes or P. pseudoalcaligenes (EP218272), P. cepacia (EP331376), P. sp. strain SD705 (WO95/06720 & WO96/27002), P. wisconsinensis (WO96/12012), GDSL-type Streptomyces lipases (W010/065455), cutinase from Magnaporthe grisea (W010/107560), cutinase from Pseudomonas mendocina (US5,389,536), lipase from Thermobifida fusca (W01 1/084412), Geobacillus stearothermophilus lipase (W01 1/084417), lipase from Bacillus subtilis (W01 1/084599), and lipase from Streptomyces griseus (W01 1/150157) and S. pristinaespiralis (W012/137147).
Other examples are lipase variants such as those described in EP407225, WO92/05249, WO94/01541 , W094/25578, W095/14783, WO95/30744, W095/35381 , W095/22615, WO96/00292, WO97/04079, WO97/07202, WO00/34450, WO00/60063, WO01/92502, WO07/87508 and WO09/109500.
Preferred commercial lipase products include include Lipolase™, Lipex™; Lipolex™ and Lipoclean™ (Novozymes A/S), Lumafast (originally from Genencor) and Lipomax (originally from Gist-Brocades).
Still other examples are lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to Candida antarctica lipase A (WO10/1 1 1 143), acyltransferase from Mycobacterium smegmatis (WO05/56782), perhydrolases from the CE 7 family (WO09/67279), and variants of the M. smegmatis perhydrolase in particular the S54V variant used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd (W010/100028). Amylases
Suitable amylases which can be used together with the subtilase variants of the invention may be an alpha-amylase or a glucoamylase and may be of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, alpha-amylases obtained from Bacillus, e.g., a special strain of Bacillus licheniformis, described in more detail in GB 1 ,296,839. Suitable amylases include amylases having SEQ ID NO: 2 in WO 95/10603 or variants having 90% sequence identity to SEQ ID NO: 3 thereof. Preferred variants are described in WO 94/02597, WO 94/18314, WO 97/43424 and SEQ ID NO: 4 of WO 99/019467, such as variants with substitutions in one or more of the following positions: 15, 23, 105, 106, 124, 128, 133, 154, 156, 178, 179, 181 , 188, 190, 197, 201 , 202, 207, 208, 209, 21 1 , 243, 264, 304, 305, 391 , 408, and 444.
Different suitable amylases include amylases having SEQ ID NO: 6 in WO 02/010355 or variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a deletion in positions 181 and 182 and a substitution in position 193.
Other amylases which are suitable are hybrid alpha-amylase comprising residues 1 -33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36-483 of the B. licheniformis alpha-amylase shown in SEQ ID NO: 4 of WO 2006/066594 or variants having 90% sequence identity thereof. Preferred variants of this hybrid alpha-amylase are those having a substitution, a deletion or an insertion in one of more of the following positions: G48, T49, G107, H156, A181 , N190, M197, 1201 , A209 and Q264. Most preferred variants of the hybrid alpha-amylase comprising residues 1 -33 of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006/066594 and residues 36-483 of SEQ ID NO: 4 are those having the substitutions:
M197T;
H156Y+A181T+N190F+A209V+Q264S; or
G48A+T49I+G107A+H156Y+A181T+N190F+I201 F+A209V+Q264S.
Further amylases which are suitable are amylases having SEQ ID NO: 6 in WO 99/019467 or variants thereof having 90% sequence identity to SEQ ID NO: 6. Preferred variants of SEQ ID NO: 6 are those having a substitution, a deletion or an insertion in one or more of the following positions: R181 , G182, H183, G184, N195, I206, E212, E216 and K269. Particularly preferred amylases are those having deletion in positions R181 and G182, or positions H183 and G184.
Additional amylases which can be used are those having SEQ ID NO: 1 , SEQ ID NO: 3, SEQ ID NO: 2 or SEQ ID NO: 7 of WO 96/023873 or variants thereof having 90% sequence identity to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7. Preferred variants of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 7 are those having a substitution, a deletion or an insertion in one or more of the following positions: 140, 181 , 182, 183, 184, 195, 206, 212, 243, 260, 269, 304 and 476, using SEQ ID 2 of WO 96/023873 for numbering. More preferred variants are those having a deletion in two positions selected from 181 , 182, 183 and 184, such as 181 and 182, 182 and 183, or positions 183 and 184. Most preferred amylase variants of SEQ ID NO: 1 , SEQ ID NO: 2 or SEQ ID NO: 7 are those having a deletion in positions 183 and 184 and a substitution in one or more of positions 140, 195, 206, 243, 260, 304 and 476. Other amylases which can be used are amylases having SEQ ID NO: 2 of WO 08/153815, SEQ ID NO: 10 in WO 01/66712 or variants thereof having 90% sequence identity to SEQ ID NO: 2 of WO 08/153815 or 90% sequence identity to SEQ ID NO: 10 in WO 01/66712. Preferred variants of SEQ ID NO: 10 in WO 01/66712 are those having a substitution, a deletion or an insertion in one of more of the following positions: 176, 177, 178, 179, 190, 201 , 207, 21 1 and 264.
Further suitable amylases are amylases having SEQ ID NO: 2 of WO 09/061380 or variants having 90% sequence identity to SEQ ID NO: 2 thereof. Preferred variants of SEQ ID NO: 2 are those having a truncation of the C-terminus and/or a substitution, a deletion or an insertion in one of more of the following positions: Q87, Q98, S125, N128, T131 , T165, K178, R180, S181 , T182, G183, M201 , F202, N225, S243, N272, N282, Y305, R309, D319, Q320, Q359, K444 and G475. More preferred variants of SEQ ID NO: 2 are those having the substitution in one of more of the following positions: Q87E,R, Q98R, S125A, N128C, T131 I, T165I, K178L, T182G, M201 L, F202Y, N225E,R, N272E,R, S243Q,A,E,D, Y305R, R309A, Q320R, Q359E, K444E and G475K and/or deletion in position R180 and/or S181 or of T182 and/or G183. Most preferred amylase variants of SEQ ID NO: 2 are those having the substitutions:
N128C+K178L+T182G+Y305R+G475K;
N 128C+K178L+T182G+F202Y+Y305R+D319T+G475K;
S125A+N128C+K178L+T182G+Y305R+G475K; or
S125A+N 128C+T131 I+T165I+K178L+T182G+Y305R+G475K wherein the variants are
C-terminally truncated and optionally further comprises a substitution at position 243 and/or a deletion at position 180 and/or position 181.
Further suitable amylases are amylases having SEQ ID NO: 1 of W013184577 or variants having 90% sequence identity to SEQ ID NO: 1 thereof. Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: K176, R178, G179, T180, G181 , E187, N192, M199, I203, S241 , R458, T459, D460, G476 and G477. More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: K176L, E187P, N 192FYH, M199L, I203YF, S241 QADN, R458N, T459S, D460T, G476K and G477K and/or deletion in position R178 and/or S179 or of T180 and/or G181. Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
E187P+I203Y+G476K
E187P+I203Y+R458N+T459S+D460T+G476K,
wherein the variants optionally further comprises a substitution at position 241 and/or a deletion at position 178 and/or position 179.
Further suitable amylases are amylases having SEQ ID NO: 1 of W010104675 or variants having 90% sequence identity to SEQ ID NO: 1 thereof. Preferred variants of SEQ ID NO: 1 are those having a substitution, a deletion or an insertion in one of more of the following positions: N21 , D97, V128 K177, R179, S180, 1181 , G182, M200, L204, E242, G477 and G478. More preferred variants of SEQ ID NO: 1 are those having the substitution in one of more of the following positions: N21 D, D97N, V128I K177L, M200L, L204YF, E242QA, G477K and G478K and/or deletion in position R179 and/or S180 or of 1181 and/or G182. Most preferred amylase variants of SEQ ID NO: 1 are those having the substitutions:
N21 D+D97N+V128I,
wherein the variants optionally further comprises a substitution at position 200 and/or a deletion at position 180 and/or position 181.
Other suitable amylases are the alpha-amylase having SEQ ID NO: 12 in WO01/66712 or a variant having at least 90% sequence identity to SEQ ID NO: 12. Preferred amylase variants are those having a substitution, a deletion or an insertion in one of more of the following positions of SEQ ID NO: 12 in WO01/66712: R28, R1 18, N174; R181 , G182, D183, G184, G186, W189, N195, M202, Y298, N299, K302, S303, N306, R310, N314; R320, H324, E345, Y396, R400, W439, R444, N445, K446, Q449, R458, N471 , N484. Particular preferred amylases include variants having a deletion of D183 and G184 and having the substitutions R1 18K, N195F, R320K and R458K, and a variant additionally having substitutions in one or more position selected from the group: M9, G149, G182, G186, M202, T257, Y295, N299, M323, E345 and A339, most preferred a variant that additionally has substitutions in all these positions.
Other examples are amylase variants such as those described in WO201 1/098531 , WO2013/001078 and WO2013/001087. Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™, Stainzyme ™, Stainzyme Plus™, Natalase™, Liquozyme X and BAN™ (from Novozymes A/S), and Rapidase™ , Purastar™/Effectenz™, Powerase, Preferenz S1000, Preferenz S100 and Preferenz S1 10 (from Genencor International Inc./DuPont).
Peroxidases/Oxidases
Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from Coprinus, e.g., from C. cinereus, and variants thereof as those described in WO 93/24618, WO 95/10602, and WO 98/15257.
Commercially available peroxidases include Guardzyme™ (Novozymes A/S).
The detergent enzyme(s) may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e., a separate additive or a combined additive, can be formulated, for example, as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries. Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661 ,452 and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 238,216.
Adjunct materials
Any detergent components known in the art for use in laundry detergents may also be utilized. Other optional detergent components include anti-corrosion agents, anti-shrink agents, anti-soil redeposition agents, anti-wrinkling agents, bactericides, binders, corrosion inhibitors, disintegrants/disintegration agents, dyes, enzyme stabilizers (including boric acid, borates, CMC, and/or polyols such as propylene glycol), fabric conditioners including clays, fillers/processing aids, fluorescent whitening agents/optical brighteners, foam boosters, foam (suds) regulators, perfumes, soil-suspending agents, softeners, suds suppressors, tarnish inhibitors, and wicking agents, either alone or in combination. Any ingredient known in the art for use in laundry detergents may be utilized. The choice of such ingredients is well within the skill of the artisan.
Dispersants: The detergent compositions of the present invention can also contain dispersants. In particular powdered detergents may comprise dispersants. Suitable water- soluble organic materials include the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms. Suitable dispersants are for example described in Powdered Detergents, Surfactant science series volume 71 , Marcel Dekker, Inc.
Dye Transfer Inhibiting Agents: The detergent compositions of the present invention may also include one or more dye transfer inhibiting agents. Suitable polymeric dye transfer inhibiting agents include, but are not limited to, polyvinylpyrrolidone polymers, polyamine N- oxide polymers, copolymers of N-vinylpyrrolidone and N-vinylimidazole, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof. When present in a subject composition, the dye transfer inhibiting agents may be present at levels from about 0.0001 % to about 10%, from about 0.01 % to about 5% or even from about 0.1 % to about 3% by weight of the composition.
Fluorescent whitening agent: The detergent compositions of the present invention will preferably also contain additional components that may tint articles being cleaned, such as fluorescent whitening agent or optical brighteners. Where present the brightener is preferably at a level of about 0,01 % to about 0,5%.. Any fluorescent whitening agent suitable for use in a laundry detergent composition may be used in the composition of the present invention. The most commonly used fluorescent whitening agents are those belonging to the classes of diaminostilbene-sulphonic acid derivatives, diarylpyrazoline derivatives and bisphenyl-distyryl derivatives. Examples of the diaminostilbene-sulphonic acid derivative type of fluorescent whitening agents include the sodium salts of: 4,4'-bis-(2-diethanolamino-4-anilino-s-triazin-6- ylamino) stilbene-2,2'-disulphonate; 4,4'-bis-(2,4-dianilino-s-triazin-6-ylamino) stilbene-2.2'- disulphonate; 4,4'-bis-(2-anilino-4(N-methyl-N-2-hydroxy-ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-disulphonate, 4,4'-bis-(4-phenyl-2,1 ,3-triazol-2-yl)stilbene-2,2'-disulphonate; 4,4'- bis-(2-anilino-4(1 -methyl-2-hydroxy-ethylamino)-s-triazin-6-ylamino) stilbene-2,2'-disulphonate and 2-(stilbyl-4"-naptho-1 .,2':4,5)-1 ,2,3-trizole-2"-sulphonate. Preferred fluorescent whitening agents are Tinopal DMS and Tinopal CBS available from Ciba-Geigy AG, Basel, Switzerland. Tinopal DMS is the disodium salt of 4,4'-bis-(2-morpholino-4 anilino-s-triazin-6-ylamino) stilbene disulphonate. Tinopal CBS is the disodium salt of 2,2'-bis-(phenyl-styryl) disulphonate. Also preferred are fluorescent whitening agents is the commercially available Parawhite KX, supplied by Paramount Minerals and Chemicals, Mumbai, India. Other fluorescers suitable for use in the invention include the 1 -3-diaryl pyrazolines and the 7-alkylaminocoumarins. Suitable fluorescent brightener levels include lower levels of from about 0.01 , from 0.05, from about 0.1 or even from about 0.2 wt % to upper levels of 0.5 or even 0.75 wt%.
Soil release polymers: The detergent compositions of the present invention may also include one or more soil release polymers which aid the removal of soils from fabrics such as cotton and polyester based fabrics, in particular the removal of hydrophobic soils from polyester based fabrics. The soil release polymers may for example be nonionic or anionic terephthalte based polymers, polyvinyl caprolactam and related copolymers, vinyl graft copolymers, polyester polyamides see for example Chapter 7 in Powdered Detergents, Surfactant science series volume 71 , Marcel Dekker, Inc. Another type of soil release polymers are amphiphilic alkoxylated grease cleaning polymers comprising a core structure and a plurality of alkoxylate groups attached to that core structure. The core structure may comprise a polyalkylenimine structure or a polyalkanolamine structure as described in detail in WO 2009/087523 (hereby incorporated by reference). Furthermore random graft co-polymers are suitable soil release polymers Suitable graft co-polymers are described in more detail in WO 2007/138054, WO 2006/108856 and WO 2006/1 13314 (hereby incorporated by reference). Other soil release polymers are substituted polysaccharide structures especially substituted cellulosic structures such as modified cellulose deriviatives such as those described in EP 1867808 or WO 2003/040279 (both are hereby incorporated by reference). Suitable cellulosic polymers include cellulose, cellulose ethers, cellulose esters, cellulose amides and mixtures thereof. Suitable cellulosic polymers include anionically modified cellulose, nonionically modified cellulose, cationically modified cellulose, zwitterionically modified cellulose, and mixtures thereof. Suitable cellulosic polymers include methyl cellulose, carboxy methyl cellulose, ethyl cellulose, hydroxyl ethyl cellulose, hydroxyl propyl methyl cellulose, ester carboxy methyl cellulose, and mixtures thereof.
Anti-redeposition agents: The detergent compositions of the present invention may also include one or more anti-redeposition agents such as carboxymethylcellulose (CMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), polyoxyethylene and/or polyethyleneglycol (PEG), homopolymers of acrylic acid, copolymers of acrylic acid and maleic acid, and ethoxylated polyethyleneimines. The cellulose based polymers described under soil release polymers above may also function as anti-redeposition agents.
Other suitable adjunct materials include, but are not limited to, anti-shrink agents, anti- wrinkling agents, bactericides, binders, carriers, dyes, enzyme stabilizers, fabric softeners, fillers, foam regulators, hydrotropes, perfumes, pigments, sod suppressors, solvents, and structurants for liquid detergents and/or structure elasticizing agents.
Formulation of Detergent Products
The detergent composition of the invention may be in any convenient form, e.g., a bar, a homogenous tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compact powder, a granule, a paste, a gel, or a regular, compact or concentrated liquid. There are a number of detergent formulation forms such as layers (same or different phases), pouches, as well as forms for machine dosing unit.
Pouches can be configured as single or multicompartments. It can be of any form, shape and material which is suitable for hold the composition, e.g. without allowing the release of the composition from the pouch prior to water contact. The pouch is made from water soluble film which encloses an inner volume. The inner volume can be devided into compartments of the pouch. Preferred films are polymeric materials preferably polymers which are formed into a film or sheet. Preferred polymers, copolymers or derivates thereof are selected polyacrylates, and water soluble acrylate copolymers, methyl cellulose, carboxy methyl cellulose, sodium dextrin, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, malto dextrin, poly methacrylates, most preferably polyvinyl alcohol copolymers and, hydroxyprpyl methyl cellulose (HPMC). Preferably the level of polymer in the film for example PVA is at least about 60%. Preferred average molecular weight will typically be about 20,000 to about 150,000. Films can also be of blend compositions comprising hydrolytically degradable and water soluble polymer blends such as polyactide and polyvinyl alcohol (known under the Trade reference M8630 as sold by Chris Craft In. Prod. Of Gary, Ind., US) plus plasticisers like glycerol, ethylene glycerol, Propylene glycol, sorbitol and mixtures thereof. The pouches can comprise a solid laundry detergent composition or part components and/or a liquid cleaning composition or part components separated by the water soluble film. The compartment for liquid components can be different in composition than compartments containing solids. Ref: (US2009/001 1970 A1 ).
Detergent ingredients can be separated physically from each other by compartments in water dissolvable pouches or in different layers of tablets. Thereby negative storage interaction between components can be avoided. Different dissolution profiles of each of the compartments can also give rise to delayed dissolution of selected components in the wash solution.
A liquid or gel detergent, which is not unit dosed, may be aqueous, typically containing at least 20% by weight and up to 95% water, such as up to about 70% water, up to about 65% water, up to about 55% water, up to about 45% water, up to about 35% water. Other types of liquids, including without limitation, alkanols, amines, diols, ethers and polyols may be included in an aqueous liquid or gel. An aqueous liquid or gel detergent may contain from 0-30% organic solvent. A liquid or gel detergent may be non-aqueous.
Laundry Soap Bars
The enzymes of the invention may be added to laundry soap bars and used for hand washing laundry, fabrics and/or textiles. The term laundry soap bar includes laundry bars, soap bars, combo bars, syndet bars and detergent bars. The types of bar usually differ in the type of surfactant they contain, and the term laundry soap bar includes those containing soaps from fatty acids and/or synthetic soaps. The laundry soap bar has a physical form which is solid and not a liquid, gel or a powder at room temperature. The term solid is defined as a physical form which does not significantly change over time, i.e. if a solid object (e.g. laundry soap bar) is placed inside a container, the solid object does not change to fill the container it is placed in. The bar is a solid typically in bar form but can be in other solid shapes such as round or oval.
The laundry soap bar may contain one or more additional enzymes, protease inhibitors such as peptide aldehydes (or hydrosulfite adduct or hemiacetal adduct), boric acid, borate, borax and/or phenylboronic acid derivatives such as 4-formylphenylboronic acid, one or more soaps or synthetic surfactants, polyols such as glycerine, pH controlling compounds such as fatty acids, citric acid, acetic acid and/or formic acid, and/or a salt of a monovalent cation and an organic anion wherein the monovalent cation may be for example Na+, K+ or NH4 + and the organic anion may be for example formate, acetate, citrate or lactate such that the salt of a monovalent cation and an organic anion may be, for example, sodium formate.
The laundry soap bar may also contain complexing agents like EDTA and HEDP, perfumes and/or different type of fillers, surfactants e.g. anionic synthetic surfactants, builders, polymeric soil release agents, detergent chelators, stabilizing agents, fillers, dyes, colorants, dye transfer inhibitors, alkoxylated polycarbonates, suds suppressers, structurants, binders, leaching agents, bleaching activators, clay soil removal agents, anti-redeposition agents, polymeric dispersing agents, brighteners, fabric softeners, perfumes and/or other compounds known in the art.
The laundry soap bar may be processed in conventional laundry soap bar making equipment such as but not limited to: mixers, plodders, e.g. a two stage vacuum plodder, extruders, cutters, logo-stampers, cooling tunnels and wrappers. The invention is not limited to preparing the laundry soap bars by any single method. The premix of the invention may be added to the soap at different stages of the process. For example, the premix containing a soap, an enzyme, optionally one or more additional enzymes, a protease inhibitor, and a salt of a monovalent cation and an organic anion may be prepared and the mixture is then plodded. The enzyme and optional additional enzymes may be added at the same time as the protease inhibitor for example in liquid form. Besides the mixing step and the plodding step, the process may further comprise the steps of milling, extruding, cutting, stamping, cooling and/or wrapping.
Granular detergent formulations
A granular detergent may be formulated as described in WO09/092699, EP1705241 , EP1382668, WO07/001262, US6472364, WO04/074419 or WO09/102854. Other useful detergent formulations are described in WO09/124162, WO09/124163, WO09/1 17340, WO09/1 17341 , WO09/1 17342, WO09/072069, WO09/063355, WO09/132870, WO09/121757, WO09/1 12296, WO09/1 12298, WO09/103822, WO09/087033, WO09/050026, WO09/047125, WO09/047126, WO09/047127, WO09/047128, WO09/021784, WO09/010375, WO09/000605, WO09/122125, WO09/095645, WO09/040544, WO09/040545, WO09/024780, WO09/004295, WO09/004294, WO09/121725, WO09/1 15391 , WO09/1 15392, WO09/074398, WO09/074403, WO09/068501 , WO09/065770, WO09/021813, WO09/030632, and WO09/015951.
WO201 1025615, WO201 1016958, WO201 1005803, WO201 1005623, WO201 1005730, WO201 1005844, WO201 1005904, WO201 1005630, WO201 1005830, WO201 1005912, WO201 1005905, WO201 1005910, WO201 1005813, WO2010135238, WO2010120863, WO2010108002, WO20101 1 1365, WO2010108000, WO2010107635, WO2010090915, WO2010033976, WO2010033746, WO2010033747, WO2010033897, WO2010033979, WO2010030540, WO2010030541 , WO2010030539, WO2010024467, WO2010024469, WO2010024470, WO2010025161 , WO2010014395, WO2010044905,
WO2010145887, WO2010142503, WO2010122051 , WO2010102861 , WO2010099997, WO2010084039, WO2010076292, WO2010069742, WO2010069718, WO2010069957, WO2010057784, WO2010054986, WO2010018043, WO2010003783, WO2010003792,
WO201 1023716, WO2010142539, WO20101 18959, WO20101 15813, WO2010105942, WO2010105961 , WO2010105962, WO2010094356, WO2010084203, WO2010078979, WO2010072456, WO2010069905, WO2010076165, WO2010072603, WO2010066486, WO2010066631 , WO2010066632, WO2010063689, WO2010060821 , WO2010049187, WO2010031607, WO2010000636.
Uses
The present invention is also directed to methods for using the subtilase variants according to the invention or compositions thereof in laundering of textile and fabrics, such as house hold laundry washing and industrial laundry washing. The invention is also directed to methods for using the variants according to the invention or compositions thereof in cleaning hard surfaces such as floors, tables, walls, roofs etc. as well as surfaces of hard objects such as cars (car wash) and dishes (dish wash).
The subtilase variants of the present invention may be added to and thus become a component of a detergent composition. Thus one aspect of the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 in a cleaning process such as laundering and/or hard surface cleaning.
In another aspect, the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261 W, N261 F, L262C, L262E and L262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 1 in a cleaning process such as laundering and/or hard surface cleaning.
In another aspect, the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting of X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261W, X261Y, X261 F, X262C, X262E and X262Q, wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 and wherein the subtilase variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 in a cleaning process such as laundering and/or hard surface cleaning.
In a further aspect, the invention relates to the use of a subtilase variant having protease activity and having at least 25% improved stability compared to the parent subtilase when measured as described in the accelerated storage stability assay in Example 3 herein comprising one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 wherein the variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 1 in a cleaning process such as laundering and/or hard surface cleaning.
In another aspect, the invention relates to the use of a subtilase variant one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261 W, N261 F, L262C, L262E and L262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 wherein the variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 1 in a cleaning process such as laundering and/or hard surface cleaning and wherein the subtilase variant has improved stability, in particular improved in storage stability, relative to the polypeptide of SEQ ID NO: 1 when measured using the 'accelerated storage stability assay' as described in example 3 in the Materials and Methods section herein.
In another aspect, the invention relates to the use of a subtilase variant one or more substitutions selected from the group consisting of X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261W, X261Y, X261 F, X262C, X262E and X262Q, wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 wherein the variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 in a cleaning process such as laundering and/or hard surface cleaning and wherein the subtilase variant has improved stability, in particular improved in storage stability, relative to the polypeptide of SEQ ID NO: 2 when measured using the 'accelerated storage stability assay' as described in example 3 in the Materials and Methods section herein. The subtilase variants of the present invention may be added to and thus become a component of a detergent composition. Thus one aspect of the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, 172V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 in a cleaning process such as laundering and/or hard surface cleaning and wherein the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance relative to the parent or relative to a protease parent having the identical amino acid sequence of the variant but excluding the substitutions at one or more of the positions when measured using the 'accelerated storage stability assay' and the Automatic Mechanical Stress Assay (AMSA) for laundry respectively as described in the Materials and Methods section herein.
In another aspect, the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C, S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261 W, N261 F, L262C, L262E and L262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 wherein the variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 1 in a cleaning process such as laundering and/or hard surface cleaning and wherein the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance relative to SEQ ID NO: 1 measured using the 'accelerated storage stability assay and the Automatic Mechanical Stress Assay (AMSA) for laundry respectively as described in the Materials and Methods section herein.
In a further aspect, the invention relates to the use of a subtilase variant comprising one or more substitutions selected from the group consisting X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C, X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261 W, X261Y, X261 F, X262C, X262E and X262Q wherein the position corresponds to the position of the polypeptide of SEQ ID NO: 2 wherein the variant has a sequence identity of at least 60%, such as at least 65%, such as at least 70%, e.g., at least 75%, at least 76% at least 77% at least 78% at least 79% at least 80%, at least 81 % at least 82% at least 83% at least 84% at least 85%, at least 86% at least 87% at least 88% at least 89%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95% identity, at least 96%, at least 97%, or at least 98%, but less than 100%, sequence identity to the polypeptide of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 or SEQ ID NO:12 in a cleaning process such as laundering and/or hard surface cleaning and wherein the subtilase variant has improved stability, in particular improved in storage stability, and on par or improved wash performance relative to the polypeptide of SEQ ID NO: 2, when measured using the 'Accelerated storage stability assay' and the Automatic Mechanical Stress Assay (AMSA) for laundry respectively as described in the Materials and Methods section herein.
A detergent composition of the present invention may be formulated, for example, as a hand or machine laundry detergent composition including a laundry additive composition suitable for pre-treatment of stained fabrics and a rinse added fabric softener composition, or be formulated as a detergent composition for use in general household hard surface cleaning operations, or be formulated for hand or machine dishwashing operations.
In a specific aspect, the present invention provides a detergent additive comprising a polypeptide of the present invention as described herein.
The cleaning process or the textile care process may for example be a laundry process, a dishwashing process or cleaning of hard surfaces such as bathroom tiles, floors, table tops, drains, sinks and washbasins. Laundry processes can for example be household laundering, but it may also be industrial laundering. Furthermore, the invention relates to a process for laundering of fabrics and/or garments where the process comprises treating fabrics with a washing solution containing a detergent composition, and at least one protease variant of the invention. The cleaning process or a textile care process can for example be carried out in a machine washing process or in a manual washing process. The washing solution can for example be an aqueous washing solution containing a detergent composition.
The last few years there has been an increasing interest in replacing components in detergents, which is derived from petrochemicals with renewable biological components such as enzymes and polypeptides without compromising the wash performance. When the components of detergent compositions change new enzyme activities or new enzymes having alternative and/or improved properties compared to the common used detergent enzymes such as proteases, lipases and amylases is needed to achieve a similar or improved wash performance when compared to the traditional detergent compositions.
The invention further concerns the use of subtilase variants of the invention in a proteinaceous stain removing processes. The proteinaceous stains may be stains such as food stains, e.g., baby food, sebum, cocoa, egg, blood, milk, ink, grass, or a combination hereof.
Typical detergent compositions include various components in addition to the enzymes, these components have different effects, some components like the surfactants lower the surface tension in the detergent, which allows the stain being cleaned to be lifted and dispersed and then washed away, other components like bleach systems remove discolor often by oxidation and many bleaches also have strong bactericidal properties, and are used for disinfecting and sterilizing. Yet other components like builder and chelator softens, e.g., the wash water by removing the metal ions form the liquid.
In a particular embodiment, the invention concerns the use of a composition comprising a subtilase variant of the invention and one or more detergent components, such as surfactants, hydrotropes, builders, co-builders, chelators or chelating agents, bleaching system or bleach components, polymers, fabric hueing agents, fabric conditioners, foam boosters, suds suppressors, dispersants, dye transfer inhibitors, fluorescent whitening agents, perfume, optical brighteners, bactericides, fungicides, soil suspending agents, soil release polymers, anti- redeposition agents, enzyme inhibitors or stabilizers, enzyme activators, antioxidants, and solubilizers.
In a particular embodiment, the invention concerns the use of a composition comprising a subtilase variant of the invention and one or more additional enzymes selected from the group comprising of proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidaes, haloperoxygenases, catalases and mannanases, or any mixture thereof.
In a particular embodiment, the invention concerns the use of a composition comprising a subtilase variant of the invention, one or more additional enzymes selected from the group comprising of proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidaes, haloperoxygenases, catalases and mannanases, or any mixture thereof and one or more detergent components, such as surfactants, hydrotropes, builders, co-builders, chelators or chelating agents, bleaching system or bleach components, polymers, fabric hueing agents, fabric conditioners, foam boosters, suds suppressors, dispersants, dye transfer inhibitors, fluorescent whitening agents, perfume, optical brighteners, bactericides, fungicides, soil suspending agents, soil release polymers, anti-redeposition agents, enzyme inhibitors or stabilizers, enzyme activators, antioxidants, and solubilizers.
Washing Method
The present invention relates to a method of cleaning a fabric, a dishware or hard surface with a detergent composition comprising a protease variant of the invention.
A preferred embodiment concerns a method of cleaning, the method comprising the steps of: contacting an object with a detergent composition comprising a protease variant of the invention under conditions suitable for cleaning the object. In a preferred embodiment the detergent composition is used in a laundry or a dish wash process.
Still another embodiment relates to a method for removing stains from fabric or dishware which comprises contacting the fabric or dishware with a composition comprising a protease of the invention under conditions suitable for cleaning the object.
Also contemplated are compositions and methods of treating fabrics (e.g., to desize a textile) using one or more of the protease of the invention. The protease can be used in any fabric-treating method which is well known in the art (see, e.g., US6,077,316). For example, in one aspect, the feel and appearance of a fabric is improved by a method comprising contacting the fabric with a protease in a solution. In one aspect, the fabric is treated with the solution under pressure.
The detergent compositions of the present invention are suited for use in laundry and hard surface applications, including dish wash. Accordingly, the present invention includes a method for laundering a fabric or washing dishware. The method comprises the steps of contacting the fabric/dishware to be cleaned with a solution comprising the detergent composition according to the invention. The fabric may comprise any fabric capable of being laundered in normal consumer use conditions. The dishware may comprise any dishware such as crockery, cutlery, ceramics, plastics such as melamine, metals, china, glass and acrylics. The solution preferably has a pH from about 5.5 to about 1 1.5. The compositions may be employed at concentrations from about 100 ppm, preferably 500 ppm to about 15,000 ppm in solution. The water temperatures typically range from about 5°C to about 95°C, including about 10°C, about 15°C, about 20°C, about 25°C, about 30°C, about 35°C, about 40°C, about 45°C, about 50°C, about 55°C, about 60°C, about 65°C, about 70°C, about 75°C, about 80°C, about 85°C and about 90°C. The water to fabric ratio is typically from about 1 :1 to about 30:1 . The enzyme(s) of the detergent composition of the invention may be stabilized using conventional stabilizing agents and protease inhibitors, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, different salts such as NaCI; KCI; lactic acid, formic acid, boric acid, or a boric acid derivative, e.g., an aromatic borate ester, or a phenyl boronic acid derivative such as 4-formylphenyl boronic acid , or a peptide aldehyde such as di-, tri- or tetrapeptide aldehydes or aldehyde analogues (either of the form B1 -B0-R wherein, R is H, CH3, CX3, CHX2, or CH2X (X=halogen), BO is a single amino acid residue (preferably with an optionally substituted aliphatic or aromatic side chain); and B1 consists of one or more amino acid residues (preferably one, two or three), optionally comprising an N-terminal protection group, or as described in WO091 18375, W098/13459) or a protease inhibitor of the protein type such as RASI, BASI, WASI (bifunctional alpha-amylase/subtilisin inhibitors of rice, barley and wheat) or CI2 or SSI. The composition may be formulated as described in e.g. WO 92/19709, WO 92/19708 and US 6,472,364. In some embodiments, the enzymes employed herein are stabilized by the presence of water-soluble sources of zinc (II), calcium (II) and/or magnesium (II) ions in the finished compositions that provide such ions to the enzymes, as well as other metal ions (e.g., barium (II), scandium (II), iron (II), manganese (II), aluminum (III), Tin (II), cobalt (II), copper (II), Nickel (II), and oxovanadium (IV)).
In some preferred embodiments, the detergent compositions provided herein are typically formulated such that, during use in aqueous cleaning operations, the wash water has a pH of from about 5.0 to about 1 1 .5, or in alternative embodiments, even from about 6.0 to about 10.5. In some preferred embodiments, granular or liquid laundry products are formulated to have a pH from about 6 to about 8. Techniques for controlling pH at recommended usage levels include the use of buffers, alkalis, acids, etc., and are well known to those skilled in the art.
The present invention is further described by the following examples that should not be construed as limiting the scope of the invention.
EXAMPLES Materials and Methods
Wash performance assays
Automatic Mechanical Stress Assay (AMSA) for Laundry.
In order to assess the wash performance in laundry, washing experiments are performed using the Automatic Mechanical Stress Assay (AMSA). With the AMSA, the wash performance of many small volume enzyme-detergent solutions can be examined. The AMSA plate has a number of slots for test solutions and a lid that firmly squeezes the textile to be washed against the slot openings. During the wash, the plate, test solutions, textile and lid are vigorously shaken to bring the test solution in contact with the textile and apply mechanical stress in a regular, periodic, oscillating manner. For further description see WO02/42740 especially the paragraph "Special method embodiments" at page 23-24.
The laundry experiments are conducted under the experimental conditions specified below:
Table 3
Figure imgf000169_0001
Automatic Mechanical Stress Assay (AMSA) for Automatic Dish Wash
Washing experiments were performed in order to assess the wash performance of selected protease variants in dish wash detergent compositions. The proteases of the present application were tested using the Automatic Mechanical Stress Assay (AMSA). With the AMSA, the wash performance of many small volume enzyme-detergent solutions can be examined. The AMSA plate has a number of slots for test solutions and a lid that firmly squeezes the melamine tile to be washed against the slot openings. During the wash, the plate, test solutions, melamine tile and lid was vigorously shaken to bring the test solution in contact with the soiled melamine tile and apply mechanical stress in a regular, periodic oscillating manner. For further description see WO 02/42740 especially the paragraph "Special method embodiments" at page 23-24.
The experiment was conducted under the experimental conditions as specified in tables 4 and 5 below.
Table 4: AMSA Experimental Conditions using ADW model detergent with MGDA
Figure imgf000169_0002
Temperature 45 °C
Water hardness 21 °dH
Enzyme concentration in test solution 5.3, 10,7 mg enzyme protein/liter
Test material Egg yolk melamine tile (DM-21 )
Table 5: AMSA Experimental Conditions using ADW model detergent with STPP
ADW model detergent with STPP As defined in table 6
Detergent dosage 3.33 g/L
Test solution volume 160 micro L pH 10,0
Wash time 20 minutes
Temperature 45°C
Water hardness 21 °dH
Enzyme concentration in test solution 5.3, 10,7 mg enzyme protein/liter
Test material Egg yolk melamine tile (DM-21 )
Water hardness was adjusted to 21 °dH by addition of CaCI2, MgCI2, and NaHC03 (Ca2+:Mg2+:C03 2" = 4:1 :10) to the test system. After washing the egg yolk melamine tiles were flushed in tap water and dried.
The performance of the enzyme variant was measured as the brightness of the colour of the melamine tile (and textile for laundry) washed with that specific subtilase variant. Brightness can also be expressed as the intensity of the light reflected from the sample when illuminated with white light. When the sample is stained the intensity of the reflected light is lower, than that of a clean sample. Therefore the intensity of the reflected light can be used to measure wash performance of a protease. Color measurements were made with a professional flatbed scanner (EPSON EXPRESSION 10000XL, Atea A/S, Lautrupvang 6, 2750 Ballerup, Denmark), which is used to capture an image of the washed melamine tiles.
To extract a value for the light intensity from the scanned images, a special designed software application is used (Novozymes Colour Vector Analyzer). The program retrieves the 24 bit pixel values from the image and converts them into values for red, green and blue (RGB). The intensity value (Int) is calculated by adding the RGB values together as vectors and then taking the length of the resulting vector: Table 6: Composition of model detergents and test materials Model detergent and test materials were as follows:
Figure imgf000171_0001
pH adjusted to 9
MGSodium carbonate 0.66 g/l
Sodium percarbonate (Dream) 0.33 g/l
Sodium disilicate 0.17 g/l
TAED (Dream) 0.10 g/l
Sokalan CP5 (39.5%) 0.42 g/l
MGDA model detergent Surfac 23-6.5 (100%) 0.17 g/l
Sodium sulphate 1 .06 g
CaCI2 3 mM
MgCI2 0.75 mM
NaHC03 7.5 mM pH adjusted to 10.0
STPP 1 .65 g/l
Sodium carbonate 0.66 g/l
Sodium percarbonate (Dream) 0.33 g/l
Sodium disilicate 0.17 g/l
TAED (Dream) 0.10 g/l
Sokalan CP5 (39.5%) 0.42 g/l
STPP model detergent
Surfac 23-6.5 (100%) 0.17 g/l
Phosphonate (tetrasodium HEDP) 0.07 g/l
CaCI2 3 mM
MgCI2 0.75 mM
NaHC03 7.5 mM pH adjusted to 10.0
EMPA1 12 (Cocoa on cotton)
PC-05 (Blood/milk/ink on cotton/polyester)
Test material
WFK10PPM (Vegetable oil/milk/pigment on cotton)
C-10 (Oil/milk/pigment on cotton)
Test materials are obtained from EMPA Testmaterials AG, Movenstrasse 12, CH-9015 St. Gallen, Switzerland, from Center For Testmaterials BV, P.O. Box 120, 3133 KT Vlaardingen, the Netherlands, and WFK Testgewebe GmbH, Christenfeld 10, D-41379 Bruggen, Germany.
Water hardness was adjusted to 15°dH by addition of CaCI2, MgCI2, and NaHC03
(Ca2+:Mg2+ = 4:1 :7.5) to the test system. After washing the textiles were flushed in tap water and dried.
Protease activity assays: 1 ) Suc-AAPF-pNA activity assay:
The proteolytic activity can be determined by a method employing the Suc-AAPF-PNA substrate. Suc-AAPF-PNA is an abbreviation for N-Succinyl-Alanine-Alanine-Proline- Phenylalanine-p-Nitroanilide, and it is a blocked peptide which can be cleaved by endo- proteases. Following cleavage a free PNA molecule is liberated and it has a yellow colour and thus can be measured by visible spectrophotometry at wavelength 405nm. The Suc-AAPF-PNA substrate is manufactured by Bachem (cat. no. L1400, dissolved in DMSO).
The protease sample to be analyzed was diluted in residual activity buffer (100mM Tris pH 8.6). The assay was performed by transferring 30μΙ of diluted enzyme samples to 96 well microtiter plate and adding 70μΙ substrate working solution (0.72mg/ml in 100mM Tris pH8.6). The solution was mixed at room temperature and absorption is measured every 20 sec. over 5 minutes at OD 405 nm.
The slope (absorbance per minute) of the time dependent absorption-curve is directly proportional to the activity of the protease in question under the given set of conditions. The protease sample should be diluted to a level where the slope is linear.
General molecular biology methods:
Unless otherwise mentioned the DNA manipulations and transformations w< performed using standard methods of molecular biology (Sambrook et al. (1989); Ausubel et (1995); Harwood and Cutting (1990).
Example 1 : Preparation and Expression of variants
The following summarizes the mutation and introduction of an expression cassette into Bacillus subtilis. All DNA manipulations were done by PCR (e.g. Sambrook et al.; Molecular Cloning; Cold Spring Harbor Laboratory Press) and can be repeated by everybody skilled in the art.
Recombinant B. subtilis constructs encoding subtilase variants were used to inoculate shakeflasks containing a rich media (e.g. 100 g/L Sucrose (Danisco cat.no. 109-0429), 40 g/L crust soy (soy bean flour), 10g/L Na2HP04.12H20 (Merck cat.no. 6579), 0.1 ml/L replace- Dowfax63N10 (Dow). Cultivation typically takes 4 days at 30oC shaking with 220rpm. Example 2: Purification of Variants
The culture broth was centrifuged (26000 x g, 20 min) and the supernatant was carefully decanted from the precipitate. The supernatant was filtered through a Nalgene 0.2μηι filtration unit in order to remove the rest of the Bacillus host cells. pH in the 0.2μηι filtrate was adjusted to pH 8 with 3M Tris base and the pH adjusted filtrate was applied to a MEP Hypercel column (from Pall corporation) equilibrated in 20mM Tris/HCI, 1 mM CaCI2, pH 8.0. After washing the column with the equilibration buffer, the column was step-eluted with 20mM CH3COOH/NaOH, 1 mM CaCI2, pH 4.5. Fractions from the column were analysed for protease activity (using the Suc-AAPF-pNA assay at pH 9) and peak-fractions were pooled. The pH of the pool from the MEP Hypercel column was adjusted to pH 6 with 20% (v/v) CH3COOH or 3M Tris base and the pH adjusted pool was diluted with deionized water to the same conductivity as 20mM MES/NaOH, 2mM CaCI2, pH 6.0. The diluted pool was applied to a SP-sepharose FF column (from GE Healthcare) equilibrated in 20mM MES/NaOH, 2mM CaCI2, pH 6.0. After washing the column with the equilibration buffer, the protease was eluted with a linear NaCI gradient (0— > 0.5M) in the same buffer over five column volumes. Fractions from the column were analysed for protease activity (using the Suc-AAPF- pNA assay at pH 9) and active fractions were analysed by SDS-PAGE. The fractions, where only one band was seen on the coomassie stained SDS-PAGE gel, were pooled as the purified preparation and was used for further experiments.
Example 3: Accelerated storage stability assay
Storage stability of protease variants in liquid detergent was evaluated using an accelerated assay with incubation at elevated temperatures for up to 24 hours.
All purified protease samples were diluted to concentrations of 0.2 and 0.1 mg/ml based on absorbance at 280 nm and theoretical extinction coefficient using 0.01 % Triton X-100. For each variant 2 wells with high protease concentration and 2 wells with low concentration were included. As reference SEQ ID NO 3 was included on each microtiter plate. 30 μΙ protease sample was mixed with 270 μΙ detergent (Model O or CNS EDTA pH9) in the well of a microtiter plate (Nunc U96 PP 0.5 ml) using a magnetic bar (on Zephyr pipetting station (Caliper LifeSciences) for 30 min). 20 μΙ of this mixture was then transferred to another microtiter plate (Nunc U96 PP 0.5 ml with added magnetic bars) and mixed with 150 μΙ 100mM Tris pH 8.6 (at least 5 min on Zephyr). 30 μΙ of this dilution was transferred to a Nunc F 96-MTP, and after addition of 70 μΙ substrate solution initial activity of unstressed sample was determined by measuring absorbance at 405 nm every 20 sec for 5 min (on a SpectraMax Plus). After sealing, the detergent plate was incubated at appropriate temperature (50-62°C for Model O, 35°C for CNS EDTA pH9) in an Eppendorf Thermomixer (no shaking). After 1 -4 and 20-25 hours incubation, 20 μΙ samples were withdrawn and residual activity of stressed sample was measured as with the initial, unstressed activity.
Decrease in activity during incubation with detergent was assumed to be exponential. Half lifes (T½) were found from linear regression of Log(Activity) versus incubation time (0, 1 -4 and 20-25 hours), and half life improvement factors (T½ IF) were calculated as half life of protease variant relative to half life of SEQ ID NO 3 reference. Table 8 shows the half-life improvement of single mutations variants of SEQ ID NO 3. Table 7
Figure imgf000175_0001
Table 8: Accelerated storage stability of variants T½ IF: Half life improvement factor was measured for single mutation variants of SEQ ID NO 3 relative to SEQ ID NO 3
S9C 3,97
S9D 2,26
S9E 4,6
S9Q 2,18
N43A 1,88
N43C 2,43
N43L 1,71
N43R 2,42
N43W 1,92
I72A 2,48
172V 1,91
S78D 1,27
V104F 1,32
A114V 1,41
G115T 1,81
G115W 2,66
H120I 1,63
H120T 1,44
H120V 2,18
P129D 2,05
V147W 1,56
V149C 1,55
V149N 1,42
A158E 2,06
G160D 2,69
G160P 2,67
S161C 1,38
S161E 1,69
S163A 1,37
S163D 1,55
Q182C 1,36
Q182E 2,71
N185C 1,47
N185E 1,75 S188C 1,25
S188D 1,31
S188E 1,89
Q191N 2,16
N204D 2,47
N204V 4,11
V205I 2,43
Q206E 1,68
Q206I 2,73
Q206K 1,6
Q206L 5,36
Q206T 1,51
Q206V 3,56
Q206W 3,83
Q206C 14,17
Y209W 5,1
S212A 1,5
S212D 2,29
S212G 2,79
S212N 2,06
S216I 1,82
S216T 1,89
S216V 1,94
L217C 5,3
L217M 2,74
N218T 2,3
M222C 1,77
M222R 1,26
P225A 10,04
T255C 1,79
T255E 1,55
S256A 1,47
S256C 2,28
S256D 2,24
S256V 1,36
S256Y 1,46
S259D 3,09
T260E 2,6
T260P 1,31
N261C 2,88
N261E 3,49
N261L 2,47 N261 M 1 ,64
N261V 2,18
N261W 4,07
N261Y 3,38
L262C 5,12
L262E 9,46
L262Q 2,72
Table 8 shows that all the mutations above improve the stability compared to the parent protease (in this example SEQ ID NO 3) with at least 25 %.
Table 9: Accelerated storage stability of variants T½ IF: Half life improvement factor was measured relative to SEQ ID NO 3
Figure imgf000177_0001
N76D+N261 E+L262E 4.6
N76D+N261V+L262E 4.6
N76D+Q206L+Y209W 4.5
N76D+N261Y+L262E 4.5
N76D+V205I+Q206W 4.1
N76D+G160D+S161 E 4.0
N76D+V205I+Q206E 4.0
N76D+Q206L+S256D 4.0
N76D+G1 15T+H120T 3.7
N76D+G160D+S161Y 3.5
N76D+N18S+V205I 3.2
N76D+A194P+M222S 3.2
N76D+Y209W+S256D 3.2
N76D+N18S+Q206E 2.7
N76D+Y209W+S256C 2.5
N76D+G1 15T+H120V 2.4
N76D+T255E+S256D 2.3
N76D+G1 15T+H120I 2.0
N76D+T255Q+S256D 1.8
Example 4: Accelerated storage stability assay
Storage stability of protease variants in liquid detergent was evaluated using an accelerated assay with incubation at elevated temperatures for up to 24 hours.
Culture supernatants containing the protease variants were diluted 8 times using 0.01 %
Triton X-100. Each culture supernatant was tested in duplicates. As reference purified Savinase (SEQ ID NO 1 ) diluted to concentrations of 0.2 and 0.1 mg/ml with 0.01 % Triton X-100 was included on each microtiter plate. 30 μΙ protease sample was mixed with 270 μΙ Model O detergent in the well of a microtiter plate (Nunc U96 PP 0.5 ml) using a magnetic bar (on Zephyr pipetting station (Caliper LifeSciences) for 15 min). 20 μΙ of this mixture was then transferred to another microtiter plate (Nunc U96 PP 0.5 ml with added magnetic bars) and mixed with 150 μΙ 100mM Tris pH 8.6 (at least 5 min on Zephyr). 30 μΙ of this dilution was transferred to a Nunc F 96-MTP, and after addition of 70 μΙ substrate solution initial activity of unstressed sample was determined by measuring absorbance at 405 nm every 20 sec for 5 min (on a SpectraMax Plus). After sealing, the detergent plate was incubated at 50°C in an Eppendorf Thermomixer (no shaking). After 1 , 4 and 24 hours incubation, 20 μΙ samples were withdrawn and residual activity of stressed sample was measured as with the initial, unstressed activity.
Decrease in activity during incubation with detergent was assumed to be exponential. Half lifes (T½) were found from linear regression of Log(Activity) versus incubation time (0, 1,4 and 24 hours), and half life improvement factors (T½ IF) were calculated as half life of protease variant relative to half life of Savinase reference (SEQ ID NO 1).
Table 10: Accelerated storage stability of variants in Model O at 50°C. T½ IF: Half life improvement factor relative to Savinase reference (SEQ ID NO 1).
Mutations T½IF
P129D 1,96
Q206L 1,90
Q206C 1,83
S188C 1,80
S9C 1,72
S9E 1,68
A133H 1,68
Q206W 1,58
Y209W 1,49
V205I 1,48
N204D 1,47
L262C 1,47
L262E 1,43
S259D 1,42
S9D 1,42
Q206E 1,39
N43L 1,33
N43C 1,32
S256D 1,31
N43W 1,29
Q191N 1,29
172 A 1,25
S161C 1,23
N261E 1,22
G160D 1,21
N185C 1,21
S9Q 1,21
A215K 1,21
S216I 1,14
N261C 1,14
H120T 1,12 S256C 1 ,09
Table 10 shows that all the mutations above improve the stability compared to the parent protease (in this example SEQ ID NO 1 ).
Example 5: In Wash Stability
In Wash Stability Assay
In wash stability was measured according to the 'In wash stability assay' as described below using the MGDA and STPP model detergents as defined in table 6. The results are presented in table 1 1 .
Both detergents are dissolved in 50 mM CHES buffer (N-Cyclohexyl-2- aminoethanesulfonic acid, Sigma C2885) to ensure that pH is maintained during the experiment at 10.0 also after addition of protease sample.
Protease culture supernatants are pre-diluted 2-4 times and purified protease samples are diluted to approximately 0.1 and 0.05 mg/ml using deionized water. 10 μΙ diluted protease sample is then mixed with 190 μΙ model detergent solution in a well of a 0.2 ml 96-well PCR plate. After mixing, 20 μΙ is transferred to a 96-well microtiter plate (Nunc F) and initial protease activity is measured by adding 100 μΙ Suc-AAPF-pNA substrate solution (0.72 mg/ml Suc-Ala- Ala-Pro-Phe-pNA (Bachem L-1400) in 0.1 M Tris, pH 8.6) to each well, mixing and measuring absorbance at 405 nm every 20 s for 5 min on a SpectraMax Plus (Molecular Devices). Slope from linear regression on initial absorbance measurements is used for activity calculations.
The proteases in the PCR plate are then stressed by 30 min incubation at 58°C for
STPP model detergent and 60 or 62°C for MGDA model detergent in a BioRad T100 Thermal Cycler. After rapid cooling to room temperature, 20 μΙ is transferred to a 96 well microtiter plate and residual activity is measured as described for the initial protease activity. The temperatures in the stress step are chosen to give suitable residual activities of the reference protease (SEQ ID NO 8) and the polypeptides (preferably in the interval 10 to 80% of the initial activity).
The decrease in activity during the stress step is assumed to be exponential. Thus, the half-life during the stress step is calculated using the formula:
T½ = T * ln(2) / ln(A(lnitial) / A(Residual)) where T½ is the half-life, T is the incubation time (30 min), A(lnitial) is the initial protease activity, and A(Residual) is the protease activity after the stress step. All protease samples are tested twice (using 2 times the same sample dilution for culture supernatants and 0.1 and 0.05 mg/ml for purified protease samples). Relative in wash stability improvement factor is then calculated by: Relative In Wash Stability Improvement Factor = Avg(T½(Sample)) / Avg(T½(Reference) where Avg(T½(Samples)) is the average of the half-lifes for the given protease sample and Avg(T½(Reference)) is the average of the half-lifes for the reference protease (SEQ ID NO 8).
Table 1 1 : In Wash Stability Data using MGDA and STPP model detergents
Figure imgf000181_0001
Example 6: Wash performance in Automatic Mechanical Stress Assay (AMSA) for Automatic Dish Wash
Washing experiments are performed in order to assess the wash performance of selected protease polypeptides in dish wash detergent compositions. The proteases of the present application are tested using the Automatic Mechanical Stress Assay (AMSA) for dish wash as described above. The results are shown in table 12 below. The subtilase variants have improved wash performance in dish wash compared to the protease with SEQ ID NO 1 .
Table 12
Figure imgf000182_0001
Example 7: Accelerated storage stability assay
Storage stability of subtilase variants in liquid detergent was evaluated using an accelerated assay with incubation at elevated temperatures for up to 24 hours.
All purified protease samples were diluted to concentrations of 0.2 and 0.1 mg/ml based on absorbance at 280 nm and theoretical extinction coefficient using 0.01 % Triton X-100. For each variant 2 wells with high protease concentration and 2 wells with low concentration were included. As reference, SEQ ID NO: 3 was included on each microtiter plate. 30 μΙ protease sample was mixed with 270 μΙ detergent (Model O or CNS EDTA pH9) in the well of a microtiter plate (Nunc U96 PP 0.5 ml) using a magnetic bar (on Zephyr pipetting station (Caliper LifeSciences) for 30 min). 20 μΙ of this mixture was then transferred to another microtiter plate (Nunc U96 PP 0.5 ml with added magnetic bars) and mixed with 150 μΙ 100mM Tris pH 8.6 (at least 5 min on Zephyr). 30 μΙ of this dilution was transferred to a Nunc F 96-MTP, and after addition of 70 μΙ substrate solution initial activity of unstressed sample was determined by measuring absorbance at 405 nm every 20 sec for 5 min (on a SpectraMax Plus). After sealing, the detergent plate was incubated at appropriate temperature (50-62°C for Model O, 35°C for CNS EDTA pH9) in an Eppendorf Thermomixer (no shaking). After 1 -4 and 20-25 hours incubation, 20 μΙ samples were withdrawn and residual activity of stressed sample was measured as with the initial, unstressed activity.
Decrease in activity during incubation with detergent was assumed to be exponential. Half lifes (T½) were found from linear regression of Log(Activity) versus incubation time (0, 1 -4 and 20-25 hours), and half life improvement factors (T½ IF) were calculated as half life of protease variant relative to half life of SEQ ID NO 3 reference.
Table 13 Detergent Model 0 or CNS EDTA
pH 9
Temperature 52 to 58°C
Table 14: Accelerated storage stability of variants T½ IF: Half life improvement factor was measured relative to SEQ ID NO 3
Figure imgf000183_0001
Table 14 shows that all the variants above have improved the stability compared to SEQ
ID NO 3.

Claims

Claims
1 . A subtilase variant of a subtilase parent having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 , when measured as described in the accelerated storage stability assay in Example 3 herein, wherein the variant subtilase is a polypeptide that has at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% but less than 100% sequence identity to the polypeptide of SEQ ID NO: 1 .
2. A subtilase variant according to claim 1 , wherein said subtilase variants comprises one or more, preferably two or more of the substitutions selected from the group consisting of X9C, X9D, X9E, X9Q, X43A, X43C, X43L, X43R, X43W, X72A, X72V, X78D, X104F, X1 14V, X1 15T, X1 15W, X120I, X120T, X120V, X129D, X147W, X149C, X149N, X158E, X160D, X160P, X161 C, X161 E, X163A, X163D, X182C, X182E, X185C, X185E, X188C,
X188D, X188E, X191 N, X204D, X204V, X205I, X206C, X206E, X206I, X206K, X206L, X206T, X206V, X206W, X209W, X212A, X212D, X212G, X212N, X216I, X216T, X216V, X217C, X217M, X218T, X222C, X222R, X225A, X255C, X255E, X256A, X256C, X256D, X256V, X256Y, X259D, X260E, X260P, X261 C, X261 E, X261 L, X261 M, X261V, X261 W, X261Y, X261 F, X262C, X262E and X262Q, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2.
3. The subtilase variant of any of claims 1 to 2, wherein the total number of alterations compared to SEQ ID NO: 1 is between 3 and 30, preferably between 3 and 20, more preferably between 3 and 15, even more preferably between 3 and 10, most preferably between 3 and 8 alterations.
4. The subtilase variant of any of claims 1 to 3, wherein the parent subtilase is selected from a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1 , SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:1 1 and SEQ ID NO:12.
5. The variant of any of claims 1 to 4, further comprising one or more of the substitutions selected from the group consisting of S3T, V4I, A15T, S24G, S24R, V68A, S99D, S99E, S101 R, S101 K, S101 N, S101 M, S101 E, S101 D, S101 L, S101 I, S103A, V104I, S128A, S128L, S128S, P129N, P129Q S130A, V199M, L217Y, L217D, L217E, L217Q, N218D, N218E, Q245K and Q245R (numbering according to SEQ ID NO: 2).
6. The variant of any of claims 1 to 5, which has improved stability compared to the subtilase with SEQ ID NO 1 , when measured as described in the accelerated storage stability assay in Example 3.
7. The variant of any of claims 1 to 6, which has an improved wash performance compared to the subtilase with SEQ ID NO: 1 , when measured in AMSA assay.
8. A detergent composition comprising a variant according to any of claims 1 to 7, wherein the detergent further comprise one or more detergent components.
9. The detergent composition according to claim 8, further comprising one or more additional enzymes selected from the group comprising of proteases, amylases, lipases, cutinases, cellulases, endoglucanases, xyloglucanases, pectinases, pectin lyases, xanthanases, peroxidaes, haloperoxygenases, catalases and mannanases, or any mixture thereof.
10. The detergent composition according to any of claims 8 to 9 in form of a bar, a homogenous tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compact powder, a granule, a paste, a gel, or a regular, compact or concentrated liquid.
1 1 . Use of the detergent composition according to any of claims 8 to 10 in a cleaning process, such as laundry or hard surface cleaning such as dish wash.
12. A method for producing a subtilase variant having protease activity and having at least 25% improved stability compared to a subtilase with SEQ ID NO: 1 when measured as described in the accelerated storage stability assay in Example 3 herein, comprising a. introducing into a parent subtilase one or more alterations from the group consisting of S9C, S9D, S9E, S9Q, N43A, N43C, N43L, N43R, N43W, I72A, I72V, S78D, V104F, A1 14V, G1 15T, G1 15W, H120I, H120T, H120V, P129D, V147W, V149C, V149N, A158E, G160D, G160P, S161 C, S161 E, S163A, S163D, Q182C, Q182E, N185C, N185E, S188C,
S188D, S188E, Q191 N, N204D, N204V, V205I, Q206C, Q206E, Q206I, Q206K, Q206T, Q206V, Q206W, Q206L Y209W, S212A, S212D, S212G, S212N, S216I, S216T, S216V, L217C, L217M, N218T, M222C, M222R, P225A, T255C, T255E, S256A, S256C, S256D, S256V, S256Y, S259D, T260E, T260P, N261 C, N261 E, N261 L, N261 M, N261V, N261Y, N261W, N261 F, L262C, L262E and L262Q, wherein each position corresponds to the position of SEQ ID NO: 2 and
recovering the variant.
PCT/EP2015/065375 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same WO2016001449A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202211569078.6A CN116240202A (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
CN201580035374.XA CN106661566A (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
US15/323,633 US10550381B2 (en) 2014-07-04 2015-07-06 Variant proteases and amylases having enhanced storage stability
CA2950380A CA2950380A1 (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
EP17206371.1A EP3327122B1 (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
BR112017000102-0A BR112017000102B1 (en) 2014-07-04 2015-07-06 SUBTYLASE VARIANTS OF A PROGENITOR SUBTYLASE, DETERGENT COMPOSITION, USE THEREOF AND METHOD FOR PRODUCING A SUBTYLASE VARIANT THAT HAS PROTEASE ACTIVITY
EP21156683.1A EP3878960A1 (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
EP15736432.4A EP3140399B1 (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same
US16/715,806 US11015183B2 (en) 2014-07-04 2019-12-16 Subtilase variants with enhanced storage stability
US17/246,266 US20220064620A1 (en) 2014-07-04 2021-04-30 Subtilase Variants And Polynucleotides Encoding Same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400367 2014-07-04
DKPA201400367 2014-07-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/323,633 A-371-Of-International US10550381B2 (en) 2014-07-04 2015-07-06 Variant proteases and amylases having enhanced storage stability
US16/715,806 Division US11015183B2 (en) 2014-07-04 2019-12-16 Subtilase variants with enhanced storage stability

Publications (1)

Publication Number Publication Date
WO2016001449A1 true WO2016001449A1 (en) 2016-01-07

Family

ID=53541651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/065375 WO2016001449A1 (en) 2014-07-04 2015-07-06 Subtilase variants and polynucleotides encoding same

Country Status (6)

Country Link
US (3) US10550381B2 (en)
EP (3) EP3327122B1 (en)
CN (2) CN106661566A (en)
BR (1) BR112017000102B1 (en)
CA (1) CA2950380A1 (en)
WO (1) WO2016001449A1 (en)

Cited By (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016087617A1 (en) * 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016162558A1 (en) 2015-04-10 2016-10-13 Novozymes A/S Detergent composition
WO2016162556A1 (en) 2015-04-10 2016-10-13 Novozymes A/S Laundry method, use of dnase and detergent composition
WO2017064253A1 (en) 2015-10-14 2017-04-20 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
WO2017089366A1 (en) 2015-11-24 2017-06-01 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
EP3227425A1 (en) * 2014-12-04 2017-10-11 Novozymes A/S Liquid cleaning compositions comprising protease variants
WO2017177153A1 (en) 2016-04-07 2017-10-12 Novozymes A/S Methods for selecting enzymes having protease activity
WO2017186943A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017192692A1 (en) 2016-05-03 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017210295A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
WO2017207762A1 (en) * 2016-06-03 2017-12-07 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2017220422A1 (en) 2016-06-23 2017-12-28 Novozymes A/S Use of enzymes, composition and method for removing soil
WO2018002261A1 (en) 2016-07-01 2018-01-04 Novozymes A/S Detergent compositions
WO2018007573A1 (en) 2016-07-08 2018-01-11 Novozymes A/S Detergent compositions with galactanase
WO2018011277A1 (en) 2016-07-13 2018-01-18 Novozymes A/S Bacillus cibi dnase variants
EP3275985A1 (en) * 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275989A1 (en) * 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
WO2018060216A1 (en) 2016-09-29 2018-04-05 Novozymes A/S Use of enzyme for washing, method for washing and warewashing composition
WO2018077938A1 (en) 2016-10-25 2018-05-03 Novozymes A/S Detergent compositions
WO2018108865A1 (en) 2016-12-12 2018-06-21 Novozymes A/S Use of polypeptides
WO2018118917A1 (en) * 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
WO2018184004A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Alpha-amylase combinatorial variants
WO2018177938A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having dnase activity
WO2018177936A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having dnase activity
WO2018178061A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having rnase activity
WO2018185181A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Glycosyl hydrolases
WO2018185152A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptide compositions and uses thereof
WO2018185150A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptides
WO2018185267A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2018184873A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Detergent compositions and uses thereof
WO2019036721A2 (en) 2017-08-18 2019-02-21 Danisco Us Inc Alpha-amylase variants
WO2019057902A1 (en) 2017-09-22 2019-03-28 Novozymes A/S Novel polypeptides
WO2019057758A1 (en) 2017-09-20 2019-03-28 Novozymes A/S Use of enzymes for improving water absorption and/or whiteness
DE102017125560A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANSING COMPOSITIONS CONTAINING DISPERSINE III
WO2019081721A1 (en) 2017-10-27 2019-05-02 Novozymes A/S Dnase variants
DE102017125559A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANSING COMPOSITIONS CONTAINING DISPERSINE II
DE102017125558A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANING COMPOSITIONS CONTAINING DISPERSINE I
WO2019084349A1 (en) 2017-10-27 2019-05-02 The Procter & Gamble Company Detergent compositions comprising polypeptide variants
WO2019086532A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Methods for cleaning medical devices
WO2019086528A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Polypeptides and compositions comprising such polypeptides
WO2019086530A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Polypeptides and compositions comprising such polypeptides
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019201793A1 (en) 2018-04-17 2019-10-24 Novozymes A/S Polypeptides comprising carbohydrate binding activity in detergent compositions and their use in reducing wrinkles in textile or fabric.
WO2020002604A1 (en) 2018-06-28 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
WO2020002608A1 (en) 2018-06-29 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
WO2020002255A1 (en) * 2018-06-29 2020-01-02 Novozymes A/S Subtilase variants and compositions comprising same
WO2020007875A1 (en) 2018-07-03 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020008024A1 (en) 2018-07-06 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020007863A1 (en) 2018-07-02 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020028443A1 (en) 2018-07-31 2020-02-06 Danisco Us Inc Variant alpha-amylases having amino acid substitutions that lower the pka of the general acid
WO2020070014A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition comprising anionic surfactant and a polypeptide having rnase activity
WO2020070063A2 (en) 2018-10-01 2020-04-09 Novozymes A/S Detergent compositions and uses thereof
WO2020070199A1 (en) 2018-10-03 2020-04-09 Novozymes A/S Polypeptides having alpha-mannan degrading activity and polynucleotides encoding same
WO2020070009A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Endonuclease 1 ribonucleases for cleaning
WO2020070011A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition
WO2020070209A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition
WO2020074545A1 (en) 2018-10-11 2020-04-16 Novozymes A/S Cleaning compositions and uses thereof
WO2020077331A2 (en) 2018-10-12 2020-04-16 Danisco Us Inc Alpha-amylases with mutations that improve stability in the presence of chelants
EP3647397A1 (en) 2018-10-31 2020-05-06 Henkel AG & Co. KGaA Cleaning compositions containing dispersins iv
EP3647398A1 (en) 2018-10-31 2020-05-06 Henkel AG & Co. KGaA Cleaning compositions containing dispersins v
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
US20200172890A1 (en) * 2018-11-29 2020-06-04 Henkel Ag & Co. Kgaa Performance-enhanced and storage stable protease variants
WO2020114965A1 (en) 2018-12-03 2020-06-11 Novozymes A/S LOW pH POWDER DETERGENT COMPOSITION
WO2020127775A1 (en) 2018-12-21 2020-06-25 Novozymes A/S Detergent pouch comprising metalloproteases
WO2020127796A2 (en) 2018-12-21 2020-06-25 Novozymes A/S Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same
WO2020188095A1 (en) 2019-03-21 2020-09-24 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
EP3715442A1 (en) 2016-03-23 2020-09-30 Novozymes A/S Use of polypeptide having dnase activity for treating fabrics
WO2020201403A1 (en) 2019-04-03 2020-10-08 Novozymes A/S Polypeptides having beta-glucanase activity, polynucleotides encoding same and uses thereof in cleaning and detergent compositions
WO2020207944A1 (en) 2019-04-10 2020-10-15 Novozymes A/S Polypeptide variants
WO2020247582A1 (en) 2019-06-06 2020-12-10 Danisco Us Inc Methods and compositions for cleaning
WO2021009067A1 (en) 2019-07-12 2021-01-21 Novozymes A/S Enzymatic emulsions for detergents
WO2021030400A1 (en) 2019-08-13 2021-02-18 Novozymes Bioag A/S Pesticidal combinations of yersinia and proteases
WO2021037895A1 (en) 2019-08-27 2021-03-04 Novozymes A/S Detergent composition
WO2021053127A1 (en) 2019-09-19 2021-03-25 Novozymes A/S Detergent composition
WO2021064068A1 (en) 2019-10-03 2021-04-08 Novozymes A/S Polypeptides comprising at least two carbohydrate binding domains
WO2021080948A2 (en) 2019-10-24 2021-04-29 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2021122121A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins ix
WO2021123307A2 (en) 2019-12-20 2021-06-24 Novozymes A/S Polypeptides having proteolytic activity and use thereof
WO2021122118A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins vi
WO2021121394A1 (en) 2019-12-20 2021-06-24 Novozymes A/S Stabilized liquid boron-free enzyme compositions
WO2021122117A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning composition coprising a dispersin and a carbohydrase
EP3892708A1 (en) 2020-04-06 2021-10-13 Henkel AG & Co. KGaA Cleaning compositions comprising dispersin variants
WO2021214059A1 (en) 2020-04-21 2021-10-28 Novozymes A/S Cleaning compositions comprising polypeptides having fructan degrading activity
EP3936593A1 (en) 2020-07-08 2022-01-12 Henkel AG & Co. KGaA Cleaning compositions and uses thereof
WO2022074037A2 (en) 2020-10-07 2022-04-14 Novozymes A/S Alpha-amylase variants
WO2022084303A2 (en) 2020-10-20 2022-04-28 Novozymes A/S Use of polypeptides having dnase activity
US20220162528A1 (en) * 2019-04-02 2022-05-26 Novozymes A/S Liquid Dishwashing Detergent Compositions
EP4032966A1 (en) 2021-01-22 2022-07-27 Novozymes A/S Liquid enzyme composition with sulfite scavenger
WO2022165107A1 (en) 2021-01-29 2022-08-04 Danisco Us Inc Compositions for cleaning and methods related thereto
WO2022171872A1 (en) 2021-02-12 2022-08-18 Novozymes A/S Stabilized biological detergents
WO2022171780A2 (en) 2021-02-12 2022-08-18 Novozymes A/S Alpha-amylase variants
WO2022189521A1 (en) 2021-03-12 2022-09-15 Novozymes A/S Polypeptide variants
EP4060036A1 (en) 2021-03-15 2022-09-21 Novozymes A/S Polypeptide variants
WO2022194673A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Dnase variants
WO2022268885A1 (en) 2021-06-23 2022-12-29 Novozymes A/S Alpha-amylase polypeptides
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
CN114921440B (en) * 2022-05-16 2023-05-05 北京昕大洋科技发展有限公司 Xylanase mutant and application thereof
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
EP4206309A1 (en) 2021-12-30 2023-07-05 Novozymes A/S Protein particles with improved whiteness
EP3660151B1 (en) 2018-11-29 2023-07-19 Henkel AG & Co. KGaA Variant proteases having improved performance and storage stability
WO2023165950A1 (en) 2022-03-04 2023-09-07 Novozymes A/S Dnase variants and compositions
WO2023165507A1 (en) 2022-03-02 2023-09-07 Novozymes A/S Use of xyloglucanase for improvement of sustainability of detergents
WO2023194204A1 (en) 2022-04-08 2023-10-12 Novozymes A/S Hexosaminidase variants and compositions
WO2023250301A1 (en) 2022-06-21 2023-12-28 Danisco Us Inc. Methods and compositions for cleaning comprising a polypeptide having thermolysin activity
WO2024131880A2 (en) 2022-12-23 2024-06-27 Novozymes A/S Detergent composition comprising catalase and amylase
WO2024156628A1 (en) 2023-01-23 2024-08-02 Novozymes A/S Cleaning compositions and uses thereof
WO2024194245A1 (en) 2023-03-21 2024-09-26 Novozymes A/S Detergent compositions based on biosurfactants
WO2024213513A1 (en) 2023-04-12 2024-10-17 Novozymes A/S Compositions comprising polypeptides having alkaline phosphatase activity
WO2024226828A2 (en) 2023-04-26 2024-10-31 Novozymes A/S Cleaning composition and cleaning method

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3327122B1 (en) 2014-07-04 2021-02-17 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2017089093A1 (en) * 2015-11-25 2017-06-01 Unilever N.V. A liquid detergent composition
CA3027745A1 (en) * 2016-06-17 2017-12-21 Danisco Us Inc. Protease variants and uses thereof
EP3656838B1 (en) * 2018-11-26 2021-05-12 Global Cosmed Group spolka akcyjna Liquid laundry detergent
CN113302296A (en) * 2019-01-28 2021-08-24 诺维信公司 Subtilase variants and compositions comprising the same
CN112501149B (en) 2020-12-21 2022-03-18 天津科技大学 Alkaline protease mutant and gene, engineering bacterium, preparation method and application thereof
US11464384B1 (en) 2022-03-31 2022-10-11 Techtronic Cordless Gp Water soluable package for a floor cleaner
EP4446411A1 (en) 2023-04-14 2024-10-16 Peaccel Variant subtilisin proteases
CN118415175B (en) * 2024-07-03 2024-09-06 云南省农业科学院药用植物研究所 Method for preventing and treating rhizome rot of paris polyphylla

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006279A1 (en) * 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
WO2010123754A1 (en) * 2009-04-24 2010-10-28 Danisco Us Inc. Proteases with modified pro regions
WO2013120948A1 (en) * 2012-02-17 2013-08-22 Novozymes A/S Subtilisin variants and polynucleotides encoding same
WO2014029820A1 (en) * 2012-08-22 2014-02-27 Novozymes A/S Detergent compositions comprising metalloproteases
WO2014124927A2 (en) * 2013-02-14 2014-08-21 Novozymes A/S Industrial and institutional laundering using multi-enzyme compositions

Family Cites Families (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1296839A (en) 1969-05-29 1972-11-22
GB1483591A (en) 1973-07-23 1977-08-24 Novo Industri As Process for coating water soluble or water dispersible particles by means of the fluid bed technique
GB1590432A (en) 1976-07-07 1981-06-03 Novo Industri As Process for the production of an enzyme granulate and the enzyme granuate thus produced
DK187280A (en) 1980-04-30 1981-10-31 Novo Industri As RUIT REDUCING AGENT FOR A COMPLETE LAUNDRY
US5185258A (en) 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
DK263584D0 (en) 1984-05-29 1984-05-29 Novo Industri As ENZYMOUS GRANULATES USED AS DETERGENT ADDITIVES
JPH0697997B2 (en) 1985-08-09 1994-12-07 ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ New enzymatic detergent additive
EG18543A (en) 1986-02-20 1993-07-30 Albright & Wilson Protected enzyme systems
EP0258068B1 (en) 1986-08-29 1994-08-31 Novo Nordisk A/S Enzymatic detergent additive
US5389536A (en) 1986-11-19 1995-02-14 Genencor, Inc. Lipase from Pseudomonas mendocina having cutinase activity
EP0305216B1 (en) 1987-08-28 1995-08-02 Novo Nordisk A/S Recombinant Humicola lipase and process for the production of recombinant humicola lipases
DE68924654T2 (en) 1988-01-07 1996-04-04 Novonordisk As Specific protease.
JP3079276B2 (en) 1988-02-28 2000-08-21 天野製薬株式会社 Recombinant DNA, Pseudomonas sp. Containing the same, and method for producing lipase using the same
DE68911131T2 (en) 1988-03-24 1994-03-31 Novonordisk As CELLULOSE PREPARATION.
US5776757A (en) 1988-03-24 1998-07-07 Novo Nordisk A/S Fungal cellulase composition containing alkaline CMC-endoglucanase and essentially no cellobiohydrolase and method of making thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DK316989D0 (en) 1989-06-26 1989-06-26 Novo Nordisk As ENZYMES
GB8915658D0 (en) 1989-07-07 1989-08-23 Unilever Plc Enzymes,their production and use
DK0493398T3 (en) 1989-08-25 2000-05-22 Henkel Research Corp Alkaline, proteolytic enzyme and process for its preparation
DK0531372T4 (en) 1990-05-09 2004-08-09 Novozymes As Cellulase preparation comprising an endoglucanase enzyme
DK115890D0 (en) 1990-05-09 1990-05-09 Novo Nordisk As ENZYME
DE69129988T2 (en) 1990-09-13 1999-03-18 Novo Nordisk A/S, Bagsvaerd LIPASE VARIANTS
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
ES2174820T3 (en) 1991-01-16 2002-11-16 Procter & Gamble COMPOSITIONS OF COMPACT DETERGENTS WITH HIGH ACTIVITY CELL.
ATE136055T1 (en) 1991-04-30 1996-04-15 Procter & Gamble LIQUID DETERGENTS CONTAINING BRACKETS WITH BORIC ACID-POLYOL COMPLEX FOR PTOTEOLYTIC ENZYMIN INHIBITION
EP0511456A1 (en) 1991-04-30 1992-11-04 The Procter & Gamble Company Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
KR100258460B1 (en) 1991-05-01 2000-06-01 한센 핀 베네드 Stabilized enzymes and detergent compositions
US5340735A (en) 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
BR9206918A (en) 1991-12-13 1995-11-21 Procter & Gamble Acylated citrate esters used as peracid precursors
DK28792D0 (en) 1992-03-04 1992-03-04 Novo Nordisk As NEW ENZYM
DK43192D0 (en) * 1992-03-31 1992-03-31 Novo Nordisk As detergent composition
DK72992D0 (en) 1992-06-01 1992-06-01 Novo Nordisk As ENZYME
DK88892D0 (en) 1992-07-06 1992-07-06 Novo Nordisk As CONNECTION
DE69334295D1 (en) 1992-07-23 2009-11-12 Novo Nordisk As MUTIER -g (a) -AMYLASE, DETERGENT AND DISHWASHER
KR100303619B1 (en) 1992-10-06 2001-11-22 피아 스타르 Cellulase Variants
ES2126743T5 (en) 1993-02-11 2010-02-05 Genencor International, Inc. OXIDATIVELY STABLE ALFA-AMYLASE.
WO1994025578A1 (en) 1993-04-27 1994-11-10 Gist-Brocades N.V. New lipase variants for use in detergent applications
DK52393D0 (en) 1993-05-05 1993-05-05 Novo Nordisk As
FR2704860B1 (en) 1993-05-05 1995-07-13 Pasteur Institut NUCLEOTIDE SEQUENCES OF THE LOCUS CRYIIIA FOR THE CONTROL OF THE EXPRESSION OF DNA SEQUENCES IN A CELL HOST.
JP2859520B2 (en) 1993-08-30 1999-02-17 ノボ ノルディスク アクティーゼルスカブ Lipase, microorganism producing the same, method for producing lipase, and detergent composition containing lipase
EP0722490B2 (en) 1993-10-08 2013-10-23 Novozymes A/S Amylase variants
EP0724631A1 (en) 1993-10-13 1996-08-07 Novo Nordisk A/S H 2?o 2?-stable peroxidase variants
AU8079794A (en) 1993-10-14 1995-05-04 Procter & Gamble Company, The Protease-containing cleaning compositions
JPH07143883A (en) 1993-11-24 1995-06-06 Showa Denko Kk Lipase gene and mutant lipase
DE4343591A1 (en) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Process for the evolutionary design and synthesis of functional polymers based on shape elements and shape codes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE69527835T2 (en) 1994-02-22 2003-04-10 Novozymes A/S, Bagsvaerd METHOD FOR PRODUCING A VARIANT OF A LIPOLYTIC ENZYME
DK1921148T3 (en) 1994-02-24 2011-09-26 Henkel Ag & Co Kgaa Enhanced enzymes and detergents containing these
AU1890095A (en) 1994-03-08 1995-09-25 Novo Nordisk A/S Novel alkaline cellulases
EP0755442B1 (en) 1994-05-04 2002-10-09 Genencor International, Inc. Lipases with improved surfactant resistance
BR9507817A (en) 1994-06-03 1997-09-16 Novo Nordisk Biotech Inc Construction of recombinant vector enzyme recombinant host cell laccase ascomycete or deuteromycete processes to obtain a laccase enzyme to improve the yield of recombinant enzyme to polymerize a lignin or lignosulfate substrate in solution to depolymerize the kraft paste to oxidize dyes or dye precursors to dye hair and to polymerize or oxidize a phenolic compound or aniline dye composition and container containing the same
AU2884595A (en) 1994-06-20 1996-01-15 Unilever Plc Modified pseudomonas lipases and their use
WO1996000292A1 (en) 1994-06-23 1996-01-04 Unilever N.V. Modified pseudomonas lipases and their use
US5919691A (en) 1994-10-06 1999-07-06 Novo Nordisk A/S Enzyme and enzyme preparation with endoglucanase activity
BE1008998A3 (en) 1994-10-14 1996-10-01 Solvay Lipase, microorganism producing the preparation process for the lipase and uses thereof.
US5827719A (en) 1994-10-26 1998-10-27 Novo Nordisk A/S Enzyme with lipolytic activity
AR000862A1 (en) 1995-02-03 1997-08-06 Novozymes As VARIANTS OF A MOTHER-AMYLASE, A METHOD TO PRODUCE THE SAME, A DNA STRUCTURE AND A VECTOR OF EXPRESSION, A CELL TRANSFORMED BY SUCH A DNA STRUCTURE AND VECTOR, A DETERGENT ADDITIVE, DETERGENT COMPOSITION, A COMPOSITION FOR AND A COMPOSITION FOR THE ELIMINATION OF
JPH08228778A (en) 1995-02-27 1996-09-10 Showa Denko Kk New lipase gene and production of lipase using the same
NZ303162A (en) 1995-03-17 2000-01-28 Novo Nordisk As Enzyme preparations comprising an enzyme exhibiting endoglucanase activity appropriate for laundry compositions for textiles
AU5644896A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Protease variants and compositions
AU6414196A (en) 1995-07-14 1997-02-18 Novo Nordisk A/S A modified enzyme with lipolytic activity
AU6513096A (en) 1995-07-19 1997-02-18 Novo Nordisk A/S Treatment of fabrics
DE19528059A1 (en) 1995-07-31 1997-02-06 Bayer Ag Detergent and cleaning agent with imino disuccinates
ES2221934T3 (en) 1995-08-11 2005-01-16 Novozymes A/S NEW LIPOLITIC ENZYMES.
US5763385A (en) 1996-05-14 1998-06-09 Genencor International, Inc. Modified α-amylases having altered calcium binding properties
WO1998008940A1 (en) 1996-08-26 1998-03-05 Novo Nordisk A/S A novel endoglucanase
JP3532576B2 (en) 1996-09-17 2004-05-31 ノボザイムス アクティーゼルスカブ Cellulase mutant
CA2266527A1 (en) 1996-09-24 1998-04-02 John Mcmillan Mciver Liquid detergents containing proteolytic enzyme, peptide aldehyde and calcium ions
CA2265734A1 (en) 1996-10-08 1998-04-16 Novo Nordisk A/S Diaminobenzoic acid derivatives as dye precursors
BR9712360A (en) 1996-10-18 2001-06-19 Procter & Gamble Detergent compositions
ATE510910T1 (en) 1996-11-04 2011-06-15 Novozymes As SUBTILASE VARIANTS AND COMPOUNDS
CN1530443A (en) 1996-11-04 2004-09-22 ŵ����÷�����޹�˾ subtilase variants and compositions
ATE385254T1 (en) 1997-08-29 2008-02-15 Novozymes As PROTEASE VARIANTS AND COMPOSITIONS
DK2302027T3 (en) 1997-10-13 2013-12-02 Novozymes As The alpha-amylase mutants
AR016969A1 (en) 1997-10-23 2001-08-01 Procter & Gamble PROTEASE VARIANTE, ADN, EXPRESSION VECTOR, GUEST MICROORGANISM, CLEANING COMPOSITION, ANIMAL FOOD AND COMPOSITION TO TREAT A TEXTILE
US5955310A (en) 1998-02-26 1999-09-21 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide in a bacillus cell
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
JP2003530440A (en) 1998-10-13 2003-10-14 ザ、プロクター、エンド、ギャンブル、カンパニー Detergent composition or ingredient
US6831053B1 (en) 1998-10-23 2004-12-14 The Procter & Gamble Company Bleaching compositions comprising multiply-substituted protease variants
AU1503800A (en) 1998-12-04 2000-06-26 Novozymes A/S Cutinase variants
WO2000060063A1 (en) 1999-03-31 2000-10-12 Novozymes A/S Lipase variant
NZ531394A (en) 1999-08-31 2005-10-28 Novozymes As Residual protease II (RPII) and variants thereof useful in detergent compositions
WO2001044452A1 (en) 1999-12-15 2001-06-21 Novozymes A/S Subtilase variants having an improved wash performance on egg stains
CN100482790C (en) 2000-03-08 2009-04-29 诺维信公司 Variants with altered properties
CA2408406C (en) 2000-06-02 2014-07-29 Novozymes A/S Cutinase variants
EP1370648A2 (en) 2000-08-01 2003-12-17 Novozymes A/S Alpha-amylase mutants with altered properties
CN1337553A (en) 2000-08-05 2002-02-27 李海泉 Underground sightseeing amusement park
AR030462A1 (en) 2000-08-21 2003-08-20 Novozymes As NOVEDOS SUBTILASAS ENZYMES THAT HAVE A REDUCED TREND TOWARDS THEIR INHIBITION FOR SUBSTANCES PRESENT IN EGGS
AU2302002A (en) 2000-11-27 2002-06-03 Novozymes As Automated mechanical stress assay for screening cleaning ingredients
CN101864406B (en) 2001-06-06 2016-03-30 诺维信公司 Endo-beta-1,4-glucanase
DK200101090A (en) 2001-07-12 2001-08-16 Novozymes As Subtilase variants
CA2455013A1 (en) 2001-07-27 2003-02-13 Francesca Storici Systems for in vivo site-directed mutagenesis using oligonucleotides
GB0127036D0 (en) 2001-11-09 2002-01-02 Unilever Plc Polymers for laundry applications
EP1382668B1 (en) 2002-06-11 2009-08-12 Unilever N.V. Detergent tablets
US20060228791A1 (en) 2002-06-26 2006-10-12 Novozymes A/S Subtilases and subtilase variants having altered immunogenicity
TWI319007B (en) 2002-11-06 2010-01-01 Novozymes As Subtilase variants
EP1597344A2 (en) 2003-02-18 2005-11-23 Novozymes A/S Detergent compositions
GB0314210D0 (en) 2003-06-18 2003-07-23 Unilever Plc Laundry treatment compositions
WO2005003275A1 (en) 2003-06-18 2005-01-13 Unilever Plc Laundry treatment compositions
GB0314211D0 (en) 2003-06-18 2003-07-23 Unilever Plc Laundry treatment compositions
CN1871344A (en) 2003-10-23 2006-11-29 诺和酶股份有限公司 Protease with improved stability in detergents
EP1694847B1 (en) 2003-11-19 2012-06-13 Danisco US Inc. Serine proteases, nucleic acids encoding serine enzymes and vectors and host cells incorporating same
PL1689859T3 (en) 2003-12-03 2011-10-31 Procter & Gamble Perhydrolase
WO2005105826A1 (en) 2004-04-28 2005-11-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Tyropeptin a analogue
CA2593920A1 (en) 2004-12-23 2006-06-29 Novozymes A/S Alpha-amylase variants
ATE404660T1 (en) 2005-03-23 2008-08-15 Unilever Nv BODY-SHAPED DETERGENT OR CLEANING COMPOSITIONS
CA2601272C (en) 2005-04-15 2011-11-08 The Procter & Gamble Company Liquid laundry detergent compositions with modified polyethyleneimine polymers and lipase enzyme
EP1869154B1 (en) 2005-04-15 2010-11-03 The Procter & Gamble Company Cleaning compositions with alkoxylated polyalkylenimines
EP1888734A2 (en) 2005-05-31 2008-02-20 The Procter and Gamble Company Polymer-containing detergent compositions and their use
JP4837733B2 (en) 2005-06-17 2011-12-14 ザ プロクター アンド ギャンブル カンパニー Organocatalysts with enhanced enzyme compatibility
ATE529505T1 (en) 2005-07-08 2011-11-15 Novozymes As SUBTLE VARIANTS
AR055444A1 (en) 2005-10-12 2007-08-22 Procter & Gamble USE AND PRODUCTION OF NEUTRAL METALOPRETASE STABLE TO STORAGE
US8518675B2 (en) 2005-12-13 2013-08-27 E. I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
DK2371948T5 (en) 2006-01-23 2017-07-24 Novozymes As lipase variants
CA2635927A1 (en) 2006-01-23 2007-08-02 The Procter And Gamble Company A composition comprising a lipase and a bleach catalyst
BRPI0707215A2 (en) 2006-01-23 2011-04-26 Procter & Gamble detergent compositions
WO2007087258A2 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company A composition comprising a lipase and a bleach catalyst
BRPI0707209A2 (en) 2006-01-23 2011-04-26 Procter & Gamble detergent compositions
EP1976965A2 (en) 2006-01-23 2008-10-08 The Procter and Gamble Company Enzyme and fabric hueing agent containing compositions
CA2635947A1 (en) 2006-01-23 2007-08-02 The Procter & Gamble Company Enzyme and photobleach containing compositions
ATE474906T1 (en) 2006-05-31 2010-08-15 Procter & Gamble CLEANING AGENT WITH AMPHIPHIL GRAFTING POLYMERS BASED ON POLYALKYLENE OXIDES AND VINYL ESTERS
DE202006009003U1 (en) 2006-06-06 2007-10-25 BROSE SCHLIEßSYSTEME GMBH & CO. KG Motor vehicle lock
ATE503011T1 (en) 2006-07-07 2011-04-15 Procter & Gamble DETERGENT COMPOSITIONS
KR20100029081A (en) 2007-05-30 2010-03-15 다니스코 유에스 인크. Variants of an alpha-amylase with improved production levels in fermentation processes
BRPI0813386A2 (en) 2007-06-22 2014-12-30 Unilever Nv GRANULAR ENZYMATIC DETERGENT COMPOSITION, DETERGENT TABLET, TISSUE WASHING PROCESS, AND MANUFACTURING PROCESS.
ES2364193T3 (en) 2007-07-02 2011-08-26 THE PROCTER &amp; GAMBLE COMPANY COMPOSITION FOR MULTIPLE COMPARTMENT BAG FOR CLOTHING WASHING.
GB0712988D0 (en) 2007-07-05 2007-08-15 Reckitt Benckiser Nv Improvements in or relating to compositions
GB0712991D0 (en) 2007-07-05 2007-08-15 Reckitt Benckiser Nv Improvement in or relating to compositions
CN101743299B (en) 2007-07-16 2012-03-28 荷兰联合利华有限公司 A solid detergent composition
DE102007036392A1 (en) 2007-07-31 2009-02-05 Henkel Ag & Co. Kgaa Compositions containing perhydrolases and alkylene glycol diacetates
DE102007038029A1 (en) 2007-08-10 2009-02-12 Henkel Ag & Co. Kgaa Detergents or cleaners with polyester-based soil release polymer
WO2009021784A1 (en) 2007-08-14 2009-02-19 Unilever N.V. Detergent tablet
GB0716228D0 (en) 2007-08-20 2007-09-26 Reckitt Benckiser Nv Detergent composition
DE102007041754A1 (en) 2007-09-04 2009-03-05 Henkel Ag & Co. Kgaa Polycyclic compounds as enzyme stabilizers
GB0718777D0 (en) 2007-09-26 2007-11-07 Reckitt Benckiser Nv Composition
GB0718944D0 (en) 2007-09-28 2007-11-07 Reckitt Benckiser Nv Detergent composition
WO2009047127A1 (en) 2007-10-12 2009-04-16 Unilever Plc Granular detergent compositions with contrasting lamellar visual cues
EP2201093B1 (en) 2007-10-12 2011-11-02 Unilever PLC Laundry detergent with pretreatment additive and its use
MX2010003985A (en) 2007-10-12 2010-04-27 Unilever Nv Improved visual cues for perfumed laundry detergents.
BRPI0818084A2 (en) 2007-10-12 2017-07-04 Unilever Nv granular detergent composition comprising a plurality of film particles
WO2009050026A2 (en) 2007-10-17 2009-04-23 Unilever Nv Laundry compositions
CA2704791A1 (en) 2007-11-05 2009-05-14 Danisco Us Inc. Variants of bacillus sp. ts-23 alpha-amylase with altered properties
EP2214911A1 (en) 2007-11-13 2010-08-11 The Procter & Gamble Company Process for creating a unit dose product with a printed water soluble material
DE102007056166A1 (en) 2007-11-21 2009-05-28 Henkel Ag & Co. Kgaa Granules of a sensitive detergent or cleaning agent ingredient
DE102007057583A1 (en) 2007-11-28 2009-06-04 Henkel Ag & Co. Kgaa Detergents with stabilized enzymes
ATE550420T1 (en) 2007-12-05 2012-04-15 Procter & Gamble PACKAGING WITH A CLEANING AGENT
DE102007059677A1 (en) 2007-12-10 2009-06-25 Henkel Ag & Co. Kgaa cleaning supplies
DE102007059970A1 (en) 2007-12-11 2009-09-10 Henkel Ag & Co. Kgaa cleaning supplies
ES2568768T3 (en) 2008-01-04 2016-05-04 The Procter & Gamble Company A laundry detergent composition comprising glycosyl hydrolase
WO2009087033A1 (en) 2008-01-10 2009-07-16 Unilever Plc Granules
BRPI0906743A2 (en) 2008-01-24 2015-07-07 Unilever Nv Detergent composition, dishwashing method and composition use
WO2009095645A1 (en) 2008-01-28 2009-08-06 Reckitt Benckiser N.V. Composition
US20090209447A1 (en) 2008-02-15 2009-08-20 Michelle Meek Cleaning compositions
AR070490A1 (en) 2008-02-29 2010-04-07 Novozymes As THERMOMYCES LANUGINOSUS POLYPEPTIDES WITH LIPASE ACTIVITY AND POLYUCLEOTIDES CODING THEM
WO2009112296A1 (en) 2008-03-14 2009-09-17 Unilever Plc Laundry treatment compositions
ES2390112T3 (en) 2008-03-14 2012-11-06 Unilever N.V. Washing treatment composition comprising polymeric lubricants
EP2103676A1 (en) 2008-03-18 2009-09-23 The Procter and Gamble Company A laundry detergent composition comprising the magnesium salt of ethylene diamine-n'n' -disuccinic acid
EP2103678A1 (en) 2008-03-18 2009-09-23 The Procter and Gamble Company Detergent composition comprising a co-polyester of dicarboxylic acids and diols
DE102008014759A1 (en) 2008-03-18 2009-09-24 Henkel Ag & Co. Kgaa Use of imidazolium salts in detergents and cleaners
DE102008014760A1 (en) 2008-03-18 2009-09-24 Henkel Ag & Co. Kgaa Imidazolium salts as enzyme stabilizers
EP2103675A1 (en) 2008-03-18 2009-09-23 The Procter and Gamble Company Detergent composition comprising cellulosic polymer
PL2271660T3 (en) 2008-03-26 2020-11-02 Novozymes A/S Stabilized liquid enzyme compositions
GB0805908D0 (en) 2008-04-01 2008-05-07 Reckitt Benckiser Inc Laundry treatment compositions
PT3061744T (en) 2008-04-01 2018-06-19 Unilever Nv Preparation of free flowing granules of methylglycine diacetic acid
EP2107105B1 (en) 2008-04-02 2013-08-07 The Procter and Gamble Company Detergent composition comprising reactive dye
EP2107106A1 (en) 2008-04-02 2009-10-07 The Procter and Gamble Company A kit of parts comprising a solid laundry detergent composition and a dosing device
ES2647500T3 (en) 2008-04-02 2017-12-21 The Procter & Gamble Company Detergent composition comprising non-ionic detersive surfactant and reagent dye
DE102008017103A1 (en) 2008-04-02 2009-10-08 Henkel Ag & Co. Kgaa Detergents and cleaning agents containing proteases from Xanthomonas
US20090253602A1 (en) 2008-04-04 2009-10-08 Conopco, Inc. D/B/A Unilever Novel personal wash bar
EP2268784B2 (en) 2008-05-02 2015-10-28 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Reduced spotting granules
PL2291505T3 (en) 2008-07-03 2013-05-31 Henkel Ag & Co Kgaa Solid fabric care composition with a polysaccharide
BRPI0914211A2 (en) 2008-07-09 2015-11-03 Unilever Nv alginate granule production process, alginate granule obtained, use of alginate and detergent composition for washing fabrics
ES2400781T3 (en) 2008-07-11 2013-04-12 Unilever N.V. Copolymers and detergent compositions
EP2154235A1 (en) 2008-07-28 2010-02-17 The Procter and Gamble Company Process for preparing a detergent composition
ATE482264T1 (en) 2008-08-14 2010-10-15 Unilever Nv BUILDING COMPOSITION
EP2163605A1 (en) 2008-08-27 2010-03-17 The Procter and Gamble Company A detergent composition comprising cello-oligosaccharide oxidase
CN102197125B (en) 2008-09-01 2014-08-27 宝洁公司 Composition comprising polyoxyalkylene-based polymer composition
US8450262B2 (en) 2008-09-01 2013-05-28 The Procter & Gamble Company Hydrophobic group-containing copolymer and process for the production thereof
JP5606026B2 (en) 2008-09-01 2014-10-15 株式会社日本触媒 Polymer composition and production method thereof
EP2163608A1 (en) 2008-09-12 2010-03-17 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye and fatty acid soap
EP2166077A1 (en) 2008-09-12 2010-03-24 The Procter and Gamble Company Particles comprising a hueing dye
EP2166078B1 (en) 2008-09-12 2018-11-21 The Procter & Gamble Company Laundry particle made by extrusion comprising a hueing dye
DE102008047941A1 (en) 2008-09-18 2010-03-25 Henkel Ag & Co. Kgaa Bleach-containing cleaning agent
BRPI0920516A2 (en) 2008-09-19 2019-09-24 Procter & Gamble dual character biopolymer useful in cleaning products
BRPI0918871A2 (en) 2008-09-19 2019-09-24 Procter & Gamble modified biopolymer-containing detergent composition for foam reinforcement and stabilization.
JP2012503023A (en) 2008-09-22 2012-02-02 ザ プロクター アンド ギャンブル カンパニー Certain polybranched polyaldehydes, polyalcohols, and surfactants, and consumer products based thereon
EP2350249B1 (en) 2008-10-31 2014-04-16 Henkel AG & Co. KGaA Dishwasher detergent
WO2010056671A1 (en) 2008-11-11 2010-05-20 Danisco Us Inc. Compositions and methods comprising a subtilisin variant
EP2647692A3 (en) 2008-11-11 2014-01-22 The Procter and Gamble Company Compositions and methods comprising serine protease variants
WO2010054986A1 (en) 2008-11-12 2010-05-20 Unilever Plc Fabric whiteness measurement system
WO2010057784A1 (en) 2008-11-20 2010-05-27 Unilever Plc Fabric whiteness measurement system
DE102008059447A1 (en) 2008-11-27 2010-06-02 Henkel Ag & Co. Kgaa Detergents and cleaning agents containing proteases from Bacillus pumilus
EP2367923A2 (en) 2008-12-01 2011-09-28 Danisco US Inc. Enzymes with lipase activity
DE102008060469A1 (en) 2008-12-05 2010-06-10 Henkel Ag & Co. Kgaa Automatic dishwashing tablet
DE102008060886A1 (en) 2008-12-09 2010-06-10 Henkel Ag & Co. Kgaa Photolabile fragrance storage materials
WO2010066631A1 (en) 2008-12-12 2010-06-17 Henkel Ag & Co. Kgaa Laundry article having cleaning and conditioning properties
WO2010066632A1 (en) 2008-12-12 2010-06-17 Henkel Ag & Co. Kgaa Laundry article having cleaning and conditioning properties
DE102008061858A1 (en) 2008-12-15 2010-06-17 Henkel Ag & Co. Kgaa Machine dishwashing detergent
DE102008061859A1 (en) 2008-12-15 2010-06-17 Henkel Ag & Co. Kgaa Machine dishwashing detergent
WO2010069718A1 (en) 2008-12-16 2010-06-24 Unilever Nv Solid builder composition
TR201906017T4 (en) 2008-12-17 2019-05-21 Unilever Nv Laundry detergent composition.
EP2367922A1 (en) 2008-12-18 2011-09-28 Unilever NV Laundry detergent composition
DE102008063801A1 (en) 2008-12-19 2010-06-24 Henkel Ag & Co. Kgaa Machine dishwashing detergent
DE102008063070A1 (en) 2008-12-23 2010-07-01 Henkel Ag & Co. Kgaa Use of star-shaped polymers having peripheral negatively charged groups and / or peripheral silyl groups to finish surfaces
CN102333517B (en) 2008-12-29 2014-12-03 荷兰联合利华有限公司 Structured aqueous detergent compositions
DE102009004524A1 (en) 2009-01-09 2010-07-15 Henkel Ag & Co. Kgaa Color protective machine dishwashing detergent
BRPI1006985B1 (en) 2009-01-26 2019-04-30 Unilever N.V. DETERGENT GRANULAR TISSUE WASH COMPOSITION
DE102009000409A1 (en) 2009-01-26 2010-07-29 Henkel Ag & Co. Kgaa Washing Amendment
EP2216393B1 (en) 2009-02-09 2024-04-24 The Procter & Gamble Company Detergent composition
WO2010094356A1 (en) 2009-02-18 2010-08-26 Henkel Ag & Co. Kgaa Pro-fragrance copolymeric compounds
EP2403931B1 (en) 2009-03-05 2014-03-19 Unilever PLC Dye radical initiators
US20110302724A1 (en) 2009-03-06 2011-12-15 Huntsman International Llc Enzymatic textile bleach-whitening methods
WO2010104675A1 (en) 2009-03-10 2010-09-16 Danisco Us Inc. Bacillus megaterium strain dsm90-related alpha-amylases, and methods of use, thereof
WO2010102861A1 (en) 2009-03-12 2010-09-16 Unilever Plc Dye-polymers formulations
US20100229312A1 (en) 2009-03-16 2010-09-16 De Buzzaccarini Francesco Cleaning method
US8153574B2 (en) 2009-03-18 2012-04-10 The Procter & Gamble Company Structured fluid detergent compositions comprising dibenzylidene polyol acetal derivatives and detersive enzymes
US20120028318A1 (en) 2009-03-18 2012-02-02 Danisco Us Inc. Fungal cutinase from magnaporthe grisea
US8293697B2 (en) 2009-03-18 2012-10-23 The Procter & Gamble Company Structured fluid detergent compositions comprising dibenzylidene sorbitol acetal derivatives
DE102009001693A1 (en) 2009-03-20 2010-09-23 Henkel Ag & Co. Kgaa 4-aminopyridine derivatives as catalysts for the cleavage of organic esters
DE102009001691A1 (en) 2009-03-20 2010-09-23 Henkel Ag & Co. Kgaa Washing or cleaning agent with optionally in situ produced bleach-enhancing transition metal complex
DE102009001692A1 (en) 2009-03-20 2010-09-23 Henkel Ag & Co. Kgaa Washing or cleaning agent with optionally in situ produced bleach-enhancing transition metal complex
WO2010111143A2 (en) 2009-03-23 2010-09-30 Danisco Us Inc. Cal a-related acyltransferases and methods of use, thereof
EP2233557A1 (en) 2009-03-26 2010-09-29 The Procter & Gamble Company A perfume encapsulate, a laundry detergent composition comprising a perfume encapsulate, and a process for preparing a perfume encapsulate
DE102009002262A1 (en) 2009-04-07 2010-10-14 Henkel Ag & Co. Kgaa Prebiotic hand dishwashing detergents
DE102009002384A1 (en) 2009-04-15 2010-10-21 Henkel Ag & Co. Kgaa Granular detergent, cleaning or treatment agent additive
US8263543B2 (en) 2009-04-17 2012-09-11 The Procter & Gamble Company Fabric care compositions comprising organosiloxane polymers
WO2010122051A1 (en) 2009-04-24 2010-10-28 Unilever Plc High active detergent particles
JP6000848B2 (en) 2009-05-19 2016-10-05 ザ プロクター アンド ギャンブル カンパニー Method for printing water-soluble film
DE102009026810A1 (en) 2009-06-08 2010-12-09 Henkel Ag & Co. Kgaa Nanoparticulate manganese dioxide
WO2010142503A1 (en) 2009-06-12 2010-12-16 Unilever Plc Cationic dye polymers
MX2011013762A (en) 2009-06-15 2012-02-22 Unilever Nv Anionic dye polymers.
CA2767110A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company Continuous process for making a laundry detergent composition
WO2011005844A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company Method of laundering fabric using a compacted laundry detergent composition
EP2451921B1 (en) 2009-07-09 2016-08-17 The Procter and Gamble Company A mildly alkaline, low-built, solid fabric treatment detergent composition comprising phthalimido peroxy caproic acid
US20110005001A1 (en) 2009-07-09 2011-01-13 Eric San Jose Robles Detergent Composition
EP2451925A1 (en) 2009-07-09 2012-05-16 The Procter & Gamble Company Method of laundering fabric using a compacted laundry detergent composition
US20110005002A1 (en) 2009-07-09 2011-01-13 Hiroshi Oh Method of Laundering Fabric
EP2451915A1 (en) 2009-07-09 2012-05-16 The Procter & Gamble Company A catalytic laundry detergent composition comprising relatively low levels of water-soluble electrolyte
EP2451918A1 (en) 2009-07-09 2012-05-16 The Procter & Gamble Company Method of laundering fabric using a compacted laundry detergent composition
WO2011005623A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company Laundry detergent composition comprising low level of bleach
WO2011005813A1 (en) 2009-07-09 2011-01-13 The Procter & Gamble Company Method of laundering fabric using a compacted laundry detergent composition
US20110009307A1 (en) 2009-07-09 2011-01-13 Alan Thomas Brooker Laundry Detergent Composition Comprising Low Level of Sulphate
WO2011016958A2 (en) 2009-07-27 2011-02-10 The Procter & Gamble Company Detergent composition
HUE029942T2 (en) 2009-08-13 2017-04-28 Procter & Gamble Method of laundering fabrics at low temperature
DE102009028891A1 (en) 2009-08-26 2011-03-03 Henkel Ag & Co. Kgaa Improved washing performance by free radical scavengers
JP5947213B2 (en) 2009-09-25 2016-07-06 ノボザイムス アクティーゼルスカブ Use of protease variants
AU2010299800B2 (en) 2009-09-25 2014-08-07 Novozymes A/S Use of protease variants
US8741609B2 (en) 2009-12-21 2014-06-03 Danisco Us Inc. Detergent compositions containing Geobacillus stearothermophilus lipase and methods of use thereof
US20120258900A1 (en) 2009-12-21 2012-10-11 Danisco Us Inc. Detergent compositions containing bacillus subtilis lipase and methods of use thereof
CA2783972A1 (en) 2009-12-21 2011-07-14 Christian Adams Detergent compositions containing thermobifida fusca lipase and methods of use thereof
CN113186178A (en) 2010-02-10 2021-07-30 诺维信公司 Variants and compositions comprising variants with high stability in the presence of chelating agents
CN102858970B (en) * 2010-04-15 2017-07-21 丹尼斯科美国公司 Composition and method comprising misfolded proteins enzyme
ES2625751T3 (en) * 2010-05-06 2017-07-20 The Procter & Gamble Company Consumer products with protease variants
WO2011150157A2 (en) 2010-05-28 2011-12-01 Danisco Us Inc. Detergent compositions containing streptomyces griseus lipase and methods of use thereof
EP2694537A1 (en) 2011-04-08 2014-02-12 Danisco US Inc. Compositions
MX338925B (en) 2011-05-05 2016-05-06 Procter & Gamble Compositions and methods comprising serine protease variants.
EP3543333B1 (en) 2011-06-30 2022-01-05 Novozymes A/S Method for screening alpha-amylases
US9434932B2 (en) 2011-06-30 2016-09-06 Novozymes A/S Alpha-amylase variants
EP4026902A1 (en) 2012-06-08 2022-07-13 Danisco US Inc. Variant alpha amylases with enhanced activity on starch polymers
EP3739029A1 (en) * 2014-07-04 2020-11-18 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3327122B1 (en) 2014-07-04 2021-02-17 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016087617A1 (en) 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3814489A1 (en) * 2018-06-29 2021-05-05 Novozymes A/S Subtilase variants and compositions comprising same
US20230212548A1 (en) * 2020-05-26 2023-07-06 Novozymes A/S Subtilase variants and compositions comprising same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006279A1 (en) * 1988-01-07 1989-07-13 Novo-Nordisk A/S Mutated subtilisin genes
WO2010123754A1 (en) * 2009-04-24 2010-10-28 Danisco Us Inc. Proteases with modified pro regions
WO2013120948A1 (en) * 2012-02-17 2013-08-22 Novozymes A/S Subtilisin variants and polynucleotides encoding same
WO2014029820A1 (en) * 2012-08-22 2014-02-27 Novozymes A/S Detergent compositions comprising metalloproteases
WO2014124927A2 (en) * 2013-02-14 2014-08-21 Novozymes A/S Industrial and institutional laundering using multi-enzyme compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NIEHAUS F ET AL: "Enzymes for the laundry industries: tapping the vast metagenomic pool of alkaline proteases", MICROBIAL BIOTECHNOLOGY, vol. 4, no. 6, November 2011 (2011-11-01), pages 767 - 776, XP002743787 *

Cited By (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075493B (en) * 2014-12-04 2020-09-01 诺维信公司 Subtilase variants and polynucleotides encoding same
US11851639B2 (en) 2014-12-04 2023-12-26 Novozymes A/S Liquid cleaning compositions comprising protease variants
US10683491B2 (en) 2014-12-04 2020-06-16 Novozymes A/S Subtilase variants and polynucleotides encoding same
CN107075493A (en) * 2014-12-04 2017-08-18 诺维信公司 Subtilase variants and the polynucleotides for encoding them
EP3227425A1 (en) * 2014-12-04 2017-10-11 Novozymes A/S Liquid cleaning compositions comprising protease variants
EP3690037A1 (en) * 2014-12-04 2020-08-05 Novozymes A/S Subtilase variants and polynucleotides encoding same
US11591585B2 (en) 2014-12-04 2023-02-28 Novozymes A/S Subtilase variants and polynucleotides encoding same
WO2016087617A1 (en) * 2014-12-04 2016-06-09 Novozymes A/S Subtilase variants and polynucleotides encoding same
US11174452B2 (en) 2014-12-04 2021-11-16 Novozymes A/S Liquid cleaning compositions comprising protease variants
WO2016162556A1 (en) 2015-04-10 2016-10-13 Novozymes A/S Laundry method, use of dnase and detergent composition
WO2016162558A1 (en) 2015-04-10 2016-10-13 Novozymes A/S Detergent composition
WO2017064253A1 (en) 2015-10-14 2017-04-20 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
WO2017089366A1 (en) 2015-11-24 2017-06-01 Novozymes A/S Polypeptides having protease activity and polynucleotides encoding same
EP3715442A1 (en) 2016-03-23 2020-09-30 Novozymes A/S Use of polypeptide having dnase activity for treating fabrics
WO2017177153A1 (en) 2016-04-07 2017-10-12 Novozymes A/S Methods for selecting enzymes having protease activity
EP3693449A1 (en) 2016-04-29 2020-08-12 Novozymes A/S Detergent compositions and uses thereof
WO2017186943A1 (en) 2016-04-29 2017-11-02 Novozymes A/S Detergent compositions and uses thereof
CN109715791A (en) * 2016-05-03 2019-05-03 丹尼斯科美国公司 protease variants and uses thereof
US12104187B2 (en) 2016-05-03 2024-10-01 Dansico Us Inc. Protease variants and uses thereof
WO2017192692A1 (en) 2016-05-03 2017-11-09 Danisco Us Inc Protease variants and uses thereof
EP3845642A1 (en) 2016-05-05 2021-07-07 Danisco US Inc. Protease variants and uses thereof
WO2017192300A1 (en) 2016-05-05 2017-11-09 Danisco Us Inc Protease variants and uses thereof
WO2017210295A1 (en) 2016-05-31 2017-12-07 Danisco Us Inc. Protease variants and uses thereof
CN109715792A (en) * 2016-06-03 2019-05-03 诺维信公司 Subtilase variants and the polynucleotides that it is encoded
WO2017207762A1 (en) * 2016-06-03 2017-12-07 Novozymes A/S Subtilase variants and polynucleotides encoding same
EP3475404A1 (en) * 2016-06-23 2019-05-01 Novozymes A/S Use of enzymes, composition and method for removing soil
CN109563449A (en) * 2016-06-23 2019-04-02 诺维信公司 Purposes, composition and the method for removing dirt of enzyme
WO2017220422A1 (en) 2016-06-23 2017-12-28 Novozymes A/S Use of enzymes, composition and method for removing soil
US11001787B2 (en) * 2016-06-23 2021-05-11 Novozymes A/S Use of enzymes, composition and method for removing soil
CN109563449B (en) * 2016-06-23 2022-01-25 诺维信公司 Use of enzymes, compositions and methods for removing soils
US20190233766A1 (en) * 2016-06-23 2019-08-01 Novozymes A/S Use of enzymes, composition and method for removing soil
WO2018002261A1 (en) 2016-07-01 2018-01-04 Novozymes A/S Detergent compositions
WO2018007573A1 (en) 2016-07-08 2018-01-11 Novozymes A/S Detergent compositions with galactanase
WO2018011276A1 (en) 2016-07-13 2018-01-18 The Procter & Gamble Company Bacillus cibi dnase variants and uses thereof
EP3950941A2 (en) 2016-07-13 2022-02-09 Novozymes A/S Dnase polypeptide variants
WO2018011277A1 (en) 2016-07-13 2018-01-18 Novozymes A/S Bacillus cibi dnase variants
EP3275985A1 (en) * 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
EP3275989A1 (en) * 2016-07-26 2018-01-31 The Procter and Gamble Company Automatic dishwashing detergent composition
WO2018060216A1 (en) 2016-09-29 2018-04-05 Novozymes A/S Use of enzyme for washing, method for washing and warewashing composition
WO2018077938A1 (en) 2016-10-25 2018-05-03 Novozymes A/S Detergent compositions
WO2018108865A1 (en) 2016-12-12 2018-06-21 Novozymes A/S Use of polypeptides
WO2018118917A1 (en) * 2016-12-21 2018-06-28 Danisco Us Inc. Protease variants and uses thereof
CN110312795A (en) * 2016-12-21 2019-10-08 丹尼斯科美国公司 Ease variants and application thereof
WO2018177938A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having dnase activity
WO2018177936A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having dnase activity
WO2018178061A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having rnase activity
WO2018184004A1 (en) 2017-03-31 2018-10-04 Danisco Us Inc Alpha-amylase combinatorial variants
WO2018185150A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptides
WO2018185152A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Polypeptide compositions and uses thereof
WO2018185181A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Glycosyl hydrolases
EP3967756A1 (en) 2017-04-06 2022-03-16 Novozymes A/S Detergent compositions and uses thereof
EP3626809A1 (en) 2017-04-06 2020-03-25 Novozymes A/S Cleaning compositions and uses thereof
WO2018184873A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Detergent compositions and uses thereof
WO2018185267A1 (en) 2017-04-06 2018-10-11 Novozymes A/S Cleaning compositions and uses thereof
WO2019036721A2 (en) 2017-08-18 2019-02-21 Danisco Us Inc Alpha-amylase variants
WO2019057758A1 (en) 2017-09-20 2019-03-28 Novozymes A/S Use of enzymes for improving water absorption and/or whiteness
WO2019057902A1 (en) 2017-09-22 2019-03-28 Novozymes A/S Novel polypeptides
WO2019084350A1 (en) 2017-10-27 2019-05-02 The Procter & Gamble Company Detergent compositions comprising polypeptide variants
WO2019084349A1 (en) 2017-10-27 2019-05-02 The Procter & Gamble Company Detergent compositions comprising polypeptide variants
WO2019081721A1 (en) 2017-10-27 2019-05-02 Novozymes A/S Dnase variants
WO2019081724A1 (en) 2017-10-27 2019-05-02 Novozymes A/S Dnase variants
DE102017125559A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANSING COMPOSITIONS CONTAINING DISPERSINE II
WO2019086526A1 (en) 2017-11-01 2019-05-09 Henkel Ag & Co. Kgaa Cleaning compositions containing dispersins iii
WO2019086520A1 (en) 2017-11-01 2019-05-09 Henkel Ag & Co. Kgaa Cleaning compositions containing dispersins i
WO2019086521A1 (en) 2017-11-01 2019-05-09 Henkel Ag & Co. Kgaa Cleaning compositions containing dispersins ii
WO2019086532A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Methods for cleaning medical devices
DE102017125558A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANING COMPOSITIONS CONTAINING DISPERSINE I
WO2019086528A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Polypeptides and compositions comprising such polypeptides
EP4379029A1 (en) 2017-11-01 2024-06-05 Novozymes A/S Polypeptides and compositions comprising such polypeptides
WO2019086530A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Polypeptides and compositions comprising such polypeptides
DE102017125560A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANSING COMPOSITIONS CONTAINING DISPERSINE III
WO2019108599A1 (en) 2017-11-29 2019-06-06 Danisco Us Inc Subtilisin variants having improved stability
WO2019201793A1 (en) 2018-04-17 2019-10-24 Novozymes A/S Polypeptides comprising carbohydrate binding activity in detergent compositions and their use in reducing wrinkles in textile or fabric.
WO2020002604A1 (en) 2018-06-28 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
WO2020002608A1 (en) 2018-06-29 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
WO2020002255A1 (en) * 2018-06-29 2020-01-02 Novozymes A/S Subtilase variants and compositions comprising same
US12012573B2 (en) 2018-07-02 2024-06-18 Novozymes A/S Cleaning compositions and uses thereof
WO2020007863A1 (en) 2018-07-02 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020007875A1 (en) 2018-07-03 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020008024A1 (en) 2018-07-06 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020028443A1 (en) 2018-07-31 2020-02-06 Danisco Us Inc Variant alpha-amylases having amino acid substitutions that lower the pka of the general acid
WO2020070063A2 (en) 2018-10-01 2020-04-09 Novozymes A/S Detergent compositions and uses thereof
WO2020070014A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition comprising anionic surfactant and a polypeptide having rnase activity
WO2020070009A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Endonuclease 1 ribonucleases for cleaning
WO2020070011A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition
WO2020070209A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition
WO2020070199A1 (en) 2018-10-03 2020-04-09 Novozymes A/S Polypeptides having alpha-mannan degrading activity and polynucleotides encoding same
WO2020074545A1 (en) 2018-10-11 2020-04-16 Novozymes A/S Cleaning compositions and uses thereof
WO2020077331A2 (en) 2018-10-12 2020-04-16 Danisco Us Inc Alpha-amylases with mutations that improve stability in the presence of chelants
WO2020088958A1 (en) 2018-10-31 2020-05-07 Henkel Ag & Co. Kgaa Cleaning compositions containing dispersins v
EP3647397A1 (en) 2018-10-31 2020-05-06 Henkel AG & Co. KGaA Cleaning compositions containing dispersins iv
EP3647398A1 (en) 2018-10-31 2020-05-06 Henkel AG & Co. KGaA Cleaning compositions containing dispersins v
WO2020088957A1 (en) 2018-10-31 2020-05-07 Henkel Ag & Co. Kgaa Cleaning compositions containing dispersins iv
WO2020112599A1 (en) 2018-11-28 2020-06-04 Danisco Us Inc Subtilisin variants having improved stability
EP3660151B1 (en) 2018-11-29 2023-07-19 Henkel AG & Co. KGaA Variant proteases having improved performance and storage stability
US11746341B2 (en) * 2018-11-29 2023-09-05 Henkel Ag & Co. Kgaa Performance-enhanced and storage stable protease variants
EP3660146B1 (en) 2018-11-29 2023-11-15 Henkel AG & Co. KGaA Storage stable protease variants with improved performance
US20200172890A1 (en) * 2018-11-29 2020-06-04 Henkel Ag & Co. Kgaa Performance-enhanced and storage stable protease variants
WO2020114965A1 (en) 2018-12-03 2020-06-11 Novozymes A/S LOW pH POWDER DETERGENT COMPOSITION
WO2020127775A1 (en) 2018-12-21 2020-06-25 Novozymes A/S Detergent pouch comprising metalloproteases
WO2020127796A2 (en) 2018-12-21 2020-06-25 Novozymes A/S Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same
WO2020188095A1 (en) 2019-03-21 2020-09-24 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
US20220162528A1 (en) * 2019-04-02 2022-05-26 Novozymes A/S Liquid Dishwashing Detergent Compositions
WO2020201403A1 (en) 2019-04-03 2020-10-08 Novozymes A/S Polypeptides having beta-glucanase activity, polynucleotides encoding same and uses thereof in cleaning and detergent compositions
WO2020207944A1 (en) 2019-04-10 2020-10-15 Novozymes A/S Polypeptide variants
WO2020247582A1 (en) 2019-06-06 2020-12-10 Danisco Us Inc Methods and compositions for cleaning
WO2021009067A1 (en) 2019-07-12 2021-01-21 Novozymes A/S Enzymatic emulsions for detergents
WO2021030400A1 (en) 2019-08-13 2021-02-18 Novozymes Bioag A/S Pesticidal combinations of yersinia and proteases
WO2021037895A1 (en) 2019-08-27 2021-03-04 Novozymes A/S Detergent composition
WO2021053127A1 (en) 2019-09-19 2021-03-25 Novozymes A/S Detergent composition
WO2021064068A1 (en) 2019-10-03 2021-04-08 Novozymes A/S Polypeptides comprising at least two carbohydrate binding domains
WO2021080948A2 (en) 2019-10-24 2021-04-29 Danisco Us Inc Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2021123307A2 (en) 2019-12-20 2021-06-24 Novozymes A/S Polypeptides having proteolytic activity and use thereof
WO2021122121A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins ix
WO2021122117A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning composition coprising a dispersin and a carbohydrase
WO2021121394A1 (en) 2019-12-20 2021-06-24 Novozymes A/S Stabilized liquid boron-free enzyme compositions
WO2021122118A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins vi
EP3892708A1 (en) 2020-04-06 2021-10-13 Henkel AG & Co. KGaA Cleaning compositions comprising dispersin variants
WO2021214059A1 (en) 2020-04-21 2021-10-28 Novozymes A/S Cleaning compositions comprising polypeptides having fructan degrading activity
WO2022008387A1 (en) 2020-07-08 2022-01-13 Henkel Ag & Co. Kgaa Cleaning compositions and uses thereof
EP3936593A1 (en) 2020-07-08 2022-01-12 Henkel AG & Co. KGaA Cleaning compositions and uses thereof
WO2022074037A2 (en) 2020-10-07 2022-04-14 Novozymes A/S Alpha-amylase variants
WO2022084303A2 (en) 2020-10-20 2022-04-28 Novozymes A/S Use of polypeptides having dnase activity
WO2022157311A1 (en) 2021-01-22 2022-07-28 Novozymes A/S Liquid enzyme composition with sulfite scavenger
EP4032966A1 (en) 2021-01-22 2022-07-27 Novozymes A/S Liquid enzyme composition with sulfite scavenger
WO2022165107A1 (en) 2021-01-29 2022-08-04 Danisco Us Inc Compositions for cleaning and methods related thereto
WO2022171780A2 (en) 2021-02-12 2022-08-18 Novozymes A/S Alpha-amylase variants
WO2022171872A1 (en) 2021-02-12 2022-08-18 Novozymes A/S Stabilized biological detergents
WO2022189521A1 (en) 2021-03-12 2022-09-15 Novozymes A/S Polypeptide variants
EP4060036A1 (en) 2021-03-15 2022-09-21 Novozymes A/S Polypeptide variants
WO2022194668A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Polypeptide variants
WO2022194673A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Dnase variants
WO2022268885A1 (en) 2021-06-23 2022-12-29 Novozymes A/S Alpha-amylase polypeptides
WO2023278297A1 (en) 2021-06-30 2023-01-05 Danisco Us Inc Variant lipases and uses thereof
WO2023034486A2 (en) 2021-09-03 2023-03-09 Danisco Us Inc. Laundry compositions for cleaning
WO2023114988A2 (en) 2021-12-16 2023-06-22 Danisco Us Inc. Variant maltopentaose/maltohexaose-forming alpha-amylases
WO2023126254A1 (en) 2021-12-30 2023-07-06 Novozymes A/S Protein particles with improved whiteness
EP4206309A1 (en) 2021-12-30 2023-07-05 Novozymes A/S Protein particles with improved whiteness
WO2023165507A1 (en) 2022-03-02 2023-09-07 Novozymes A/S Use of xyloglucanase for improvement of sustainability of detergents
WO2023165950A1 (en) 2022-03-04 2023-09-07 Novozymes A/S Dnase variants and compositions
WO2023194204A1 (en) 2022-04-08 2023-10-12 Novozymes A/S Hexosaminidase variants and compositions
CN114921440B (en) * 2022-05-16 2023-05-05 北京昕大洋科技发展有限公司 Xylanase mutant and application thereof
WO2023250301A1 (en) 2022-06-21 2023-12-28 Danisco Us Inc. Methods and compositions for cleaning comprising a polypeptide having thermolysin activity
WO2024131880A2 (en) 2022-12-23 2024-06-27 Novozymes A/S Detergent composition comprising catalase and amylase
WO2024156628A1 (en) 2023-01-23 2024-08-02 Novozymes A/S Cleaning compositions and uses thereof
WO2024194245A1 (en) 2023-03-21 2024-09-26 Novozymes A/S Detergent compositions based on biosurfactants
WO2024213513A1 (en) 2023-04-12 2024-10-17 Novozymes A/S Compositions comprising polypeptides having alkaline phosphatase activity
WO2024226828A2 (en) 2023-04-26 2024-10-31 Novozymes A/S Cleaning composition and cleaning method

Also Published As

Publication number Publication date
EP3878960A1 (en) 2021-09-15
EP3140399B1 (en) 2018-03-28
CA2950380A1 (en) 2016-01-07
EP3140399A1 (en) 2017-03-15
BR112017000102B1 (en) 2023-11-07
US20170137798A1 (en) 2017-05-18
US20220064620A1 (en) 2022-03-03
US10550381B2 (en) 2020-02-04
BR112017000102A2 (en) 2018-01-23
CN106661566A (en) 2017-05-10
EP3327122B1 (en) 2021-02-17
US20200109389A1 (en) 2020-04-09
US11015183B2 (en) 2021-05-25
CN116240202A (en) 2023-06-09
EP3327122A1 (en) 2018-05-30

Similar Documents

Publication Publication Date Title
US11015183B2 (en) Subtilase variants with enhanced storage stability
US11591585B2 (en) Subtilase variants and polynucleotides encoding same
US12065680B2 (en) Subtilase variants and polynucleotides encoding same
EP3013956B1 (en) Subtilase variants and polynucleotides encoding same
EP4071244A1 (en) Subtilase variants and polynucleotides encoding same
EP3013950B1 (en) Subtilase variants and polynucleotides encoding same
EP3013955A1 (en) Subtilase variants and polynucleotides encoding same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15736432

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2950380

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2015736432

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015736432

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15323633

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017000102

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112017000102

Country of ref document: BR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112017000102

Country of ref document: BR

Free format text: EXIGENCIA ANULADA. AGUARDANDO ORIENTACOES.

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112017000102

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017000102

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170103